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Abstract
This thesis sought to investigate the relationship between structural and metabolic 
heterogeneity in LDL and examine the influence of plasma triglyceride on the properties of 
this lipoprotein.
A technique to quantify individual LDL subtractions was developed which was superior to 
previously published methods and was employed to characterise three LDL subtractions in 
normals and in subjects with coronary disease, primary hyperlipidaemia and the secondary 
hyperlipidaemia observed in non insulin dependent diabetes mellitus and the nephrotic 
syndrome. In a case controlled study, a sevenfold increased risk of myocardial infarction 
was found to be associated with a concentration of small dense LDL III > lOOmg/ 100ml. 
Subjects with hypertriglyceridaemia, combined hyperlipidaemia and the secondary 
hyperlipidaemia were found to exhibit an atherogenic lipoprotein phenotype of raised 
plasma triglyceride, low HDL cholesterol and a preponderance o f small dense LDL. The 
data in the entire cohort was pooled and multivariate analysis revealed that plasma 
triglyceride was the most important independent predictor of LDL III.
Pharmacological modulation of the LDL profile was investigated in normals and in a 
variety o f hyperlipidaemic states using the main classes o f lipid lowering drugs- resins, 
nicotinic acid derivatives, fibrates and statins. Those drugs which act through the lowering 
of plasma triglyceride reduced the concentrations of LDL III and those whose mode of 
action is by activation of the LDL receptor, reduced the concentrations of the larger LDL I 
and LDL II species. An important finding was in the unexpected beneficial effect of statins 
in combined hyperlipidaemia when LDL III concentrations were lower than expected for 
the plasma triglyceride level.
Kinetic heterogeneity of LDL was studied by undertaking radioactive turnovers in normals 
and hypercholesterolaemic subjects who were given triglyceride lowering therapy. A two 
pool model for plasma LDL was developed to explain the radioactive decay curves of 
plasma and urine. One pool (pool A) was rapidly removed by the LDL receptor while the 
other (pool B) was more slowly removed and its synthesis was positively related to plasma 
triglyceride. The kinetics of apo-LDL were further examined in subjects with moderate 
hypertriglyceridaemia. Here it was necessary to expand the model to a third plasma pool 
(pool C) to account for an LDL species which was rapidly catabolised by receptor- 
independent mechanisms. A high level of receptor -independent catabolism was associated 
with an increased ratio of LDL III to LDL II. Pool C was seen in subjects with plasma 
triglyceride >2.5mmol/l in whom there was the presence o f an abnormally small, dense 
LDL.
On the basis of these observations and published VLDL metabolic studies, a model was 
postulated in which pool A LDL was produced from the delipidation of hepatic lipoproteins 
secreted in the Sf 0-60 density range and! circulated in the form LDL I and LDL II. Pool B
Ill
LDL, on the other hand, was derived from large triglyceride-rich VLDL of Sf 60-400 and 
circulates in most subjects in the form of LDL II. Neutral lipid exchange and lipolysis via 
the agency of hepatic lipase converts a proportion of pool B LDL II to LDL III, depending 
on the level o f plasma triglyceride and the activity of the lipase enzyme.
The data presented in this thesis are in line with current concepts o f the atherogenicity of 
small dense LDL and provide evidence that it is an independent risk factor for coronary 
disease. It demonstrates that the properties of LDL are strongly influenced by its pedigree. 
Furthermore it shows that there are currently available drugs that are capable of altering not 
only the quantity o f LDL but also its quality and offer hope in the continuing problem of 
tackling coronary heart disease.
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1Chapter 1 Introduction
1.1 Coronary Heart Disease and Plasma Lipids
Coronary heart disease (CHD) continues to be a major cause of death in most industrialised 
populations. However, evidence that the burden of CHD can be reduced is seen in 
countries such as the USA and Finland where appropriate preventative strategies have been 
successfully implemented. Epidemiological studies have identified a number of risk factors 
for first events and recurrent CHD. Modifiable factors include hypertension, smoking, lack 
of exercise, obesity and abnormal lipid levels, while other risk factors are age, sex, family 
history of CHD and diabetes mellitus. Men are affected by CHD at an earlier age than 
women but after the menopause women lose the protective effect o f oestrogen and the 
incidence rises. Among these risk factors abnormal blood lipid profiles have a central 
position. The largest prospective study was the Multiple Risk Factor Intervention Trial 
(MRFIT) which provided evidence that blood pressure, smoking, dyslipidaemia and 
glucose intolerance explained the majority o f CHD cases (Stamler et al, 1986). This study 
demonstrated that the relationship between CHD death and serum cholesterol was 
continuous, graded and independent of smoking and hypertension (Martin et al, 1986). In 
countries where habitual fat intake is low, mortality from CHD is low and total life 
expectancy exceeds that in many Western countries. However a positive correlation 
between CHD and cholesterol exists even in countries such as China where average 
cholesterol levels are low, ranging from 2.4 to 4.2 mmol/1 (Chen et al, 1991). Law et al 
(1994) recently highlighted the previous underestimation of the link between cholesterol 
and CHD risk by re-analysing ten prospective and three international studies based on 
single cholesterol measurements and correcting for regression dilution and surrogate 
dilution effects. He estimated that a 10 % decrease in cholesterol (0.6 mmol/1) would be 
associated with a reduction in incidence of CHD events in the cohort studies of 54% at age 
40 years, 39% at age 50 and 27% at 60.
Epidemiological studies carried out over the last three decades have consistently shown an 
association between elevated levels of plasma triglyceride and an increased risk of CHD. 
The interpretation of this relationship has been controversial as some studies found that 
following adjustment for other risk factors, in particular HDL cholesterol, triglyceride 
failed to be an independent predictor of disease. Others such as the Caerphilly and 
Framingham studies (Bainton et al, 1992 Castelli et al, 1986) found that triglyceride 
persisted as a risk factor even when other potential confounding factors were taken into 
account. Austin in 1991 comprehensively re-evaluated the epidemiological data and 
suggested that the strength of the association between triglyceride and CHD has been 
significantly underestimated because of the biological variation of this plasma lipid and 
shortcomings in the multivariate analysis approach. In a recent meta-analysis she 
confirmed an independent triglyceride/CHD link (Hokannson & Austin, 1993a). Data from 
the Helsinki Heart Study (Manninen et al, 1992) and the Prospective Cardiovascular 
Munster study (PROCAM) (Assmann & Schulte, 1992) highlight the particularly high 
CHD risk associated with moderately raised triglycerides, low HDL cholesterol and an
2LDL:HDL cholesterol ratio greater than 5. Furthermore in the Helsinki Heart Study most 
benefit from therapy with gemfibrozil was observed in this high risk group.
Further support for the benefits of cholesterol-lowering have come from the 
angiographically - monitored trials which have demonstrated arrested progression and even 
regression o f coronary lesions but the most definitive evidence has been obtained recently 
in trials using 3-hydroxy 3 methylglutaryl coenzyme A (HMGCo A) reductase inhibitors. 
The Scandinavian simvastatin survival study (4S) provided proof of the effects of 
cholesterol lowering not only on CHD but also on overall mortality o f high risk individuals 
(Scandinavian Simvastatin Survival Study Group, 1994). Over 5.4 years, simvastatin 
produced mean changes in total cholesterol, LDL cholesterol and HDL cholesterol of -25%, 
-35% and +8% respectively. The treated group had significantly less total mortality (8% vs 
12%) and fewer coronary events (19% vs 28%). The West of Scotland Coronary 
Prevention Study (WOSCOPS) showed that treatment with pravastatin led to a 22% 
reduction in overall mortality and a 30% reduction in fatal and non-fatal myocardial events 
in 6,595 middle aged men with no previous coronary disease but raised plasma and LDL 
cholesterol (Shepherd et al, 1995).
In a placebo controlled trial Coronary Atherosclerosis Intervention Trial (BCAIT), 
bezafibrate has recently been shown to induce atheroma regression in 42 men who had 
survived a first coronary below the age of 45 (Ericsson et al, 1996). The authors compared 
their results with two recent regression trials involving statin therapy and noted similar 
effects on lesion regression despite different effects on plasma lipids. The statin studies 
(Regression Growth Evaluation Statin Study (REGRESS) and Multicentre Anti-Atheroma 
Study (MAAS)) showed reductions of 20-23% in total cholesterol, 30% in LDL cholesterol 
and 7-18% in plasma triglyceride whereas in BCAIT the major lipid reduction was a 31% 
drop in serum triglyceride with little change in LDL.
Although there are minor variations among the various national and international 
guidelines for management of dyslipidaemia, there is now considerable agreement on the 
need for risk stratification and the treatment of lipid risk factors in the context of individual 
global CHD risk. LDL cholesterol remains the major target for therapy but the importance 
of HDL cholesterol and triglyceride is acknowledged. Clearer guidelines on the 
management of hypertriglyceridaemia will become possible when further intervention data 
becomes available.
1.2 Lipoprotein Structure and Function
It is estimated that as much as 80% of the carbon and hydrogen in energy substrates used 
by the human body passes through lipid intermediaries at some point before being oxidised 
to terminal products. Also there is constant bi-directional movement of the lipid 
constituents of membranes between cells and blood. Transport of lipid in plasma is chiefly 
accomplished by a system of lipid:protein complexes (lipoproteins) which generally take 
the form of spherical microemulsion particles, comprised of a core region containing the 
hydrophobic cholesteryl esters and triglycerides in variable proportions surrounded by a 
mixed monolayer of phospholipids and unesterified cholesterol. The charged head groups 
of the phospholipid and the free hydroxyl group of cholesterol associate with the water in 
the surrounding aqueous medium, while the hydrophobic fatty acid chains of the fatty acids
3and the sterol ring structure are in contact with each other and with the hydrophobic core 
lipids. Fig. 1.1 shows the structure of atypical lipoprotein particle.
ApoCII
Unesterified
Cholesterol
Phospholipid
Triglyceride
Apo E
Cholesterol Ester
apo B-100
Apo cm
Fig. 1.1 Structure o f  Very Low Density Lipoprotein
The major lipid component o f the nonpolar core is triglyceride and cholesteryl ester while the 
surface is composed o f unesterified cholesterol, phospholipid and apoproteins B, E ,C  I, C II and
cm.
A number of specific proteins (apolipoproteins) interact with the lipid microemulsion, 
associated primarily with the surface monolayers (table 1.1). A group of seven proteins 
with a relatively small molecular weight (Al, AH, AIV, Cl, CD, CHI, E) are members o f a 
gene family characterised by tandem repeats of codons (Luo et al, 1986). These proteins 
have several sequences that form amphipathic helices and are readily exchangeable among 
the lipoprotein species. In contrast, the B apolipoprotein group is comprised of two very 
large proteins (apo B100, apo B48) which are the products o f a single gene. They form 
very few amphipathic helices and contain a large amount o f (3 sheet structure. At certain 
points on the phospholipid monolayer they displace surface lipids and interact directly 
with the core lipids. Throughout their lifetime in plasma the B apoproteins remain with 
the lipoprotein particles on which they were secreted and so are a useful marker for
4investigation o f the metabolism o f those particular lipoproteins. A group o f relatively 
hydrophobic circulating proteins are associated with the lipoprotein system. They include 
apo D, cholesteryl ester transfer protein (CETP) and phospholipid transfer protein which 
function in lipid exchange mechanisms.
Table 1.1. Apolipoproteins o f  Human Plasma
■
Apo Al 130 29,016
Apo A ll 40 8,700
Apo AIV 40 44,465
Apo B100 85 512,723
Apo B48 variable 240,800
Apo C l 6 6,630
Apo CII 3 8,900
Apo CIII 12 8,800
Apo I) 10 19,000
Apo E 5 34,145
Generally, there are three roles for plasma lipoproteins in lipid transport , namely ; 
transport o f triglyceride to body tissues (the triglyceride-rich lipoproteins),delivery of 
cholesterol to the tissues (via low density lipoprotein) and retrieval o f lipids from the 
peripheral tissues (via high density lipoprotein).
Table 1.2 Physical Properties o f  the Plasma Lipoprotein Classes
S e w  7m
Chylomicron <0.93 >400 75-1,200
J « T
50-1,000x10"
' I P I P f f f iR f l l
origin
VLDL 0.93-1.006 20-400 30-80 10-80 xlO6 pre-(3
IDL 1.006-1.019 12-20 25-35 5-10 xlO6 slow prej3
LDL 1.019-1.063 0-12 18-25 2-3 xlO6 p
HDL 1.063-1.21 5-12 65-386 xlO3 a
5The separation o f the individual plasma lipoproteins was first carried out in the 1950’s 
(Gofman et al, 1950; Turner et al, 1951) employing the technique o f preparative 
ultracentrifugation. The most widely used nomenclature defines five main classes of 
lipoproteins (table 1.2) based on their hydrated density in g/ml (Havel et al, 1955). Other 
classifications include electrophoretic mobility, apolipoprotein composition or, as described 
by Lindgren et al (1972), by the rate of flotation through a salt solution expressed in 
Svedberg units (Sf).
1.2.1 Chylomicrons
Chylomicrons o f enteric origin are the largest triglyceride-rich lipoproteins that carry 
exogenous triglycerides into the plasma. Circulation o f chylomicrons serves to distribute 
dietary triglyceride to adipose tissue and to muscle. The chylomicron is characterised by 
its high triglyceride content and its specific apo B variant (tables 1.2 and 1.3). The 
intestine produces an apo B which has the same amino acid complement as the N terminal 
48% o f full length apo B, and is therefore called apo B48 (Kane et al, 1980). 
Apolipoproteins Al, A ll, A1V, Cl, CII, CIII and E are also found on chylomicrons (Green 
et al, 1979; Wu et al, 1979, Krause et al, 1981). The chylomicrons secreted by the intestine 
are transported via the thoracic duct and enter the blood stream in the left subclavianvein. 
Once the chylomicron has reached the blood stream several compositional changes take 
place. Apo Al is transferred to HDL (Tall et al, 1979, Schaefer et al, 1982) and 
apolipoproteins circulating in the plasma bound to HDL (apos Cl, CII, CIII and apo E) are 
rapidly transferred to the chylomicron (Havel et al, 1973). O f these, apo CII has a critical 
action as an activator o f lipoprotein lipase (LPL) (La Rosa et al, 1970). LIydrolysis of core 
triglyceride is mediated by endothelium bound LPL, liberating free fatty acids that are 
taken up locally. During the delipidation of the core o f the chylomicron, redundant surface 
materials (phospholipids and apoproteins) are transferred back to L1DL (Redgrave et al, 
1979, Tall et al, 1979). As a result the chylomicrons decrease in size and the core becomes 
relatively enriched in cholesteryl esters to form remnants. The delipidated chylomicron 
remnant contains apo B48, surface lipids, residual triglycerides, and accumulated 
cholesteryl esters and under normal conditions is taken up rapidly by the specific receptors 
o f the liver recognising apo E (Hoeg et al, 1985). F ig .1.2 illustrates exogenous lipid 
metabolism.
Table 1.3 Composition o f  Normal Plasma Lipoproteins
w w m sm
:■
mm *
Chylo­ 2 3 7 86 2 AL AIV. B48,
microns C, E
VLDL 7 12 18 55 8 B100, C, E
IDL 9 29 19 23 19 B100, C,E
LDL 8 42 22 6 22 B100,C,E
HDL 4 14 34 4 45 AI,AII,C.D,E
6CHUOMCRON
RBWANIS
CHYLOMCRONS
Fig. 1.2 Exogenous Lipid Metabolism
(adaptation o f an illustration by Professor Packard)
Choi cholesterol, FFA free fatty acids, Trig triglyceride, HDL high density lipoprotein, LDL-R low 
density lipoprtein receptor, LpL lipoprotein lipase, LRP low density lipoprotein receptor related 
protein receptor, apolipoproteins A, B48, C, CII, E.
1.2.2. Very Low Density Lipoprotein (VLDL)
VLDL synthesised in the liver, is the endogenous triglyceride transporter in plasma. The 
triglyceride in VLDL originates either from hepatic de novo synthesis o f fatty acids, from 
plasma free fatty acids taken up into the liver or from residual triglycerides in chylomicron 
remnants. The apo B released in VLDL is the complete apo B100 polypeptide. Like 
chylomicrons, newly secreted VLDL acquire apo Cs and apo E from circulating 
lipoprotein, mainly HDL (table 1.3). The triglyceride core is rapidly hydrolysed by the 
action o f LPL, i.e. there is a common saturable triglyceride removal mechanism for both 
chylomicrons and VLDL (Brunzell et al, 1973). VLDL is not homogeneous, and can be 
divided into at least two components o f differing size, density and metabolic properties 
(Patsch et al, 1978, Kuchinskiene et al, 1982, Packard et al, 1984). VLDLj (Sf 60-400) is 
larger and triglyceride-rich, whereas VLDL2 (Sf 20-60) is smaller and comparatively rich in 
cholesteryl ester (Packard et al, 1984). Small VLDL is derived in part by delipidation of 
large VLDL but may also be secreted by the liver (Demant et al, 1995). Parallel 
processing pathways operate within the delipidation cascade (Packard et al, 1984) so that 
large VLDLj are inefficiently converted to a class of LDL (Sf 0-12) that is cleared slowly 
from the plasma while newly synthesised VLDL2 is rapidly and quantitatively delipidated 
to an LDL species which is catabolised rapidly (Packard et al, 1984).
71.2.3 Intermediate Density Lipoprotein (IDL)
IDL is the lipoprotein with hydrated density 1.019-1.063 g/ml and a flotation Sf 12-20 and 
was initially regarded as a single class of lipoproteins generated from VLDL by lipolysis. 
Generally in the quantification of lipoproteins, IDL cholesterol is included with LDL. 
Musliner et al (1986) have shown the existence of two populations IDL! and IDL2 by 
gradient gel electrophoresis of ultracentrifugal fractions from normal subjects. IDLb the 
larger subfraction, was richer in triglycerides and was often observed to be the same size as 
small VLDL particles. On the other hand, IDL2 was relatively cholesterol enriched. The 
same group (Musliner et al, 1987) showed that small VLDL gives rise to a lipoprotein with 
the size and density of intermediate LDL.
1.2.4 Low Density Lipoprotein (LDL)
LDL is the major cholesterol carrier in plasma and its function is to deliver cholesterol to 
the peripheral tissues principally for the maintenance of cell membranes. In certain 
specialised cells the cholesterol extracted from LDL has other roles. In the adrenal gland 
and the ovary it is converted into, respectively, the steroid hormones cortisol and oestradiol, 
and in the liver it is transformed to make bile acids which have a digestive function in the 
intestine. LDL contains tocopherols and the lipoprotein acts as a transport mechanism for 
this minor lipid (Kayden et al, 1993). Each LDL particle is spherical with a diameter of 
22-28nm, and is isolated at hydrated density 1.019-1.063 g/ml or flotation rate Sf 0-12. It 
contains one copy of apo B100 which is the ligand for the LDL receptor (Goldstein & 
Brown, 1984) by which means the particle enters the cell. The apo B is disposed in a 
circumferential distribution around the lipid core (Phillips et al, 1989, Chatterton et al, 1991, 
Schumaker et al, 1994). LDL was once considered structurally and metabolically 
homogeneous but has now been shown not only to exhibit inter-individual heterogeneity 
but it also exists in the plasma of all individuals as a group of discrete but overlapping 
populations of particles (Hammond et a/,1977, Fisher et a/,1983, Krauss et a/,1980, Shen et 
al, 1981, Krauss & Burke, 1981, Chapman et al, 1988).
1.2.5 High Density Lipoprotein (HDL)
Plasma HDL lies in the density range 1.063-1.21 g/ml and is comprised of small, dense, 
spherical lipid-protein complexes consisting of approximately equal proportions of lipid 
and protein (Eisenberg et al, 1984). The major lipids are phosphatidylcholine, cholesterol, 
cholesteryl ester and triglyceride. The two main structural apoproteins are Al (MW 
28,000) and All (MW 17,000). In addition HDL contains small amounts of apo Cl, CII, 
CIII, E, and AIV (table 2.3) and trace quantities of CETP, phospholipid transfer protein and 
lecithin: cholesterol acyl transferase (LCAT), which play an important part in HDL and 
lipoprotein metabolism. HDL also contains several components of unknown function 
including apo D, apo J (clusterin), apo SAA (an acute phase reactant) and Pl-glycan- 
specific phospholipase D (Tall & JBreslow, 1996). HDL newly formed by secretion or a by­
product of lipolysis (nascent HDL) has a distinctive discoidal structure (Tall et al, 1990). 
The particle lacks neutral lipids and is an excellent substrate for the LCAT enzyme whose 
action rapidly leads to the conversion to a spherical structure. The major subclassification 
of HDL is the division into HDL2 (d 1.063-1.125 g/ml) and HDL3 (d 1.125-1.210 g/ml) in
the preparative ultracentrifuge (Eisenberg et al, 1984). HDL2 contains 60% lipid and 40% 
protein, while HDL3 consists of about 45% lipid and 55% protein. The mean diameter of 
HDL2 is 10-12nm and that of HDL3 is 8-9nm. Further subdivisions can be achieved by 
gradient gel electrophoresis (Blanche et al, 1981) which yields HDL2b, HDL2a, HDL3a, 
HDL3b and HDL3c, in decreasing order of size.
An important distinctive subclassification of HDL is based on immunochemical differences 
between HDL particles. The primary classification is based on differences in content of 
apo Al and All (Cheung et al, 1982, 1984, 1991, Duverger et al, 1993). HDL consists of 
particles containing apo Al (LpAI), apo Al and All (LpAI/AII) and apo All (LpAII). There 
is increasing evidence that Lp(AI) and Lp(AI/AII) have distinct metabolic properties as 
well as possible differences in atherogenesis. The overall metabolic function of HDL is 
related to the reverse cholesterol transport which is the centripetal movement of cholesterol 
from the periphery back to the liver. HDL is believed to remove cholesterol from cells, 
either by a process of simple diffusion or by apoprotein, particulary Al, interaction with the 
cell surface. Cholesterol in HDL is esterified and transferred to other lipoprotiens for 
subsequent clearance by the liver. Alternatively HDL cholesterol and cholesteryl ester are 
directly removed by the liver (Tall & Breslow, 1996).
1.2.6 Lipoprotein (a) (Lp(a))
Since its discovery in 1963 by Berg and his colleagues at Oslo University, Lp(a) has 
become recognised by most investigators as an independent risk factor for cardiovascular 
disease. This observation has been seen in a number o f retrospective ( Armstrong et al, 
1986, Durrington et al, 1988, Genest et al, 1991,1992) and prospective studies including 
the Lipid Research Clinics Primary Prevention Trial (Schaefer et al, 1994) and the 
Gottingen Risk Incidence and Prevention Study (Cremer et al, 1994). However two recent 
prospective studies - the Helsinki Heart Study (Jauhiainen et al, 1991) and Raker et al 
(1993) failed to show a significant association.
Lp(a) has the structure of LDL bound to a specific glycoprotein, apolipoprotein (a) via a 
disulphide bridge and non polar interactions. Apo(a) varies in mass between 300 - 800 
kDa. As a consequence of the marked size polymorphism of apo(a), the Lp(a) particle 
exhibits an important variability in size and weight (Fless et al, 1984) and impaired binding 
to a number of cell and extracellular surfaces (Maartnan-Moe et al, 1981; Armstrong et al, 
1985, Harpel et al, 1989, Salonen et al, 1989). Through sequencing cDNA, McLean et al 
(1987) showed that apo(a) has a striking similarity to plasminogen. Both proteins have 
identical secretion signal peptides and protease domains but plasminogen contains a 
zymogen region and three kringles that have no close counterpart in apo(a). The 4th and 
5th kringles have been conserved with Lp(a) having up to forty exact copies of kringle 4. 
All components of the Lp(a) particle are synthesised in the liver. The normal function of 
the particle is not known, however the homology with plasminogen has lead to the 
speculation that Lp(a) might serve as the link between thrombosis and atherosclerosis and 
this has been the focus o f recent research. This topic has recently been reviewed by Lawn 
& Scanu (1996).
91.3 Lipoprotein Metabolism
1.3.1 Intestinal Lipoprotein Secretion
The most abundant lipid in the diet is triglyceride which under normal conditions is 
absorbed virtually completely following hydrolysis by pancreatic lipase. Unesterified 
cholesterol is present in foods of animal origin and is liberated from ingested cholesteryl 
esters by a cholesteryl esterase (fig. 1.2). Enterocytes selectively absorb unesterified 
cholesterol while excluding phytosterols. This process appears to involve one or more 
transmembrane proteins (Thumhofer et al, 1991) while the intracellular transport of free 
fatty acids derived from ingested triglycerides is probably facilitated by one or more fatty 
acid binding proteins (Xu et al, 1992, Schaeffer et al, 1994). After esterification with CoA, 
the fatty acyl groups directly trans acylate the p-monoglycerides to triglycerides. Some 
free cholesterol is esterified, by acyl CoA:cholesterol acyl transferase (ACAT) to yield 
esters that appear in chylomicrons.
The form of apo B (apo B48) that is found in chylomicrons is completely homologous with 
the N terminal 48% of apo B100 and results from tissue-specific editing process that 
introduces a stop codon (Driscoll et al, 1990). The process of lipidation of apo B in the 
intestine is inferred from a more detailed knowledge of the formation and secretion of 
VLDL in hepatocytes. However caution should be exercised in this extrapolation since in 
chylomicron retention disease there is an inability to secrete chylomicrons while VLDL 
synthesis and secretion proceed normally (Roy et al, 1987), suggesting that there is a 
difference in the two processes.
Scission of a 27 amino acid signal peptide probably occurs cotranslationally and partial 
lipidaton o f nascent apoB48 chain proceeds as the protein is translocated across the 
membrane o f the endoplasmic reticulum, forming a small spherical precursor with partially 
lipidated apo B. In a second step, the partially lipidated apo B particle fuses with a large 
triglyceride droplet (Christensen et al, 1983). The nascent particles are then transported to 
the Golgi apparatus where a further complement o f phospholipid may be added and newly 
synthesised apos Al, All, and AIV are associated with the particle.
Secretion o f chylomicrons into extracellular space occurs when membranes of the trans- 
cistemae o f the Golgi fuse with the basolateral membrane. The chylomicrons then pass 
into the intestinal lacteals, transit the thoracic duct and spill into the blood via the 
subclavian vein. The rates of synthesis of the C and E apoproteins are very low in the 
intestine (Imaizumi et al, 1978a, 1978b) and so it is likely that limited amounts are present 
in chylomicrons.
The capillaries o f the intestine are fenestrated in such a way that macromolecules in the size 
range of HDL can pass into lymph spaces and this allows extensive exchange of 
phospholipid from chylomicrons to HDL and, in the reverse direction, acquisition of apo 
Cs and E by chylomicrons. Apoproteins Al, All and AIV dissociate very rapidly on 
exposure to lymph and plasma and enter the HDL pool.
The principal mechanism by which the intestine accommodates large fluxes of triglyceride 
transport is by increasing the particle volumes of the chylomicrons secreted. Synthesis of 
apo B48 appears to be increased only minimally or not at all with fat feeding in the rat 
(Imaizumi et al, 1978b) whereas triglyceride transport can increase twenty-fold.
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1.3.2 Intravascular Lipolysis o f  Chylomicrons
Lipolysis of lipoprotein-bome triglyceride takes place at the vascular endothelium. 
Electron microscopy has shown that chylomicrons and VLDL marginate on the capillary 
walls in adipose tissue and in skeletal and cardiac muscle. There is a complex interaction 
with lipoprotein lipase (LPL) (Olivecrona et al, 1993) with LPL binding both to the 
lipoprotein and heparin sulphate of endothelial proteoglycans (Eisenberg et al, 1992, 
Williams et al, 1992a) (fig. 1.2). The active form of LPL is a homodimer and it is activated 
by binding to the C terminal of apo CII. LPL is synthesised and secreted in adipose tissue, 
striated muscle and mammary gland and moves across the endothelium to the luminal 
surface of each of these tissues. LPL is regulated by poorly defined metabolic and 
endocrine signals. Fasting reduces the activity in adipose tissue and increases activity in 
cardiac and skeletal muscle (Amer et al, 1991; Enerback et al, 1988). This effect spares 
free fatty acids for use in skeletal and cardiac muscle when energy substrates are not 
abundant. In insulin deficiency there are low levels of LPL activity in adipose tissue 
(Frayn et al, 1993).
Intravascular hydrolysis o f triglyceride liberates free fatty acids and glycerol. Free fatty 
acids are taken up in the tissue where hydrolysis/ occurs and glycerol released into plasma 
is removed by tissues in which there is glycerokinase activity, principally the liver and 
intestine. Albumin is a transient ligand for the fatty acids which go to cell membranes 
where a lipid binding protein facilitates uptake (Schaeffer et al, 1994).
Depletion of the core lipids leads to the production of progressively smaller spherical 
particles until approximately 70% of the core triglyceride is removed. The surface 
monolayer of phospholipid and free cholesterol sheds amphipathic lipids to HDL apace 
with the decrease in particle diameter. This process is dependent on phospholipid transfer 
protein (PLTP) (Day et al, 1994; Tollefson et al, 1988). PLTP is synthesised in a number 
of tissues including placenta, pancreas, lung, kidney, liver and brain. Deficiency of PLTP 
leads to retention of phospholipids in chylomicrons and VLDL remnants (Malloy et al,
1994) and in homozygous PLTP deficiency there is a virtual absence of HDL.
As triglyceride hydrolysis proceeds, apolipoprotein Cs and a portion o f apo E dissociate 
from the particles and associate with HDL. Small (50-80 nm in diameter), triglyceride- 
depleted lipoprotein products o f lipolysis that contain B48 and E are termed chylomicron 
remnants. The process o f lipolysis from secretion to the remnant stage takes about 15 
minutes in normals (Stalenhoef et al, 1984)
1.3.3 Metabolism o f  Chylomicron Remnants
Chylomicron remnants are removed with great efficiency via endocytosis into the 
hepatocytes (Shafi et al, 1994) (fig. 1.2). The process is still poorly understood but is 
mediated by a receptor or receptors for which apo E is the ligand. Though chylomicron 
remnants bind the LDL receptor with high affinity, the absence of significant retention of 
chylomicron remnants in homozygous LDL receptor-defective animals and humans points 
to the existence o f an additional receptor. The LDL-receptor-like protein (LRP) may be the 
responsible receptor (lipoprotein receptors are discussed in detail in section 1.4).
Kinetic studies of endocytosis o f chylomicron remnants by the liver reveals a delay after 
binding, suggesting that modification of the particles is required before endocytosis 
proceeds. Both the triglyceride and cholesterol of chylomicron remnants are used in the
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secretion of VLDL by the liver. Tocopherols also enter the hepatocyte in endocytosed 
chylomicron remnants and are resecreted in VLDL (Kayden et al, 1993).
1.3.4 Lipoprotein Assembly in the Liver
Fatty acids employed in triglyceride synthesis come from several sources. Free fatty acids 
released by the activity of intracellular lipase (hormone-sensitive lipase, HSL) in adipose 
tissue are transported in plasma bound to albumin. About one third of plasma free fatty 
acid is extracted by the liver independent of the triglyceride level. Hence in the situation in 
which lipolysis in the adipocytes is increased, there will be an increase influx of free fatty 
acids to hepatocytes. The most potent down regulator of HSL is insulin. Plasma fatty acids 
undergo two competing fates following uptake by the liver, either oxidation or deposition 
in the storage pool as triacylglycerol, awaiting incorporation into VLDL (Gibbons et al,
1995). Biosynthesis of fatty acids proceeds using carbon sources o f glucose, amino acids 
and ethanol. Fatty acid synthesis is enhanced in the fed state and suppressed during fasting. 
Cholesterol in liver may be present as the result o f de novo synthesis or due to retrieval 
from the peripheral tissues mediated through HDL. All the body’s cells have the capacity 
to synthesise cholesterol but the bulk is made in the liver. The cholesterol biosynthetic 
pathway is initiated at acetate with multiple steps to mevalonic acid through to lathosterol 
and then cholesterol. The pathway is finely regulated by the negative feedback of 
cholesterol exerted on the rate limiting enzyme HMG Co A reductase. The liver cell has 
the unique ability to eliminate cholesterol into the bile either unchanged or following 
oxidation to bile acids (Dietschy & Wilson, 1970). This is regulated by cholesterol 7 a  
hydroxylase which is the rate limiting enzyme of bile acid secretion. The rate of hepatic 
cholesterol synthesis correlates with the rate of hepatic VLDL-apo B secretion in stable 
isotope turnover studies in normolipaemic subjects (Watts et al, 1995) and subjects with 
heterozygous familial hypercholesterolaemia (Cummings et al, 1995).
Apo B100 is the sole B protein produced in the liver and each nascent VLDL particle 
contains a single copy of B 100 (Kane et al, 1994). The protein is approximately 549 kDa 
including carbohydrate linked at up to 16 sites and contains about 40 lipophilic sequences 
distributed evenly through the molecule which allow it to associate with the moieties of 
VLDL, IDL and LDL with such high affinity that it remains with a single lipoprotein 
particle from secretion to ultimate endocytosis. These sequences include several 
amphipathic helices and a large number of sequences yielding amphipathic P structure. 
Apo B100 message appears to be constituitively expressed in Hep G2 cells (Pullinger et al,
1989), insulin inhibits the synthesis and secretion of apo B from rat hepatocytes (Patsch et 
al, 1983, Sparks et al, 1986) and oestrogens increase the synthesis of apo B in Hep G2 cells 
(Tam et al, 1986). Apo B100 may be partially lipidated cotranslationally during 
transmembrane transfer into the endoplasmic reticulum by a ‘pause transfer’ mechanism. 
The lipids at this stage of lipidation probably come from the inner leaflet of the 
endoplasmic membrane. A substantial fraction of newly synthesised apo B is degraded 
without being secreted, suggesting that lipidation may induce conformational changes to 
allow it to proceed to the second stage of lipidation (Thrift et al, 1992). Hamilton (1994) 
was one of the first to postulate that lipidation of apo B is a two step process. The first 
phase of which appears, at least in Hep G2 cells, to produce spherical particles that are
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approximately 22nm in diameter. These cells appear to lack the ability to carry out the next 
stage and consequently secrete LDL-like nascent particles (Tao et al, 1991, Spring et al
1992). The second phase seems to involve the coalescence of these small spherical 
particles with triglyceride-rich particles produced in the endoplasmic reticulum. 
Microsomal triglyceride transport protein (MTP), a heterodimeric protein that includes a 
protein disulphide isomerase subunit (Werrerau et al, 1992, Hamilton et al, 1993) appears 
to be involved in the first step and might also be involved in the formation of the 
triglyceride-rich droplets. The strongest evidence of MTP involvement comes from studies 
o f several cases of recessive abetalipoproteinaemia in which no apo B containing 
lipoproteins can be secreted from liver or intestine (Werrerau et al, 1992, Hamilton et al,
1993). In these subjects functional MTP activity is absent.
This two step approach to lipoprotein assembly suggests that the liver is capable of 
secreting particles with varying amounts of triglyceride and also apo B100 in different 
conformational states and of variable particle size. However there is still uncertainty about 
the precise mechanisms o f these events: is there an insulin-regulated step, is cholesteryl 
ester synthesis an obligatory requirement for the earliest stages of lipoprotein secretion and 
in its absence does apo B fail to assemble and be degraded, does apo B undergo incomplete 
translocation in endoplasmic reticulum and what is the pathway and regulation for 
mobilisation of triacylglycerol from intracellular storage and incorporation into VLDL? 
These topics have been reviewed recently by Pease & Leiper (1996).
1.3.5 Metabolism o f  Apo B Containing Lipoproteins
Fully lipidated VLDL is transported to the Golgi vesicles where glycosylation of the 
apoproteins proceeds before VLDL is transported to the plasma membrane and released 
into the space of Disse. Nascent VLDL isolated from the Golgi apparatus contains newly 
synthesised E and Cs. As soon as they emerge from the hepatocyte, exchanges take place 
with HDL: phospholipid to HDL mediated by phospholipid transfer protein (PLTP) 
(Tollefson et al, 1988; Malloy et al, 1994) and esterified cholesterol from HDL to VLDL 
mediated by CETP. Apoproteins C and E also associate with HDL and disassociate from 
VLDL. VLDL lipolysis takes place by LPL bound to capillary endothelium of skeletal and 
cardiac muscle and adipose tissue (fig. 1.3). Particles competing with chylomicrons have a 
higher affinity for the enzyme than VLDL. The presence of apoCII and CIII play opposing 
roles in the regulation of the rate hydrolysis of core triglycerides as apo CII is a cofactor 
(Eckel et al, 1989) whereas apo CIII has been shown to inhibit LPL activity (Wang et al, 
1985). In a study in subjects with apo CIII deficiency, Ginsberg et al (1986) observed a 
sevenfold increase in VLDL lipolysis.
In 1978 Berman et al showed that in studies with radioiodinated VLDL that apo B is 
transferred through a delipidation cascade to IDL and LDL. This concept was further 
elaborated to include the existence of VLDL-IDL-LDL delipidation parallel processing 
pathways as proposed by Fisher et al (1982). Fig.l Jt3 shows the enzymes, receptors and 
apoproteins involved in the progressive hydrolysis of core triglycerides and subsequent 
delipidation from VLDL to IDL to LDL.
VLDL! has two metabolic fates: first it is delipidated to VLDL2 and second, a substantial 
amount is removed directly from the circulation by an unknown process possibly involving 
receptor activity (discussed in section 1.4). Both appear to involve the action of LPL. In a
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study o f lipoprotein lipase deficiency, Demant et al (1991) observed a delay in the 
conversion o f VLDLi to VLDL2 as well as a 90% reduction in direct clearance o f VLDL! 
apo B. Remnants derived from VLDL] delipidation contribute to the apo B found in IDL 
and LDL but the conversion to these species is partial and inefficient (Demant et al, 1988, 
Packard et al, 1995). VLDL2 conversion to IDL and LDL does not depend on LPL as these 
steps were normal in LPL-deficient patients (Demant et al, 1991). In contrast, in hepatic 
lipase deficiency, VLDLj to VLDL2 and VLDL2 to IDL conversion is normal whereas there 
is a block on IDL to LDL conversion.
Fig. 1.3 Role o f  Enzym es and Receptors in Endogenous Lipoprotein Metabolism
(adapted from illustrations by Professor Packard).
VLDL very low density lipoprotein, IDL intermediate density lipoprotein, LDL low density 
lipoprotein, HDL high density lipoprotein, FFA free fatty acid R LDLreceptor, V-R VLDLreceptor, 
H-R HDL receptor, LRP LDL recptor related protein receptor (remnant receptor), S-R scavenger 
receptor, LpL lipoptotein lipase, HL hepatic lipase, CETP cholesterol ester transfer protein, LCA T 
lecithin cholesterol acyl transferase.
The surface components of the apo B containing lipoproteins change constantly, affecting 
the ability to interact with the various enzymes and receptors. During the course o f 
lipolysis, the C apolipoproteins are lost from the particle and so lipolysis by LPL becomes 
less efficient. Both apo B and E can potentially mediate cellular uptake and degradation 
by the LDL receptor. However it appears that these apoproteins are not always in a 
conformation appropriate for receptor binding. In normal subjects neither apo B or E on
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VLDL! are able to act as a ligand on the receptor but as lipolysis continues, their 
conformation alters towards a receptor-active state. In addition apo E acquired by 
exchange onto VLDL enhances the particle’s affinity for receptors. Thus it is possible to 
envisage a scheme where VLDL is removed by LDL receptor-related protein (LRP) or 
VLDL receptor via apo E and as lipolysis progresses the surface o f the particles alters 
facilitating removal by the classical LDL receptor (see section 1.4).
The circulating half life of LDL is approximately 2.5 days in normal humans. LDL is the 
major source of cholesterol for the maintenance o f cell membranes and also delivers 
tocopherol to the cells. Endocytosis of LDL via the LDL receptor for which apo B100 is 
the ligand accounts for about half of the uptake of LDL. Mutations in the LDL receptor in 
familial hypercholesterolaemia (FH) and in apo B100 in familial defective B 
lipoproteinaemia (FDB) lead to accumulation of LDL in plasma. LDL can also be taken up 
in all cells by non receptor mediated processes. Macrophages and transformed smooth 
muscle cells can endocytose chemically or physically modified LDL via a pair of 
structurally related scavenger receptors in a process that can lead to foam cell formation 
and atherosclerosis.
1.3.6 High Density Lipoprotein and Reverse Cholesterol Transport
HDL is the most malleable of lipoprotein species since all o f its components undergo rapid 
interparticle exchange. It is composed of a number of subspecies - pre beta HDL, HDL 2 
and HDL3, whose interconversions are governed by the exchange and lipolysis mechanisms 
among the apo B containing lipoproteins as well as by the action of the enzyme 
lecithin:cholesterol acyl transferase (LCAT). The role o f HDL is that of a cellular 
cholesterol acceptor which removes excess sterol from the cell surfaces and traps it in the 
form of cholesteryl ester and a gradient o f reverse cholesterol transport is maintained, 
mediated by cholesterol ester transfer protein (CETP), whereby HDL cholesteryl ester is 
transferred to apo B containing particles, which are subject to rapid uptake by the liver 
(Tall et al, 1990) (fig. 1.3). Pre-beta HDL is thought to play an important role in the 
initiation o f this centripetal transport pathway (von Eckardstein et al, 1994). Pre-beta HDL 
is a small sized HDL (about 60kDa), contains only Al and constitutes about 5% of normal 
HDL(Ishida et al, 1987, Kunitake et al, 1992). When plasma is exposed to cholesterol-rich 
cells in culture much of the sterol lost from the cell membrane is found initially in this 
fraction (Castro & Fielding, 1988). Apo Al is a cofactor for activity of LCAT and the 
action of the enzyme triggers a change in the disposition o f cholesterol within the particle. 
Transfer o f a fatty acid from lecithin to the hydroxyl residue on cholesterol leads to the 
generation o f lysolecithin, which dissociates readily from the lipoprotein into the aqueous 
environment and cholesteryl ester. Esterification of the sterol increases its hydrophobicity 
and causes it to partition into the nonpolar interior of the particle. The surface site vacated 
by the sterol is then available to accept additional cholesterol and the HDL increases in size 
(von Eckardstein et al, 1994). Acquisition of cholesterol proceeds until the nascent disc is 
fully transformed into a pseudomicellar spherical structure. CETP exchanges the 
cholesteryl ester in the core o f HDL for triglyceride acquired from chylomicrons or VLDL. 
The triglyceride-enriched HDL2 then becomes more susceptible to intravascular lipolysis 
by hepatic lipase which renders it smaller and denser until it becomes HDL3 (Patsch et al, 
1988). Thus the size o f circulating HDL depends on the balance between the opposing
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forces o f cholesterol reesterification, which increases particle size and lipolytic digestion, 
which decreases particle size. HDL3 is postulated to be converted back to HDL2 by the 
acquisition of phospholipid and free cholesterol shed from lipolysed chylomicrons and 
VLDL and the subsequent action of LCAT.
Recent studies have shown that mechanisms exist for regeneration of pre-beta HDL from 
mature HDL particles. James & Pometta (1994) have shown that when HDL is incubated 
with physiological concentrations o f VLDL and LDL in the presence of CETP there is 
dissociation o f up to one third of apo Al with restructuring of the remaining HDL. This apo 
Al is lipid free and its interaction with a cell surface or with redundant surface 
phospholipids, released during lipolysis of triglyceride-rich lipoproteins, is thought to lead 
to the formation of small pre-beta HDL (Hana & Yokoyama,1992, von Eckardstein et al, 
1994, Liang et al, 1994).
The validity of this exchange/lipolysis cycle in regulating HDL is demonstrated by 
examining the characteristics of HDL in a number o f deficiency states. LCAT deficiency 
is a recessive condition resulting from structural mutations in the LCAT gene and the 
manifestations are dependent on whether the deficiency is complete (classical LCAT 
deficiency) or partial (fish eye disease). Patients develop corneal opacities, anaemia and 
renal failure and are susceptible to premature coronary artery disease. The HDL levels are 
markedly reduced and apo Al levels are 25-30% of normal. There is a high proportion of 
pre-beta HDL and disc shaped larger particles are seen under electron microscopy (Torsvik 
et al, 1970, Soutar et al, 1982). Four different types of CETP genetic deficiency have been 
described in Japanese subjects. They have high levels of cholesterol-rich HDL2 and apo Al 
(Koizumi et al, 1985) and there is a gene dosage effect resulting in decreased levels of 
cholesteryl ester to triglyceride ratio in VLDL and IDL. In HL deficiency (Demant et al,
1988) HDL2 is the major if  not only HDL species and is enriched in triglyceride. Despite 
the increase HDL levels, some HL-deficient subjects have premature CHD. In 
abetalipoproteinaemia, where there are no triglyceride-rich lipoproteins to act as donors, 
HDL exists as mainly cholesteryl ester rich HDL2 (Deckelbaum et al, 1982). Studies in 
transgenic animals have shown that possession of apo Al, CIII and CETP genes is 
sufficient to cause expression of a high plasma triglyceride/low HDL phenotype in mice 
(Hayek et al, 1991). A number of genetic studies have shown that polymorphisms at the 
CETP (Kondo et al, 1994; Freeman et al, 1994) and AI/CIII/AIV and HL loci (Cohen et al, 
1994) can markedly influence HDL cholesterol levels.
1.4 Receptors in Lipoprotein Metabolism
The picture o f lipoprotein receptors drawn by Brown & Goldstein in 1986 has become 
more complicated with the appearance of several new receptors, particularly receptors of 
triglyceride-rich lipoproteins. The catabolism of these triglyceride-rich lipoproteins may be 
determined by the tissue distribution o f the functional receptor proteins. The LDL 
receptor, or the apo B/E receptor is mainly responsible for LDL catabolism mediated by 
LDL apo B100 and has been observed in all mammalian cells tested except erythrocytes 
(Brown & Goldstein, 1986). The LDL receptor-related protein (LRP) seems to bind mainly 
to chylomicron remnants through apo E and lipases and as the main organ of this 
catabolism, the liver expresses high levels of LRP. The VLDL receptor is most abundant 
in muscle and adipose tissue and may be important in the delivery of endogenous
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triglycerides carried in VLDL or IDL from the liver to places of fatty acid metabolism. The 
ligand binding to these three families of receptors is inhibited by the receptor-associated 
protein (RAP) (Mokuno et al, 1994) which may therefore play an important role in the 
regulation o f triglyceride-rich lipoprotein catabolism.
1.4.1 The LDL Receptor and its Ligands
Receptor-mediated removal of LDL and lipoprotein remnants occurs mostly via classical 
LDL receptors. The LDL receptor is a single transmembrane glycoprotein with molecular 
weight 164,000 daltons and its coding gene is localised on chromosome 19 (Schneider et 
al, 1982, Francke et al, 1984). The ligand binding domain is found in the 300 amino acid 
N-terminal segment, which consists of seven 40 amino acid repeat units, each of which is 
enriched in aspartate and glutamate residues arranged in a configuration that facilitates 
interaction with complementary arginine and lysine residues found on apo B and apo E 
(Mahley & Innerarity, 1983). The receptor therefore recognises and interacts with 
lipoprotein particles containing these proteins but with different affinities since apo E binds 
ten times more effectively than apo B, thus apo E containing lipoproteins (VLDL and IDL ) 
can be cleared very efficiently by this pathway. Cellular cholesterol content is the major 
regulator o f the synthesis o f LDL receptors and so the number o f LDL receptors 
synthesised decreases when the cholesterol content of the cell increases, and vice versa 
(Brown & Goldstein, 1986). The most important clinical implication of the LDL receptor 
relates to familial hypercholesterolaemia, an autosomal codominant genetic disorder in 
which the LDL receptor activity is decreased either because o f a reduced number of LDL 
receptors, or the formation of structurally altered LDL receptors. This leads to an elevation 
of serum cholesterol via accumulation of LDL particles in the circulation and is 
accompanied by the development of premature atherosclerosis. Recent observations that 
similar effects may result from mutations in its primary ligand, apo B100. The apo B 
arginine-to glutamine change at codon 3500 has become established as a cause of failure of 
binding of LDL to its receptor and consequent hypercholesterolaemia (Myant et al, 1993).
1.4.2 LDL Receptor Related Protein Receptor (LRP)
LRP has been described as an apo E binding protein (Beisiegel et al, 1989) and its potential 
role as a remnant receptor has been elucidated in several laboratories using (3-VLDL 
(Nykjaer et al, 1993) and human chylomicrons as ligands (Beisiegel et al, 1991). LRP 
interacts directly with apo E (Beisiegel et al, 1989), LPL (Nykajaer et al, 1993) and HL 
(Nykajaer et al, 1994). Like apo E, both lipases are heparin-binding proteins that can bind 
to cell-surface proteoglycans with high affinity. Using) heparanase-treated cells, Eisenberg 
et al (1992) demonstrated that the binding of LPL to heparan sulphate on the cell surface 
facilitated the transfer of lipoproteins to cellular receptors. Beisiegel (1995) has proposed a 
model in which first triglyceride-rich lipoprotein remnants containing apo E in a sufficient 
density bind to cell surface proteoglycans. Then they are presented to membrane receptors 
(probably LRP) which mediates internalisation o f the remnants.
In 1990, soon after the LRP sequence was published, Strickland et al and Kristensen et al 
identified it as the receptor for activated alpha2-macroglobulin. Other protease and protease 
inhibitor complexes are recognised by LRP as well as a group o f human rhinoviruses
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(Hofer et al, 1994) and tissue factor pathway inhibitor (Warshawssky et al, 1994). Studies 
on the distribution of LRP in human tissues have revealed its presence in various cell types, 
including hepatocytes, fibroblasts, neurons and monocyte-derived macrophages (Moestrup 
et al, 1992). In 1994 Bu et al confirmed the abundance of LRP in mammalian central 
neurons and on the basis of earlier studies on the presence of apo E in the brain they have 
proposed an important role for LRP in apo E metabolism in the brain. This is particularly 
interesting in light of the recently discovered connection between apo E and Alzheimer’s 
disease.
The induction of LRP during the differentiation of monocytes and macrophages (Watanabe 
et al, 1994) has opened up discussion on the role o f this receptor in the development of 
atherosclerotic plaques. The possible involvement of LRP in atherogenesis is supported by 
studies from Louma et al (1994) and Lupu et al (1994) who demonstrated that LRP was 
expressed not only in macrophages from early and advanced lesions but also in smooth 
muscle cells.
1.4.3 VLDL Receptor
In 1994, Shimano et al described a VLDL receptor in rabbits which is an LDL receptor-like 
protein that binds and internalises apo E-containing lipoproteins. In humans , the VLDL 
receptor gene has been characterised, sharing 96% homology with the rabbit (Sakai et al, 
1994) and has been assigned to chromosome 9 (Oka et al, 1994). VLDL receptor 
messenger RNA is most abundant in skeletal muscle, heart, kidney and brain (Oka et al, 
1994). In the rat, Jokinen et al (1994) have found no effect on fasting and refeeding but 
VLDL receptors were reduced by 80% in the skeletal muscle of hyperthyroid rats.
1.4.4 Scavenger Receptors
Scavenger receptors recognise chemically and biologically altered lipoproteins. Unlike 
LDL receptors, the expression of scavenger receptors is not dependent on cellular 
cholesterol content, which leads to the cholesterol accumulation in the macrophages 
(Goldstein et al, 1979). Lipid-loaded macrophages can be seen in the earliest lesions of 
atherosclerosis (Ross, 1986). Modified LDL particles extracted from the aorta (Hoff & 
Morton, 1987) differ from the normal lipoprotein by being more electronegative, like the 
artificially produced acetyl-LDL, which is avidly assimilated and deposited in macrophages 
(Goldstein et al, 1979). These cells exhibit on their membranes proteins that facilitate the 
rapid uptake of acetyl LDL to the extent of generating foam cells similar to those found in 
the atherosclerotic lesion. Because a wide variety o f negatively charged compounds can 
compete with acetyl-LDL for these receptors, they have become known as scavenger 
receptors (Brown et al, 1980). Steinberg et al (1989) have found that charge modified 
lipoproteins, in the form of oxidised LDL, compete with acetyl-LDL and cause foam cell 
formation. They concluded that modified lipoproteins may be the in vivo ligand for these 
scavenger receptors. Support for the hypothesis that oxidised LDL is important in the 
development o f atheromatous plaques comes from several lines o f evidence. Firstly, 
antibodies to oxidised LDL have shown its presence in atheromatous lesions and human 
fatty streaks(Haberland et al, 1988,Yla-Herttuala et al, 1989, 1991). Secondly, LDL 
isolated from atherosclerotic plaques is electronegative (Hoff & Morton, 1987, Yla- 
Herttuala et al, 1989) and produces foam cell transformation in vitro. Thirdly, when the
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drug probucol was administered to Watanabe rabbits, Carew et al (1987) observed that 
LDL uptake into atherosclerotic lesions fell by 65% compared to a group given lipid 
lowering drugs. This they attributed to the ability of probucol to scavenge free radicals and 
limit the rate of oxidation of LDL. The hypothesis concerning the pathophysiological 
importance of modified LDL as an atherogenic particle has been summarised by Steinberg 
et al (1989).
1.5 Structural Heterogeneity in Low Density Lipoprotein
Low density lipoprotein was once considered to be structurally and metabolically 
homogeneous but it is now known to comprise a heterogeneous spectrum of particles which 
differ in density, size and chemical composition. An increasing body o f evidence indicates 
that within this spectrum there are discrete physiochemical forms of LDL and that plasma 
concentrations and biochemical properties of these LDL subclasses may have physiological 
importance.
1.5.1 Historical Concept o f  Heterogeneity
In 1951, Lindgren, Elliot & Gofman were the first to show that it was possible to 
fractionate LDL into three subclasses by preparative ultracentrifugation in a fixed angle 
rotor. In 1969, Lingren et al showed that like the other lipoproteins, LDL (Sf 0-12) 
exhibited a range of flotation rates when subjected to centrifugation in a solvent of 
appropriate density. In particular they observed that the peak flotation rates were different 
in normal males and females. Early studies by Lee & Alaupovic (1970) used sequential 
ultracentrifugation and immunological techniques to demonstrate the presence of a series of 
LDL subfractions differing in composition and measurement of flotation rates were used by 
Hammond & Fisher (1971) to characterise a discrete series of LDL in subjects with 
hyperprebetalipoproteinaemia. The best characterised structural alteration was found in 
individuals with hypertriglyceridaemia (Fisher et al, 1983). Since then a variety of high 
resolution techniques such as density gradient ultracentrifugation and gradient gel 
electrophoresis have been employed to identify and characterise subfractions of particles 
along the LDL density spectrum. In 1982, Lee & Downs used density gradient 
ultracentrifugation to demonstrate compositional changes between LDL in normal males 
and females and in the same year Krauss & Burke identified multiple subclasses in normals 
using both density gradient ultracentrifugation and gradient gel electrophoresis. Of the 
many density gradient ultracentrifugation procedures in the literature, some isolate LDL 
first (Shen et al, 1981, Marzetta et al, 1986, Chapman et al, 1988) while others isolate the 
subtractions in a single spin directly from plasma (Lee & Alaupovic, 1986, Swinkles et al, 
1987, de Graaf et al, 1991).
The most commonly used technique of examining LDL heterogeneity is non denaturing gel 
electrophoresis, which determines particle size. Application of this technique to the 
analysis of LDL or plasma has confirmed the existence of multiple discrete subpopulations 
of LDL (Krauss & Burke, 1982, Nichols et al 1986, Campos et al, 1992a, 1992b, Williams 
et al, 1992b). The technique is suitable for large-scale clinical applications and has been 
used to examine the participants in the Framingham Offspring Study (McNamara et al, 
1987). Use of either lipid or protein staining makes it suitable for plasma or isolated LDL 
and no changes in pattern have been observed with freezing plasma at -80°C. Calibration
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can be a problem due to the lack of standards at 20nm but generally latex particles at 30 nm 
and high molecular weight markers have been used (Krauss & Burke, 1982) and in a few 
instances calibrated LDL standards (McNamara et al, 1987). Although LDL particle 
diameters calculated by this method correlate well with other methods of size measurement, 
there is a systematic bias towards larger molecular size with gel electrophoresis (Krauss & 
Blanche, 1992).
Pattern A Pattern B
28.2 24 .9  28.6 24 .6
Particle Size nm
Fig. 1.4 LDL Subclass Patterns A and B determined by gradient gel 
electrophoresis
(Adaptedfrom Austin & Krauss, 1986)
Solid bands are obtainedfrom densitometric tracing of gradient gel bands. The dotted lines are 
determined by mathematical modelling.
Austin & Krauss (1986) described a mathematical modelling technique which was used to 
facilitate the identification of LDL subclasses by separating the gradient gel electrophoresis 
curves into a series of Gaussian curves (fig. 1.4). They identified two distinct subclasses A 
and B in which A has a major peak with larger diameter >25.5 nm and B has, as the major 
component, particles of a smaller diameter. This classification is widely used and subjects 
are described as having LDL phenotype A or phenotype B, but has been criticised as not all 
gel scans fitted into these two categories. In a recent publication from the same laboratory 
(Krauss & Dreon, 1995) an intermediate subclass has been identified with a mean particle 
diameter o f 25.6-26.3 nm.
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1.5.2 Classification o f  LDL Subfractions
Application o f these techniques has revealed the existence o f many subfractions o f LDL in 
the density range 1.019-1.063 g/ml and care should be taken when reading the literature as 
there is no universal classification system and use o f the terms ‘large’, ‘buoyant’, ‘small’, 
'dense' refer to different species depending on the method o f isolation. Most investigators 
have attempted to remedy this and rationalise the number o f species identified. For 
example, Chapman et al (1988) in most recent publications from the same laboratory 
(Guerin et al, 1996) refer to five subfractions instead o f the original fifteen. Table 1.4 
shows classifications used by various laboratories.
Table 1.4 Classification o f  LDL Subfractions
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1.033-
1.040
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24.7-
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24.7
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0-4
dense 1.039-
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1.045
1.045-
1.049
IVa
IVb
1.050-
1.063
23.2-
24.2 
22 . 0 -
23.2
1.050-
1.063
1.049-
1.054
1.5.3 LDL Heterogeneity in Relation to Coronary Heart Disease
Several studies have shown the association between small dense LDL and coronary disease. 
In 1985 Crouse et al observed the presence o f a low molecular weight LDL isolated by
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sequential ultracentrifugation in 46 men with CAD and observed its association with serum 
triglyceride. Austin et al (1988a) determined the LDL particle size distribution (pattern A 
or B) in 109 subjects who had previous nonfatal myocardial infarction and in 121 healthy 
controls. There was a preponderance of pattern B associated with a three-fold risk of MI 
independent of gender, age or body weight, but dependent on HDL cholesterol and plasma 
triglyceride. Campos et al (1992b) analysed LDL particle size in 275 men with CAD and 
822 controls. CAD subjects had a decreased particle size which was dependent on serum 
triglyceride and HDL cholesterol and so was not an independent predictor of risk. In a 
study population of 100 women and 98 men undergoing elective diagnostic coronary 
angiography (Coresh et al, 1993), small LDL particles were associated with coronary 
disease independent of age, gender, smoking, diabetes, LDL cholesterol and HDL 
cholesterol but dependent on serum triglyceride levels. Tomvall et al (1991) measured 
LDL subfractions by density gradient ultracentrifugation in 36 post -MI patients and 14 
normolipidaemic controls. Dense LDL was more prevalent in CAD patients and the 
triglyceride content of both dense and light LDL was related most strongly to the 
progression of coronary atherosclerosis. The same group (Tomvall et al, 1993) showed 
that the number of apo B-containing particles and the concentration o f LDL triglyceride 
were related to the degree of coronary atherosclerosis and distinct stenosis measured by 
angiography in 64 young (<45 years) infarct patients. Very dense, triglyceride-rich 
particles and small cholesteryl ester -rich VLDL particles were also related to the severity 
of the disease.
Strong evidence for the increased atherogenicity of small dense LDL came from the 
Stanford Coronary Risk Intervention Program trial (SCRIP), a multifactorial risk reduction 
trial performed in 300 patients with angiographically verified coronary disease (Haskell et 
al, 1994). Most of the patients received a hypolipidaemic drug in addition to the 
consumption of an American Heart Association Step 2 diet. Patients with pattern A and B 
had similar disease at baseline and displayed comparable reductions in LDL concentration , 
but only in pattern B was progression of atherosclerosis reduced as measured by coronary 
angiography (Krauss et al, 1992). This outcome was also associated with a simultaneous 
decrease in serum triglyceride.
1.5.4 Determinants o f  LDL Subfraction Distribution 
Influences o f  Other Lipoproteins
Individuals with small dense LDL usually have increased levels o f plasma triglyceride, 
triglyceride-rich lipoproteins and low concentrations of HDL cholesterol (Austin et al, 
1990a). There is abounding evidence that plasma triglyceride has a significant effect on the 
properties of LDL subfractions (Deckelbaum et al, 1984, Swinkels et al, 1989, Campos et 
al, 1992a, 1992b, McNamara et al, 1992, Coresh et al, 1993, Stewart et al, 1993, Watson et 
al, 1994, Hokanson et al, 1995, Tan et al, 1995a). Nikkila et al (1994) showed that 
postprandial increment in serum triglyceride is enhanced in subjects with small dense LDL. 
Associations between LDL size and HDL cholesterol have been reported (McNamara et al, 
1987, Swinkels et al, 1989, Campos et al, 1992a, 1992b, McNamara et al, 1992, Coresh et 
al, 1993, Haffiier et al, 1993, Katzel et al, 1994, Nikkila et al, 1994). However as plasma 
triglyceride levels, HDL and LDL size are closely linked it is difficult to distinguish one 
from the other. In most studies LDL cholesterol has not been related to LDL size.
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The mechanism by which plasma triglyceride affects LDL subclass distribution and 
consequently particle size has been the focus o f many investigations. CETP, HL and LPL 
are the key factors responsible for the remodelling of circulating lipoproteins. Deckelbaum 
et al (1984) first suggested that neutral lipid transfer would be the mechanism determining 
LDL subfraction distribution. Lagrost et al (1994) have shown that CETP and HL are both 
important in this process. As the concentration of VLDL triglyceride increases, CETP- 
mediated transfer o f cholesteryl ester and triglyceride between LDL and VLDL is enhanced 
and so LDL becomes enriched in triglyceride. This triglyceride-rich LDL is a good 
substrate for HL which hydrolyses triglyceride in LDL so forming smaller and denser LDL 
particles. Differences between males and females observed by Tan et al (1995a) suggest 
that HL concentrations in the male range as well as plasma triglyceride >1 .3  mmol/1 are 
necessary to generate small LDL above lOOmg/lOOml.
Role o f  CETP
Plasma CETP is a glycoprotein and its main function is to transfer esterified cholesterol 
from HDL to VLDL/LDL in exchange for triglyceride : (Tall et al, 1990).
The activity of plasma CETP is regulated by several factors. Under physiological 
conditions the amount of acceptor lipoprotein has been shown to be the major determinant 
o f plasma CETP activity (Mann et al, 1991). In CETP deficient patients LDL consists of 
two populations of particles, one representing normal LDL in size, and another small dense 
LDL which is depleted in cholesteryl ester (Sakai et al, 1991). This natural experiment 
indicates the important part that CETP plays in regulating LDL size. In vitro studies have 
shown that CETP incubation with LDL and HDL results in an increase in particle size 
(Gambert et al, 1990, Lagrost et al, 1993).
Role o f  Hepatic Lipase and Lipoprotein Lipase
The main function of HL is to hydrolyse triglycerides in denser lipoproteins, such as IDL, 
LDL and HDL, and has a crucial role in the conversion of IDL to LDL as shown by 
Demant et al (1988) in enzyme deficient subjects. In HL deficiency LDL particles are large 
and triglyceride-rich (Auwerx et al, 1989). HL activity is lowered by oestrogens, 
hypothyroidism, and endurance training (Appelbaum et al, 1977, Kuusi et al, 1982a, 
Tikkanen et al, 1982a) and is increased with alcohol consumption, anabolic steroids, 
progestins, fibrates, smoking and thyroid hormones (Ehnholm et al, 1975, Tikkanen et al, 
1981, 1982b, Taskinen et al, 1982, Chen et al, 1989, Packard et al, 1993, Moriguichi et al,
1990).
Several studies have revealed the importance o f HL as a determinant of LDL subfraction 
distribution (Auwerx et al, 1989, Zambon et al, 1994, Jansen et al, 1994, Lagrost et al, 
1994, Watson et al, 1994, Tan et al, 1995). An inverse correlation between HL activity and 
LDL particle size being observed (Zambon et al, 1994, Jansen et al 1994, Watson et al,
1994) and Tan et al (1995a) suggested that HL concentrations >15 (pmol fatty acid/ml/h) 
are required to generate large amounts o f small dense LDL.
LPL is the rate limiting enzyme for the conversion of VLDLj into VLDL2. It does not 
have any direct action on LDL subfraction distribution but because it acts on its precursors 
it has an indirect impact. In LPL deficiency there is hypertriglyceridaemia and LDL
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particle size distribution changes towards smaller and denser particles if HL activity is 
normal.
Role o f  Apo E
In population studies serum cholesterol has been shown to progressively increase from 
homozygous E2/E2 phenotype to E4/E4 phenotype (Davignon et al, 1988), while one study 
(Wilson et al, 1994) has demonstrated the positive association between apo E4 allele and 
plasma triglyceride. Only a few studies have examined the relationship between apo E 
phenotype and LDL size with contradictory findings. No correlation was observed in 
normal healthy males (Zhao et al, 1993) and in subjects with CAD (Nikkila et al, 1994). In 
the Framingham study cohort (Schaefer et al, 1994) apo ^4phenotype was observed to be 
associated with small LDL and Nikkila et al (1996) have shown an association of E4/4 with 
small LDL in a survey of 40 and 70 year old men and women. Zhao et al (1993) have 
shown that LDL particle size is negatively correlated with plasma apo E content 
irrespective o f apo E phenotype. In this study triglyceride and apo E concentration were 
found to be the independent risk factors most closely associated with LDL size.
Gender
Premenopausal women usually have larger and less dense LDL particles than males of the 
same age, which is considered to be due to lower activity o f HL in women (McNamara et 
al, 1987, Swinkels et al, 1989, Williams et al, 1992, Watson et al, 1994, Tan et al, 1995a, 
Nikkila et al, 1996). Oestrogens decrease the activity of HL and postmenopausally, when 
ovaries no longer synthesise oestrogen, LDL subclass distribution is suggested to shift 
towards dense LDL (Tikkanen et al, 1982, Schaefer et al, 1983, McNamara et al, 1987, 
Campos et al, 1988) Austin et al,{ 1988) proposed a dominant role of inheritance for LDL 
pattern B and reported a reduced inheritance in women. Cross sectional studies have failed 
to find any increase o f small dense LDL in postmenopausal women (Campos et al, 1992a,
1993).
Body Weight
Campos et al (1991) found that small particles were associated with higher body mass 
index (BMI) and total body fat in men and women, with smaller size being associated with 
abdominal obesity in women. Serum triglyceride was elevated and HDL cholesterol was 
decreased in subjects with high waist-to-hip ratio. In contrast, no association was observed 
between LDL particle size in a cohort of Japanese men (Suehiro et al, 1995). Patients with 
small dense LDL had an increased waist to hip ratio as well as elevated concentrations of 
triglyceride and fasting serum insulin.
Weight loss is usually associated with an increase in particle size. Williams et al (1990) 
studied the effects of weight reduction by calorie restriction and by calorie expenditure on 
LDL subclasses in moderately overweight men and observed comparable increases in LDL 
particle diameter, decreases in masses of VLDL and small dense LDL. Men with pattern B 
were more resistant to effects of weight reduction.
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Exercise
Cross sectional studies have shown that subjects who train regularly have a larger average 
LDL particle size mainly due to a reduced amount of small dense LDL (Williams et al, 
1986, Lamon-Fava et al, 1989a, Berg et al, 1992). One longitudinal study (Williams et al,
1989) has shown that during exercise-induced loss of body mass there is a decrease in small 
LDL concentrations and an increase in LDL peak flotation rate. After an endurance 
triathlon, 7 out of 40 subjects had increased particle size related to an acute decrease in 
serum triglyceride (Lamon-Fava et al, 1989b). Baumstark et al (1993) investigated the 
effects of acute exercise on LDL subclasses and found an acute decrease in serum 
triglyceride and in the triglyceride content o f all subfractions. In those subjects with 
greatest reductions in triglyceride, there was a decrease in concentration of small dense 
LDL. Houmard et al (1994) observed an increase in molecular weight, particle size and 
total lipid content of LDL particles associated with a reduction in fat, plasma triglyceride 
and fasting plasma glucose in subjects who had undergone endurance exercise training.
Diet
A diet rich in carbohydrates is associated with increased levels'o f small, dense LDL 
(Campos et al 1991). The effect is mediated by serum triglyceride since excess intake of 
carbohydrates increases the influx of free fatty acids to the liver and increases the 
production of VLDL (Abbott et al, 1990). A diet rich in saturated fat on the other hand 
increased buoyant LDL in relation to an increase in LPL activity (Campos et al, 1995a). 
The decrease observed in small LDL was not associated with the changes in HL or LPL 
activities.
Dreon et al (1995) studied the effects of a reduced fat diet on LDL subclass density in 
association with the response to apo E phenotype in 105 healthy men. Subjects with E4 
allele showed the largest response which was a reduction due to a shift from buoyant LDL 
to small dense LDL. Krauss et al (1996) examined the responses in these subjects in 
relation to the distribution of LDL profile whether the subject exhibited pattern A or 
pattern B . On the low fat diet almost half o f pattern A subjects switched to pattern B; ie 
there was a shift in particle size from larger to smaller. On the other hand, subjects with B 
pattern showed greatest increases in large VLDL, greater decreases in HDL3 and greater 
reductions in LDL cholesterol, apo B, LDL II and LDL III concentrations. Suzukwa et al 
(1995) observed that fish oil supplementation increased LDL particle size with a decrease 
in serum triglyceride and an increase in LDL cholesterol, whereas com oil supplementation 
had no effect on these parameters.
Genetic Influences
The earliest report of genetic influences on LDL heterogeneity by Fisher et al, (1975) 
indicated that the molecular weight o f monodisperse LDL appeared to be inherited in 5 
families. Subsequently two large family studies, one in primarily healthy families and one 
in families with familial combined hyperlipidaemia have shown that the inheritance of LDL 
subclass phenotype B is consistent with the presence of a single major gene defect, based 
on complex segregation analysis (Austin et al, 1988b, Austin et al, 1990b). Phenotype B 
was found to be closely associated with increased levels o f triglyceride, apo B, mass of 
VLDL, mass of IDL and decreased HDL, HDL2 and apo AI. Austin et al (1990a) named
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this the atherogenic lipoprotein phenotype (ALP) a proposed genetic marker for CHD. The 
first study (Austin et al, 1988b) was based on 61 nuclear families in 29 kindreds obtained 
by community sample in San Francisco and the model providing the best fit to the family 
data was a single major locus model with a dominant mode of inheritance for the major 
gene. The allele frequency for the proposed phenotype B allele was estimated to be 0.25 
and the model included reduced penetrance in young males and premenpoausal females. 
When the same study population was analysed using the LDL peak diameter as a 
continuous variable ie adjusted for age and gender (Austin et al, 1993a,b) the mode of 
inheritance could not be distinguished. In the second study (Austin et al, 1990b), 7 large 
multigenerational kindreds with well-characterised familial combined hyperlipidaemia 
were used, including 250 individual family members. LDL subclass phenotype B was 
inherited in these families consistent with the presence of a single genetic locus and an 
additional multifactorial inheritance component. Similar to the results in the healthy 
families, the mode of inheritance for the major locus was either dominant or additive, and 
the allele frequency for phenotype B was estimated to be 0.3. Reduced penetrance was 
again found in males under 20 years and females under 50. Although segregation analysis 
is susceptible to ascertainment bias, the uniformity of these results in these two studies with 
different sampling schemes is striking. Complex segregation analysis performed in healthy 
Dutch families (de Graaf et al, 1992) have further strengthened the view of the inheritance 
of LDL distribution, the results suggesting a single gene effect with multifactorial 
inheritance, and additionally the penetrance of small dense LDL being dependent on age, 
gender, hormone use and menopausal status in women. These studies provide evidence for 
a single major gene effect on the inheritance of LDL subclass phenotypes.
Twins studies provide a different approach to detecting genetic influences and LDL 
subclasses were analysed in 348 women from the Kaiser Permanente Women Twins study 
(Austin et al, 1987). The heritability of LDL peak particle diameter was 0.54 based on the 
classical heritibality estimate and the within pair estimate was 0.48. The NHLBI (Lamon- 
Fava et al, 1991) study conducted in 250 male twin pairs in their seventies found a 
heritability estimate o f 0.52 for unadjusted LDL size and 0.39 when adjusted for BMI, 
alcohol consumption, smoking and physical activity.
Because o f the strong evidence for a major gene effect based on the studies described, a 
candidate gene approach (Lusus 1988) has been used in attempting to map the 
chromosomal location of the proposed locus controlling LDL subclass phenotypes. The 
first candidate examined was the apo B locus on chromosome 2, but linkage analysis 
showed strong evidence against linkage (La Belle et al, 1991, Austin, 1991). Nishna et al
(1992) found a significant linkage of LDL pattern B to the LDL receptor gene locus on 
chromosome 19, and moderate LOD scores between small LDL and the insulin receptor 
located on the short arm of chromosome 19. Rotter et al (1994) observed a significant 
linkage of LDL particle size with the LDL receptor gene among 260 members of 24 
kindreds in which the proband had coronary disease. In the same study the haplotypes at 
the apolipoprotein AI-CIII-AIV gene complex on chromosome 11, manganese superoxide 
dismutase locus on chromosome 6 and the CETP gene on chromosome 16 were found to be 
linked to LDL particle diameter. The AI-CIII-A IV cluster was found to be the main locus 
for familial combined hyperlipidaemia in seven families, characterised as having a 
preponderance of small LDL (Wojciechoeski et al, 1991).
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1.5.5 Properties o f  LDL Subfractions and Relationship to Coronary Heart Disease 
Oxidation o f LDL has been implicated in the formation of the fatty streak in the arterial 
intima (Steinberg et al, 1989) Oxidised LDL has diminished affinity for the classical LDL 
receptor and is more readily bound to the scavenger receptor in the macrophages thus 
loading them with cholesterol and initiating the formation of the foam cell. Several studies 
have shown that small dense LDL particles are more susceptible to oxidative modification 
in both normal individuals (de Graaf et al, 1991, Tribble et al, 1992) and in 
hypertriglyceridaemia (de Graaf et al, 1993, Chait et al, 1993) and combined 
hyperlipidaemia (Dejager et al, 1993). The prevention of oxidation of LDL using 
antioxidants is widely discussed at present as a promising antiatherogenic therapy (Witzum 
et al, 1993). oc-Tocdpherol or vitamin E is on a molar base the major antioxidant in LDL 
(Esterbaur et al, 1992) and a decreased content in small dense LDL is one possible 
explanation for its increased tendency to oxidative modification. However, Dejager et al
(1993) found that the oxidative susceptibility of LDL species was independent of vitamin 
E and could not be accounted for by enrichments in polyunsaturated fatty acids. Tribble et 
al (1993) observed greater susceptibility to oxidation of dense LDL when compared with 
buoyant LDL and related this to a reduced free cholesterol content and a 50% reduction in 
a-tocopherol content. In a later study Tribble et al (1995) observed an enhanced 
susceptibility to oxidation of the surface monolayer compared to the outer core in small 
dense LDL which may lead to the enhanced susceptibility of this species by external 
agents. This has physiological relevance and therapeutic implications depending on the 
oxidising conditions \in vivo. If  external oxidising agents are the predominant mediators of 
LDL oxidation in vivo , then the surface properties are important and the surface may then 
be the most appropriate site for intervention. Barbosa et al (1995) observed that heavy 
LDL was more susceptible to oxidation in patients with combined hyperlipidaemia 
compared to controls, hypercholesterolaemics and hypertriglyceridaemics. They also found 
that the sialic acid content was increased in heavy compared to light LDL in these subjects 
and neutral sugar content was reduced. This is in contrast to La Belle et al (1990) who 
observed reduced content o f neutral carbohydrates and sialic acid in small dense LDL. 
Sialic acid was observed to play a protective role against oxidation of heavy LDL in 
hypercholesterolemia and hypertriglyceridaemia but not in combined hyperlipidaemia 
where the sialic acid content was highest, the LDL was most susceptible to oxidation and 
desialition increased the resistance to oxidation
Orekhov et al (1989) demonstrated that the LDL from patients with CHD had a two to 
three-fold lower content of sialic acid and one and a half to two-fold lower content of 
neutral sugars (glucosamine, galactosamine, galactose, glucose) when compared to that of 
healthy subjects. Furthermore, a negative correlation was found between the capacity of 
LDL to stimulate intracellular lipid content [m vitro and its sialic acid content. The same 
group (Tertov et al, 1993) isolated a sialic acid poor subfraction in LDL and observed it 
caused an increased accumulation of cellular cholesterol when isolated from CHD patients 
when compared to controls. This LDL was found to be smaller and more dense than the 
sialic acid rich LDL fraction. This is in agreement with the La Belle & Krauss (1990) who 
found a lower sugar and sialic acid content in LDL isolated from subjects with a
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predominant B LDL phenotype. Filipovic et al (1979, 1988) have shown that desialiation 
o f LDL increases binding and uptake by fibroblasts. Taken together these findings suggest 
that desialiation may increase the atherogenicity of LDL.
LDL with low sialic acid content has shown an increased affinity to artery wall by forming 
insoluble complexes with negatively charged lipoprotein -complexing proteoglycan found 
in the artery wall (Camejo et al, 1976, Camejo et al, 1985, Avila et al, 1978). The 
atherosclerotic lesion is characterised by lipoprotein deposition and increased intimal 
proteoglycans. Proteoglycans are highly charged electronegative glycoproteins consisting 
of glycosaminoglycan chains covalently attached to a protein core through O or N- 
glycosidic linkages. These macromolecules influence the viscoelasticity and permeability 
o f arterial wall intima. There is general agreement that arterial wall proteoglycans play a 
key role in the development of atherosclerosis (Camejo et al, 1993). LDL isolated from 
post MI patients has been shown to have greater binding reactivity to arterial proteoglycans 
than normal subjects (Linden et al, 1989). Anber et al (1996) have shown that 
proteoglycan -LDL complex formation was significantly higher in subjects with ALP 
defined as LDL III concentration > lOOmg/lOOml. A recent study from Camejo’s 
laboratory (Wiklund et al, 1996) observed reductions in proteoglycan-LDL complex 
formation on treatment with gemfibrozil and/or pravastatin, the effect being greater on 
gemfibrozil. This fits in well with their earlier observations that purified large LDL 
particles have a lower affinity to proteoglycan than small dense LDL ( Hurt-Camejo et al, 
1990, Linden et al, 1989). Parks et al (1991) have suggested that proteoglycan binding 
may be related to E:B ratio in LDL. Reduced binding of large LDL to proteoglycans on 
fish oil feeding was related to decreased E content in this subfraction and may be due to 
conformational alterations on the particle surface.
Weisser et al (1993) examined the effects of purified LDL subclasses on Ca2+ content in
vascular smooth muscle cells cultured from rat aorta and found that dense LDL caused a
2+ 2+ more pronounced increase in Ca than the lighter LDL fraction. As Ca is an important
second messenger system involved in many processes leading to atherosclerosis ( Ross &
Glomset, 1976) this is another possible atherogenic mechanism o f small dense LDL.
Initiation of blood coagulation via the intrinsic pathway occurs when tissue factor (TF) is
exposed to plasma and the resulting factor VIIa-TF complex then proteolytically activates
factors IX and X (Osterund et al, 1977). Physiological regulation of this pathway is
mediated by a specific factor Xa-dependent inhibitor of the factor VIIa-TF complex known
as tissue factor pathway inhibitor (TFPI) (Broze et al, 1987). Lesnik et al (1993)
determined the distribution of TFPI among lipoprotein particles and found that it was
closely related to antithrombolytic activity which was primarily due to a preferential
interaction with small dense LDL, HDL3, VLDL and Lp(a). Small dense LDL provided the
most favourable surface structure for efficient TFPI binding and expression of its
anticoagulation activity.
Demuth et al (1996) have isolated a minor electronegative LDL with a higher sialic acid, 
apo CIII and apo E content. It has a higher proportion of dense particles than 
electropositive LDL and displayed enhanced cytotoxic effects on cultured human umbilical 
vein endothelial cells.
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1.5.6 LDL Receptor Binding and LDL Subfractions
Differences in the receptor-binding affinity of the various LDL subtractions have been 
reported, but the earliest results were inconsistent. This may be partially explained by the 
differences in the LDL subfractions isolated. In 1985, Witzum et al reported that large 
LDL is cleared more rapidly by the LDL receptor and in the same year Kleinman et al 
observed defective binding in vitro o f the small LDL from hypertriglyceridaemic subjects. 
On the other hand, Knight et al (1986) found that light and heavy LDL subfractions from a 
normolipidaemic subject bound with similar affinity to the LDL receptors of both cultured 
human fibroblasts and monocyte-derived macrophages and Swinkels et al (1987) found no 
differences to receptor binding or degradation of LDL1 (d 1.023-1.034 g/ml) or LDL2 (d 
1.036-1.041 g/ml) to LDL receptors on fibroblasts or Hep G2 cells. Since then there has 
been a general consensus o f opinion that large LDL is more rapidly removed by the LDL 
receptor. Jaakhola et al (1989), Nigon et al (1991) found that both light (d 1.031-1.037 
g/ml, d 1.0244-1.0297 g/ml respectively) and heavy (d 1.041-1.047 g/ml, d 1.0358-1.0435 
g/ml respectively) LDL subfractions had reduced affinity when compared with medium 
density LDL (d 1.037-1.041 g/ml, d 1.0297-1.0358 g/ml). These observations were 
confirmed in a recent report from the laboratory of Krauss. Campos et al (1996) examined 
receptor binding affinities of LDL (d 1.020-1.050 g/ml) isolated from subjects with 
predominantly large LDL (pattern A), predominantly small LDL (pattern B) and 
intermediate LDL pattern. They found a 16% reduction in binding affinity in pattern A and 
a 14% reduction in pattern B subjects when compared with the intermediate pattern. In the 
same report LDL I (d 1.026-1.032 g/ml), LDL II (d 1.032-1.038 g/ml) and LDL III (d 
1.038-1.050 g/ml) were isolated from individuals with pattern A and pattern B and binding 
affinities to LDL receptors measured. LDL II had similar binding affinities while affinity 
of LDL III was lower in both groups. Investigators using specific monoclonal antibodies to 
block LDL receptor binding domains on apo E and apo B have attributed these different 
binding affinities among the LDL species to conformational changes (Chen et al, 1994, 
Galeano et al, 1994, Campos et al, 1996).
1.6 Metabolic Heterogeneity of Low Density Lipoprotein
The earliest estimations of catabolism of iodinated proteins were carried out by calculating 
the urine:plasma ratios which gave an estimate of the daily catabolic potential of the protein 
injection of radioiodinated LDL (Berson & Yalow, 1954). There followed a series of 
studies on the kinetics o f LDL in which it was assumed that LDL was a homogeneous 
particle (Signurdsson et al, 1976, Packard et al, 1976, Bilheimer et al, 1979, Shepherd et 
al, 1980). At least two routes for LDL apo B catabolism were identified (Goldstein & 
Brown, 1972) one involving initial binding to the lipoprotein high affinity cell membrane 
receptors and the other occurring independently of this receptor mechanism. Comparison 
of the clearance rates o f native and chemically modified by cyclohexanedione LDL 
permitted an assessment o f the relative importance of the receptor and non-receptor 
pathways in vivo (Mahley et al, 1980). The fractional catabolic rate via the receptor 
pathway was calculated as the difference between the fractional catabolic rates of native 
LDL and cyclohexanedione modified LDL (Shepherd et al, 1979). Glycosylated LDL in 
which the lysine residues are blocked has also been used to measure receptor and receptor- 
independent LDL kinetics (Kesaniemi et al, 1983).
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It became more evident that the assumption of LDL homogeneity was invalid both from the 
measurement o f urine to plasma ratios of radioactivity and from growing evidence that 
LDL was structurally heterogeneous (Krauss & Burke, 1982). A number of studies took 
this into account when analysing the kinetics of LDL (Goebel et al, 1976, Malmendier et 
al, 1978, Wastney et al, 1982, Fisher et al, 1983), especially in hyperlipidaemic subjects 
(Fisher et al, 1980, Chait et al, 1986, Vega et al, 1986).
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Fig. 1.5 Foster’s A, B, C and D Models of LDL Kinetics
iv intravascular, ev extravasclar, U input. The plasma compartments are in the rectangles.
Model A has 1 plasma compartment, model B has 2 plasma compartments and 2 sited o f production, 
model C has 2 plasma compartments and 1 site o f input, model C is characterised by 3 plasma 
compartments and 1 site o f synthesis.
In 1986 Foster et al examined the effect of kinetic heterogeneity in the analysis of LDL apo 
B turnover and developed and tested four integrated kinetic models (fig. 1.5) which 
considered the heterogeneity of plasma LDL apo B and were consistent with the plasma 
and urine radioactivity data. The models were applied to studies in familial 
hypercholesterolaemia and familial combined hyperlipidaemia by Chait et al (1986). 
Model A assumed that LDL apo B was kinetically homogeneous and that degradation 
occurred only from the plasma compartment. To include urine data a compartment for 
whole body iodide was included which turned over at the rate of 2.5 pools/day. This model 
did not fit the data from all the individuals. Model B was characterised by two LDL apo B
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compartments, one of which was allowed extravascular exchange, and a body iodide 
compartment. This model was an extension of model A to allow for two heterogeneous 
pools of apo B LDL and was not improved by allowing both plasma compartments to 
exchange with an extravascular pool. This was compatible with all the data. Model C was 
a modification of model B and was similar to that proposed by Phair et al (1975) and used 
by Fisher et al (1980) to analyse LDL turnover in hypertriglyceridaemia. It included a 
pathway where one plasma compartment was the sole precursor for a second plasma 
compartment and the rates of removal from the two plasma compartments were identical. 
Not all individuals fitted this model as some required model B in which the rates of 
removal from the two plasma compartments were different. Model D tested the possibility 
that LDL apo B which returns from the extravascular compartment has different kinetics 
and was a radical departure from the traditional LDL apo B models. It required three 
plasma compartments and two extravascular pools but was compatible with the data. 
Different model configurations were devised to accommodate the complexity of LDL 
kinetics in different patient groups. Malmendier et al (1989a) developed a model for 
receptor and non receptor routes, each particle population having its own independent 
subsystem with their own production and catabolic rates. In a companion paper, 
Malmendier et al (1989b) the model was applied to describe the LDL kinetics in 
normocholesterolaemic volunteers at baseline and on treatment with simvastatin.
The most powerful tool that has been used in this area o f lipoprotein metabolism is the 
Simulation, Analysis And Modeling (SAAM) computer program generated by Berman & 
Weiss (1974). This package was originally devised to operate in a batch mode but is now 
available in an interactive version, CONS AM (Boston! et a l, 1982) and a windows based 
version (SAAM II). This form of the program has a conversational potential for 
interrogation, display, modification of the model and the solutions and for setting up and 
executing various modelling tasks. These modelling programs, given an observed data set 
and initial estimates, will alter the parameters in an iterative manner until they reach a 
minimum sum of squares for the residual differences between observed and calculated data. 
Multicompartmental modelling can be used for parameter estimation in complex metabolic 
pathways and is limited only by the quality and quantity of information contained in the 
data set. It also allows quantitative hypotheses to be generated and tested.
There have been very few studies designed to examine the kinetics o f individual LDL 
subfractions and to date investigators have concluded that the kinetics o f LDL is not simply 
a function of density. Teng et al (1986) examined the kinetics of ‘heavy’ LDL (mean 
density 1.048 g/ml) and Tight’ LDL (mean density 1.0405 g/ml) in normal volunteers and 
subjects with familial hypercholesterolaemia and hyperapobetalipoproteinaemia. In 
hyperapobetalipoproteinaemia there was an increased synthesis of light LDL with a normal 
conversion to heavy, whereas in FH there was a decreased conversion o f light to heavy and 
independent synthesis of heavy LDL. In 1986, Vega & Grundy examined two subfractions 
in normals and subjects with moderate and severe hypertriglyceridaemia. The densities of 
light and heavy LDL were not the same in all subjects but they found that more dense LDL 
had a higher catabolic rate than normal and in moderate hypertriglyceridaemia a similar 
picture was present. Thomson et al (1987) carried out turnovers of light and heavy LDL in 
FH and hyperapobetalipoproteinaemia and concluded that light LDL was a precursor of 
heavy LDL. In hyperbetalipoproteinaemia there was overproduction of both subfractions
31
whereas in FH the kinetics of the light fraction was normal and heavy LDL was 
independently synthesised.
The origin of LDL subclasses is likely to be remodelling of VLDL through neutral lipid 
exchange or as a result of delipidation. A seminal paper by Packard et al (1995) describes 
and defines the multicompartmental model that has been used in Glasgow in a number of 
dual radioactive label VLDL turnover studies. The model is complex but has been used to 
explain human apo B metabolism in all circumstances of primary and secondary hyper or 
dyslipoproteinaemia in which it has been employed, including moderate 
hypercholesterolaemia, FH, lipoprotein and hepatic lipase deficiencies, non insulin 
dependent diabetes mellitus, hypothyroidism, nephrotic dyslipidaemia and apo E2 and E4 
homozygosity. Following the administration of the radiolabelled tracer, transfer and 
catabolic rates can be determined by multicompartmental modelling analysis of the 
appearance and disappearance curves. Apo B derived from smaller VLDL particles 
(VLDL2) appears rapidly in LDL fraction and is cleared rapidly in a bi-exponential curve. 
On the other hand LDL apo B derived from large triglyceride-rich VLDLj was produced at 
a slower rate and the catabolism was slower and monoexponential. The interpretation for 
these differences in metabolism of large and small VLDL particles is that VLDL! gives 
rise to an LDL population whose affinity for receptors is relatively low and remains in the 
circulation for a longer time and VLDL2 contains not only VLDL r-derived lipoproteins but 
also those synthesised de novo by the liver. It is the latter fraction that is processed rapidly 
by the receptor pathway. When hepatic triglyceride levels are high (due to de novo 
synthesis or delivery of dietary lipid) large triglyceride-rich particles are formed which 
delipidate to smaller VLDL and slowly metabolised LDL. Conversely, when the liver has a 
reduced triglyceride load, smaller VLDL are made which give rise to rapidly metabolised 
LDL.
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1.7 Aims and Objectives
The aim in setting out on the work reported in this thesis was to investigate the structural 
and metabolic heterogeneity in LDL, to ascertain how important it might be in determining 
the properties of the lipoprotein and its involvement in the atherogenic process. The 
ultimate goal was to provide a quantitative description o f the important subfractions within 
LDL, their sources and their route of catabolism.
In pursuit o f this aim a number of objectives were set:
1) The development of a method to allow the quantitation in plasma o f LDL subfractions in 
both normal and hyperlipidaemic subjects.
2) Investigation of the perturbation of the LDL subfraction profile induced by lipid 
lowering drugs in order to determine both how the drugs affected the subfraction 
distribution and, because the mechanism of action in most cases was known, to reveal 
further features o f regulation o f the profile.
3) Development o f a method for quantifying the metabolic heterogeneity within LDL based 
on traditional LDL turnover methods to which multicompartmental modelling could be 
added as a technique for defining the behaviour of potential subspecies.
4) To understand the regulation o f metabolic heterogeneity within the lipoprotein in 
hyperlipidaemic subjects in the basal state and during treatment with the fibrate class of 
lipid lowering drugs.
5) To relate the results of structural and kinetic studies in a physiological model which 
describes the heterogeneity of LDL.
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Chapter 2 Materials and Methods
2.1 Materials
All reagents used were of analytical grade and the names and addresses of all suppliers are 
shown in appendix 1.
2.2 Lipid Analyses
Lipid analyses were carried out using enzymatic colorimetric assays. The final step was 
common to all i.e. the production of hydrogen peroxide which in the presence of the 
enzyme peroxidase, phenol and 4-aminophenazone produces the chromophore 4-(p- 
benzoquinone-mono-imino)-phenazone. Absorbance of this product was measured at 
505nm on a Hitachi 704 or 717 autoanalyser or the Encore chemistry centrifugal analyser 
from Baker Instruments or on a Beckman DU70 spectrophotometer or a Dynatech MR 
5000 Microtitre Plate Reader. Measurements were determined on potassium EDTA plasma 
(final concentration 1 mg/ml) or lipoprotein fractions. The salt concentration did not affect 
the analyses.
2.2.1 Cholesterol
Cholesterol was determined using a Boehringer kit (catalogue number 704121) in which 
the cholesterol esters in the sample were converted to cholesterol by cholesterol esterase. 
The enzyme cholesterol oxidase then oxidised all the cholesterol to form 4-cholestenone 
and hydrogen peroxide, the quantity of which was measured as described above. 
Cholesterol assays were standardised through the Center for Disease Control Cholesterol 
Reference Method Network. Coefficient o f variation was 1.6%.
2.2.2 Free Cholesterol
Free cholesterol was measured using Boehringer kit number 310328. The cholesterol 
esterase which was present in the cholesterol assay was omitted and so only free cholesterol 
present in the sample was measured by oxidation with cholesterol oxidase. Quality control 
was monitored with Precinorm and Precipath materials and coefficient of variation was 
4.3%.
2.2.3 Triglyceride
Triglyceride was determined using Boehringer kit number 704113. The first enzyme was 
lipase which converted the triglyceride into glycerol. Then, in the presence of ATP, 
glycerol kinase mediated the formation of glycerol-3-phosphate which was oxidised by the 
third enzyme, glycerol phosphate oxidase to form dihydroxyacetone phosphate and 
hydrogen peroxide, the quantity of which was analysed as above. Triglyceride assays were 
standardised through the Center for Disease Control Triglyceride Reference Method 
Network. Coefficient of variation was 2.1%.
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2.2.4 Phospholipid
Phospholipid was measured in lipoprotein fractions using an enzymatic colorimetric kit 
from Boehringer (catalogue number 691844). Phospholipase D converted the 
phospholipids to choline and phosphatidic acid and the second enzyme choline oxidase 
mediated the formation of betaine and hydrogen peroxide in the presence of oxygen. 
Quality control was monitored by using Precinorm and Precipath materials and coefficient 
of variation was 4.8%.
2.3 Protein and Apolipoprotein Assays
2.3.1 Protein
Protein measurements in the lipoprotein fractions and apolipoprotein B isolates were 
carried out by a modification of the method of Lowry et al (1951).
i) Reagents
a) Stock Reagents:
A 2% (w/v) Na2C 0 3 in 0. IN NaOH
B 2% (w/v) Na2C 0 3 in deionised H20
C 2% (w/v) NaK tartrate in deionised H20
D 1% (w/v) C uS04 in deionised H20
Folin - Ciocalteu Reagent (BDH)
b) Working Reagent:
Biuret reagent - To 100ml A (for lipoprotein fractions ) or B (for apolipoprotein B), 1ml 
each o f solutions C and D were added. If the samples were turbid (eg VLDL1 ) sodium 
dodecyl sulphate was added to A at a concentration of 1 mg/ml (Curry et al 1978).
ii) Standards:
a) Stock Standard
Human serum albumin (fraction V, Sigm a) at a concentration of lm g per ml was stored at 
-70 °C. A fresh aliquot was thawed immediately prior to use.
b) Working Standards
A working standard curve in the range 0-500pg/ml was prepared in duplicate by pipetting 
0-50pl stock standard. When analysing apoB, 100pi of 2N NaOH was also added. The 
final volume of the standard curve was made up to 400pi with deionised H20 .
Hi) Samples
a) Lipoprotein fractions
Appropriate aliquots of each fraction were taken and the final volume was adjusted to 
400pl with deionised H20 . Typical volumes taken were: 200pl VLDL1, lOOpl VLDL2, 
50pl IDL, 25pl LDL (Sf 0-12) and lOpl LDL (d 1.019-1.063 g/ml).
iv) Quality Control
Aliquots o f bovine serum albumin (fraction V, Sigma ) at 15 pg/lOOpl and at 30 pg/lOOpl 
were stored at -70°C. Fresh aliquots were used in each assay, the final volume of 400pl 
being reached by the addition of lOOpl 2N NaOH and 200 pi deionised H20  or 300 pi 
deionised H20 , depending on which kind of sample was being analysed.
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v) Procedure
a) Two mis of working biuret reagent was added to 400pl standard, control or sample, 
mixed and allowed to stand at room temperature for 10 minutes.
b) 200pl working Folin’s reagent (diluted 1:1 with deionised H20 )  was added and mixed 
immediately.
c) Absorbances were read at 750nm on Beckman DU70 spectrophotometer after 30 minutes 
and within 2hours and a straight line standard curve was obtained.
d) Unknown values were read from a standard curve drawn on graph paper and latterly 
these unknown values were calculated by linear regession.
vi) Precision o f  the Assay
The within batch coefficient o f variation was 1.9% and between batch was 2.4%.
2.3.2 Apolipoprotein A l
Apolipoprotein Al in plasma was quantified by immunonephelometry using a kit 
(catalogue number 67265) from Orion Diagnostics. The extent o f immunoprecipitation 
was measured at 292nm on the Encore clinical chemistry centrifugal analyser (Baker 
Instruments). In conditions of antibody excess, the amount of precipitant is proportional to 
the apoprotein concentration. The sensitivity of the assay was 0.3 g/1 and the coefficient of 
variation 5%. The quality control was monitored using lyophilised material from Immuno 
and Behring.
2.3.3 Apolipoprotein A ll
Apolipoprotein All in plasma was quantified by immunonephelometry using a kit ( 
catalogue number 67356) from Orion Diagnostics. Immunoprecipitation was measured at 
292nm on the Encore clinical chemistry centrifugal analyser (Baker Instruments). The 
sensitivity of the assay was 0.3 g/1 with a coefficient of variation o f 5%. Quality control 
was monitored using lyophilised material from Immuno and Behring.
2.3.4 Apolipoprotein B
Apolipoprotein B in plasma was quantified by immunonephelometry using a kit (catalogue 
number 67249 ) from Orion Diagnostics. Immunoprecipitation was again measured at 
292nm on the Encore clinical chemistry centrifugal analyser. The sensitivity of the assay 
was 0.3 g/1 and coefficient of variation 5%. Quality control was monitored using 
lyophilised materials from Immuno and Behring.
2.3.5 Lipoprotein (a)
Lipoprotein (a) (Lp(a)) in plasma and lipoprotein fractions was measured using the Innotest 
(Innogenetics) enzyme linked immunosorbent assay (ELISA). The wells of the polystyrene 
microplate were coated with a mouse monoclonal anti-Lp(a). A standard curve from 0 - 
lOOmg/dl or diluted sample bound to this solid-phase antibody and unbound substances 
were removed by washing. The second antibody, a sheep polyclonal anti-apo B labelled 
with the enzyme horseradish peroxidase, was added and bound to the retained Lp(a) due to 
the apo B moiety. Incubation with substrate produced a blue colour which turned yellow 
when the reaction was stopped with sulphuric acid. The amount o f colour produced was
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proportional to the amount of Lp(a) originally present in the sample or standard. Samples 
were stored at -70°C and thawed immediately prior to assay.
The assay was carried out in duplicate and read at absorbance 450nm using a Dynatech 
MR 5000 Microtitre Plate Reader. The sensitivity of the assay was 2mg/dl in diluted 
samples and concentrations as low as 0.001 mg/dl could be detected in undiluted samples. 
The between batch precision of the assay was 12% and quality control monitored using in- 
house frozen plasma and lyophilised material from Innogenetics.
2.3.6 Apolipoprotein E Phenotyping
Apo E phenotypes were determined by isoelectric focussing followed by Western blotting 
using an adaptation of the method of Havekes et al (1987).
i) Delipidation
Ten pi of plasma was first incubated for 30 minutes at 37°C with 28.5 mU neuraminidase 
(EC 3.2.1.18 from Clostridium Perfinges Type X, Sigma) in 0.02M acetate buffer, pH5.1, 
then delipidated overnight at 4°C with ethanol:ether (3:l,v/v), followed by an overnight 
incubation in ether. The resultant precipitate was dissolved in 200pl 0.1M Tris,6M 
urea,l%(w/v) SDS, pH 10.0 to which lOpl p-mercaptoethanol was added.
ii) Isoelectric focussing
Thirty pi o f sample was applied to a vertical slab gel o f 5% polyacrylamide in 8M urea 
containing l%(v/v) ampholines pH 4-6 (Serva). Electrophoresis was carried in a Hoefer 
SE 600 tank (Pharmacia) at 250 volts, 12mA per gel at room temperature overnight with 
water cooling. The upper buffer was 0.08% NaOH (w/v), pH 10.1 and lower buffer 0.1M 
sodium phosphate, pH 2.3
iii) Transfer to Nitrocellulose
Transfer from the acrylamide gel to nitrocellulose was performed as described by Towbin 
et al (1979). This was carried out at room temperature with water cooling at 100 volts for 3 
hours in 0.2M glycine, 0.02M Tris, 20%.(v/v) methanol, pH 9.0 in a Biorad transblot cell.
iv) Immuno staining
a) The nitrocellulose strip was first soaked in wash buffer (0.01M Tris, 0.05% (v/v) Tween 
20, 0.15M NaCl, pH 7.4) containing 5% (w/v) milk powder (Marvel) as a blocking agent 
and then the strip was washed for‘20 minutes with 3 changes of buffer. Incubation with the 
first antibody (mouse monoclonal anti-apoE) was overnight at room temperature with slow 
regular shaking. The strip was washed for 20 minutes and incubated with the second 
antibody (goat anti-mouse horse radish peroxidase conjugate) for 2 hours at room 
temperature. After washing a blue colour was developed by the addition of 4-chloro- 
napthol and peroxide in 0.15M saline. Apo E isoforms were identified by reading against a 
known apo E2/E2 phenotype.
2.4 Lipoproteins
2.4.1 p Quantification
Plasma VLDL cholesterol, LDL cholesterol and HDL cholesterol were analysed according 
to the Lipid Research Clinics Program Manual of Laboratory Operations (1975). VLDL (d
1.006 g/ml) was isolated by ultracentrifugation at 35,000rpm (110,000g) in a Beckman Ti
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50.2 rotor at 4° C for 18 hours. The apo B containing lipoproteins in the infranatant were 
precipitated by the addition o f an equal volume o f sodium heparin (SxlO'^unitsj/Mn Cl2 
(0.092M) (Warnick & Albers, 1978), followed by centrifugation at 10,000 rpm at 4°C for 
30 min. This left HDL in solution and cholesterol measurements were carried out on total 
plasma, VLDL and HDL. LDL cholesterol was obtained by subtracting the HDL level 
from the cholesterol content in the d >1.006 g/ml infranatant.
2.4.2 Isolation o f  VLDL,(Sf 60-400), VLDL2(Sf  20-60), IDL(Sf  12-20) ,LDL(Sf 0-12)
VLDL,, VLDL2, IDL and LDL were isolated from plasma by a modification o f the 
cumulative ultracentrifugation density gradient technique described by Lindgren et al 
(1972). Density solutions were prepared from stock solutions at d 1.006g/ml and d 1.182 
g/ml o f NaBr in 0.195M NaCl, 0.001% Na2EDTA. The densities were measured to 3 
decimal places in a Paar Scientific density meter (model DMA 35).
The density o f 2ml o f plasma was adjusted to d 1.118 g/ml by the addition o f 0.341 g NaCl 
and this was carefully layered over a cushion o f 0.5 ml d 1.182 g/ml solution in an 
ultraclear Beckman SW 40 ultracentrifuge tube which had been coated with polyvinyl 
alcohol (Holmquist,1982). This allowed the solutions to gravity feed down the side o f the 
tubes smoothly without disturbing the formation o f the gradient. A discontinuous gradient 
was formed by overlayering with d 1.0988 g/ml (1ml), d 1.0860 g/ml (1ml), d 1.0790 g/ml 
(2ml), d 1.0722 g/ml (2ml), d 1.0641 g/ml (2ml), d 1.0588 g/ml (2ml). Centrifugation was 
carried out in a Beckman SW 40 rotor at 23°C in a Beckman L8 ultracentrifuge for the 
times and speeds given in table 2.1. Rotors were decelerated without the brake. Fractions 
were removed from the top o f the tube using a finely drawn glass Pasteur pipette.
Table 2.1 Centrifugation Conditions fo r  VLDL-LDL Isolation
VLDL, 39,000 lh  38min 1.0 *
v l d l 2 18,500 15h 41min 0.5
IDL 39,000 2h 35min 0.5
LDL 30,000 21 h lOmin 1.0
*] ml removed and overlayered with 1 ml d  1.0588 g/ml density solution
2.4.3 Preparation o f  LDL(SjO-12)
LDL (Sf 0-12) for the LDL turnover protocol described in chapter 2.6 was isolated using 
solutions and materials which were sterile and equipment that was autoclaved before use. 
In addition, solutions were filtered through Amicon 0.22mp filters prior to use. LDL was 
prepared by cumulative density ultracentrifugation as described in section 2.4.2 with a few- 
minor alterations. 13 mis o f fasting K2EDTA plasma was adjusted to d 1.118 g/ml by the
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addition of 2.2165g NaCl and overlayered with NaBr solutions d 1.0988-1.0588 g/ml as 
described above. VLDL1? VLDL2 and IDL were centrifuged to the top of the tube at 
40,000 rpm for 7h 22min and 1 ml removed. After a further spin at 23°C and 34,000 rpm 
for 16 h 29 min, LDL was harvested in 1.0 ml from each tube and pooled to yield 6 ml 
LDL solution.
2.4.4 Preparation o f  LDL by Zonal Ultracentrifugation
LDL for the turnovers described in chapters 5 and 6 was isolated from plasma (within 3 h 
o f venepuncture) by the rate-zonal ultracentrifugation technique described by Patsch et al 
(1974). All solutions and materials were prepared under sterile conditions and equipment 
was autoclaved before use. In addition the solutions were filtered through Amicon 0.22mp 
filters. The density solutions d 1.0-1.3 g/ml were prepared in 0.1M Tris-0.01%(w/v) 
Na2EDTA, pH 7.6 by the addition of NaBr and densities checked using a hydrometer at 20 
°C.
A linear gradient of d 1.0-1.3 g/ml was formed in a Beckman Ti 14 zonal rotor spinning at 
3,500 rpm (capacity 665ml) using the Beckman rotating seal assembly, a gradient mixer 
(1130 LKB Ultragrad) and a peristaltic pump (LKB). The density o f 50 ml fasting K2 
EDTA plasma was raised to 1.3 g/ml by the addition o f 15 g NaBr and carefully loaded 
onto the outside of the gradient. This was followed by a cushion of 25 mis of d 1.3 g/ml to 
ensure that all the plasma was transferred into the rotor and was not adhering to the wall of 
the rotor. The loading head assembly was removed and the rotor was capped. After 
centrifugation at 45,000 rpm for 140 minutes at 10°C, the rotor was unloaded at 3,500 rpm 
by pumping density 1.3 g/ml solution through the peripheral line of the loading head. The 
eluate was monitored at OD 280nm by a Type 6 Optical Unit connected to a Model U-A 
Absorbance Monitor (Isco Instrument Specialities Co.) and collected into 14 ml fractions. 
The one or two fractions containing the peak of LDL were pooled.
The development of a zonal ultracentrifugation method for the separation of individual 
LDL subfractions was carried out in a Beckman Ti 15 zonal rotor which had a capacity of 
1665mls. Procedures for loading and unloading the gradients were similar to those 
described above. Variations o f a step wise gradient were tried as well as different 
ultracentrifugation times as will be discussed in chapter 3.
2.4.5 Isolation o f  VLDL, IDL and LDL by Sequential Flotation Ultracentrifugation 
VLDL (d 1.006 g/ml), IDL (d 1.006-1.019 g/ml), LDL (d 1.019-1.063 g/ml) and HDL (d 
1.063-1.21 g/ml) were isolated according to the method of Havel et al (1955). The density 
solutions were prepared from stock solutions at d 1.006 g/ml, d 1.182 g/ml and d 1.478 
g/ml of NaBr in 0.195M NaCl, 0.001% Na2EDTA. Densities were measured to 3 decimal 
places in a Paar Scientific density meter.
4 ml of plasma was overlayered with 2 ml density 1.006 solution and centrifuged in a 
Beckman Ti 50.3 rotor at 39,000 rpm or a Beckman Ti 50.2 rotor at 35,000 rpm for 18 
hours at 15°C. The top 2ml containing VLDL was aspirated using a finely drawn glass 
Pasteur pipette. The remaining 4 ml was adjusted to d 1.019 g/ml by the addition of 0.32 
ml d 1.182 g/ml solution and overlayered with 1.68 ml d 1.019 solution. After an overnight 
centrifugation (18 h, 15°C), IDL was removed in the top 2 ml. The infranatant (4ml) was
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adjusted to d 1.063 g/ml by the addition of 1.47 ml d 1.182 g/ml solution and overlayered 
with solution at d 1.063 g/ml. After an overnight centrifugation (18 h, 15°C), LDL was 
harvested in the top 2ml.
2.4.6 Compositional Analysis o f  Lipoproteins
The major components contributing to the total mass of lipoprotein in mg/dl in each 
fraction are triglyceride, free cholesterol, cholesteryl ester, phospholipid and protein. The 
analyses of these have been described in sections 2.3 and 2.4.1. However, the masses of 
triglyceride and cholesterol need to be converted to mg/dl by multiplying the molar 
concentrations by 88.6 and 38.7 respectively. The mass of cholesteryl esters was calculated 
as the difference between total cholesterol and free cholesterol which was multiplied by 
1.68 to correct for the mass of the esters. The contribution of each component to the total 
lipoprotein mass was then calculated by dividing their respective masses by their combined 
masses and was expressed as percentages.
2.4.7 HDL Subfractions by Analytical Ultracentrifugation
The masses o f protein in HDL2 and HDL3 were measured by analytical ultracentrifugation 
in a Beckman model L8-70 equipped with an ultraviolet scanning attachment using a 
Beckman ANF rotor ( Shepherd et al, 1984). 2 ml of plasma were adjusted to d 1.21 g/ml 
by the addition of 4 ml d 1.31 g/ml solution and total lipoproteins were prepared by 
centrifugation for 48 h at 39,000rpm and 4°C in a Beckman 50.3 rotor in a Beckman L7 
ultracentrifuge. One ml was harvested from the top o f the tube and the sample was diluted 
with d 1.20 g/ml so that during the analytical centrifugation run the total absorbance at 280 
nm did not exceed 1.0. A microcomputer was used to control the centrifuge and it 
triggered the scanner after a defined centrifugal force had been applied to the sample. 
During centrifugation, flotation of the lipoprotein was monitored by changes in the 
absorbance recorded in the analytical cell. Under these conditions HDL was buoyant and 
so absorbance at the periphery of the cell decreased progressively and centripetally as the 
lipoproteins floated in the gravitational field. The rate at which they moved was a function 
of their density. The absorbance change in the flotation interval (F1-2) 0-3.5 was due to 
HDL3 and F 1-2 of 3.5-9 was due to HDL2. (FI .2 is the negative sedimentation coefficient in 
Svedbergs of the lipoprotein at d 1.20 g/ml and 26°C). The masses of the HDL 
subtractions were expressed in mg/dl plasma.
2.4.8 LDL Subfractions by Gradient Gel Electrophoresis
The particle size distribution of LDL was examined by non-denaturing gradient gel 
electrophoresis as described by Nichols et al (1986). Electrophoresis was performed using 
commercially available polyacrylamide slab gels containing a linear gradient of 2-16% 
acrylamide (PAA 2/16, Pharmacia). The buffer system used within the electrophoersis 
apparatus (GE-4, Pharmacia) was 0.01M Tris, 0.08M boric acid, 2.5mM EDTA, pH 8.3. 
The gels were pre-equilibrated for 20 minutes at 70 volts. Samples of LDL (d 1.019-1.063 
g/ml) were mixed in a 2:1 ratio with tracking dye made up o f 4 g sucrose and lmg 
bromophenol blue in 10 ml of electrophoresis buffer. Approximately 5-10 pi of sample 
containing 5-10pg of protein was applied to the top of the gel and electrophoresed at 20
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volts for 20 minutes, 70 volts for 30 minutes and finally 120 volts for 24 hours. A high 
molecular weight marker (HMW, Pharmacia), containing thyroglobin (radius 8.5 nm), 
apoferritin (6.1 nm), lactate dehydrogenase (4.08 nm) and bovine serum albumin (3.55 nm), 
and a suspension of latex beads (diameter 38 nm, Dow Chemicals) were used to estimate 
the relative migration (Rf) rates of each band. Gels were fixed in 10% (w/v) 
sulphosalicyclic acid for 30 minutes, stained with 0.1% (w/v) Coomassie Brilliant Blue 250 
(Bio-Rad Laboratories) in methanol:acetic acid:water (4:1:5, v/v/v) for 1 hour and 
destained in 7.5% (v/v) acetic acid. The gels were scanned by computer assisted video 
densitometry in a Bio-Rad Model 620 Video Densitometer (Bio-Rad Laboratories). LDL 
size was calculated with reference to the R f values of the high molecular weight markers.
2.4.9 LDL Subfraction Analysis by Density Gradient Ultracentrifugation 
A discontinuous salt gradient was devised which permitted isoltation o f LDL subtractions 
directly from plasma within 24 hours (Griffin et al, 1990). The density solutions were 
prepared from stock solutions at d 1.006 g/ml and d 1.182 g/ml o f NaBr in 0.195M NaCl, 
0.001% (w/v) Na2EDTA. The densities were measured to 3 decimal places in a Paar 
Scientific digital densitometer.
The density of 3 ml plasma was adjusted to 1.09 g/ml by the addition of 0.38 g KBr and 
this was carefully layered over a cushion of 0.5 ml d 1.182 solution in an ultraclear 
Beckman SW 40 ultracentrifuge tube which had been coated with polyvinyl aclohol 
(Holmquist et al, 1982). This allowed the solutions to gravity feed down the side o f the 
tubes smoothly without disturbing the formation of the gradient. A discontinuous gradient 
was formed by overlayering with d 1.060 g/ml (1ml), d 1.056 g/ml (1ml), d 1.045 g/ml 
(lm l), d 1.034 g/ml (2ml), d 1.024 g/ml (2ml), d 1.019 g/ml (1ml). Centifugation was 
carried out in a Beckman SW40 rotor at 23°C using a Beckman L8 ultracentrifuge. The 
rotor was accelerated to 170rpm over 4 minutes, centrifuged at 40,000rpm for 24 hours and 
decelerated without using the brake. The gradient containing the separated LDL 
subfractions was displaced upwards by a dense, hydrophobic material (Maxidens, 1.9g/ml, 
Nyegaard Ltd) which was introduced using a constant infusion pump (Sage Instruments, 
Orion Research Inc, USA) at a flow rate of 0.69 ml/min. The eluate was continuously 
monitored at 280nm and, if  required, 0.3 ml fractions were collected using a Gilson fraction 
collector. At first the apparatus used for piercing and holding the ultracentrifuge tube in 
place was made from perspex by the Medical Physics Department at GRI and was a similar 
design to that described by Groot et al (1982). This was replaced by the density 
fractionation system from Beckman. Originally, the protein content o f the eluate was 
monitored by passing through a UV detector (MSE, Fisons) and recorded with a Chessel 
chart recorder. This caused difficulties in interpretation of the LDL profile and was 
replaced by a Beckman DU70 spectrophotmeter integrated with the Data Leader 
programme (Beckman). The procedure generated LDL subfraction profiles (fig. 2.1) from 
which it was possible to resolve three subfractions that corresponded in size and density to 
those described by Krauss et al (1981), namely LDL I (d 1.025-1.034 g/ml), LDL II (d 
1.034 - 1.044 g/ml) and LDL III (d 1.044-1.060 g/ml). The percentage areas under the 
curve for each individual subfraction was then quantified (Data Graphics, Beckman) and 
corrected for differential absorption characteristics of total lipoproteins using previously 
determined extinction coefficients. For LDL I this was 2.63, for LDL II it was 2.94 and for
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LDL III it was 1.96. This was recalculated as a percentage of total LDL (d 1.019-1.063 
g/ml) mass and was expressed in concentrations in milligrams of lipoprotein per 100ml of 
plasma. Within rotor coefficient of variation for LDL I-III concentrations was 5.4% and 
between rotors 6.5% for replicate analysis of the same plasma sample.
LDL I LDL II LDL III
1.025 1.034 1.044
D ensity  (g/ml)
1.060
Fig.2.1 LDL Subfraction Profiles
Typical LDL subfraction profiles in two subjects showing 3 fractions, LDL I, LDL II and LDL III.
2.5 Electron microscopy
The sizes of LDL (d 1.019 - 1.063 g/ml) and LDL I, LDL II and LDL III subfractions 
isolated from normal volunteers was estimated by negative contrast electron microscopy. 
The fractions, at a concentration of 0.25-0.5 mg/ml o f protein, were exhaustively dialysed 
against a volatile buffer consisting of 0.125 M ammonium acetate, 2.6 mM ammonium 
carbonate, 0.26 mM tetra sodium EDTA, pH 7.4 and then mixed with the negative stain 
phosphotungstate at pH 7.0 (Forte et al, 1986) immediately prior to examination and 
photography on Formvar-coated grids in a transmission electron microscope at a 
magnification o f x29,000 (courtesy of Mr Jim Aitken, Department o f Virology, Glasgow
42
University). The diameters of 100 randomly selected lipoprotein particles were determined 
from the images.
2.6 LDL Turnover Protocols
2.6.1 LDL Preparation
After a 14 h fast 50 ml K2 EDTA plasma was obtained from each subject. For studies in 
normals (Chapter 5) and subjects with moderate hypercholesterolaemia (Chapter 6) LDL 
was prepared by rate zonal ultracentrifugation as described in section 2.4.4. For the 
turnovers in subjects with moderate hypertriglyceridaemia (Chapter 7) LDL (Sf 0-12) was 
prepared by cumulative ultracentrifugation as described in section 2.4.3.
LDL prepared by zonal ultracentrifugation was concentrated to approximately 1 mg/ml and 
dialysed against 0.15M NaCl, 0.01% Na2EDTA (w/v), pH 8.1 using N2 pressure filtration 
through an Amicon XM100 A cellulose membrane.
The LDL prepared by cumulative ultracentrifugation was passed through a lx l0cm  column 
of Sephadex G-25 (PD 10 column, Pharmacia) using 0.15M NaCl, 0.01% Na2EDTA (w/v), 
pH 8.1 as the eluting buffer. This removed the high salt content. All solutions were 
prepared using sterile water and filtered through 0.22mp Amicon filters and all 
consumables and equipment which would come into contact with the preparation were 
sterilised by autoclaving.
An approximate protein concentration was calculated by measuring the absorbance of the 
LDL at 280nm and assuming a specific extinction coefficient of 1.0.
2.6.2 Labelling o f  LDL
125 131Radiolabelling o f LDL with either reductant-free Na I or Na I ( Amersham) was 
carried out by the iodine monochloride method of McFarlane as modified by Shepherd et 
al (1975). This labelled the tyrosine residues in LDL protein. All solutions had been 
prepared using sterile water and filtered through 0.22mp Amicon filters and all 
consumables and equipment which would come into contact with the preparation had been 
sterilised by autoclaving.
2 mis of LDL were added to 500jli1 1.0 M glycine, pHIO followed by lmCi carrier free Na
125 131I or Na I. An appropriate volume of IC1 (stock solution- 25nmoles per pi in 1.0M 
NaCl) was added to give a molar ratio o f IC1 : protein of 2.5:1 and the solution mixed 
immediately. Bound and free iodine were separated by elution from a lx l0cm  column of 
Sephadex G-25 (PD10 column, Pharmacia) with 0.15MNaCl, 0.001% (w/v) EDTA,pH 8.1.
2.6.3 Modification with 1,2-cyclohexanedione
131 I-apo LDL was treated with 1,2-cyclohexanedione to block the arginine residues on the 
apoprotein moiety (Shepherd et al, 1979). 2 mis of 131I-apo LDL in 0.15M NaCl, 0.001% 
(w/v) EDTA,pH 8.1 was incubated at 35°C for 2 hours with 4 mis o f freshly prepared 
0.15M 1,2-cyclohexanedione in 0.2M borate buffer, pH 8.1. The modified LDL was 
separated from unbound reagents by passing the mixture over a lx l0cm  column of 
Sephadex G-25 (PD10 column, Pharmacia) with 0.15M NaCl, 0.001% (w/v) EDTA,pH 8.1 
as eluant.
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2.6.4 Sterilisation and Calculation o f  Injection Dose
Labelled tracers were sterilised immediately prior to injection by filtration through a 
0.45pm filter (Acrodisc, Gelman) which had been primed with the subject’s unlabelled 
LDL. The radioactivity concentration in pCi /ml was determined after sterilisation by
• • 125 131counting a lOpl aliquot and comparing with I and I simulated standards. 
Radioactivity was measured in a twin channel Packard gamma spectrometer.
2.6.5 Subject Preparation
Thyroidal uptake of radioiodide was blocked by the oral administration of potassium iodate 
(170 mg twice daily). This was commenced three days prior to injection and was continued 
for 28 days. The turnover studies were conducted on an out-patient basis and in order to 
ensure steady state conditions the subjects were encouraged to adhere strictly to their 
regular diet and lifestyle. Subjects received detailed instructions on the collection of 24 h 
urine specimens and were introduced to the nurse who would be visiting them each day to 
collect the samples. All subjects gave written informed consent before participation.
2.6.6 Injection
Aliquots of 25pCi o f 1251-native LDL and 25pCi 131I-CHD modified LDL followed by a 
small bolus of sterile 0.15M NaCl were injected in rapid sequence into the subject’s 
antecubital vein. Ten minutes later a 10 ml sample was taken from the peripheral vein of 
the opposite arm.
2.6.7 Sampling Protocol
The patient was visited at home by a community nurse every morning for the next 14 days 
and 20 ml of fasting blood was collected into K2 EDTA as anticoagulant at a final 
concentration of 1 mg/ml. Continuous 24 hour urine samples were also collected daily for 
the duration o f the study and creatinine clearance rates were calculated.
2.6.8 Data Collection and Handling
At the end of the study, 2 ml aliquots of plasma and urine were counted for 10 minutes in a 
twin Packard gamma spectrometer. Plasma and urine radioactivity decay curves were 
constructed for the 14 days. The urine : plasma radioactivity ratios for both native and 
CHD modified apo LDL were calculated from the urinary output o f 131I or 131I in a 24 hour 
period and the plasma radioactivity at the beginning of that period. Since there is 
approximately a half day delay between the clearance of radioactivity from the plasma and 
its appearance in urine (Boston, 1982, Foster 1986), the latter value represents the relevant 
mean plasma radioactivity for the 24-h urine collection.
2.6.9 Calculation o f  Apo-LDL Pool Size
LDL d 1.019-1.063 g/ml was prepared from 2ml fasting plasma on four occasions by 
sequential ultracentrifugation as described an section 2.4.5 and the composition of the 
protein, free cholesterol, cholesteryl ester, triglyceride and phospholipid analysed. A pool 
size for apo-LDL was derived from the product of plasma volume (calculated by isotope
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dilution or 4% of body weight if  the subject had a normal BMI) and the mean protein 
concentration.
2.6.10 Kinetic Analysis
Plasma radioactivity data was analysed by the procedure of Matthews (1957) as adopted by 
Shepherd et al (1979) to determine fractional catabolic rates (FCR) for total, receptor-
125dependent and receptor-independent apo-LDL catabolism. The rate o f elimination of I-
131labelled native apo-LDL represents total catabolism of this fraction, while that o f the I- 
CHD modified tracer is used as a measure of receptor-independent activity. The difference 
between these two FCR’s (native and CHD) therefore provides an index of the activity of 
the receptor pathway. The synthetic rate for apo-LDL was calculated as the product of the 
apo-LDL circulating mass and the FCR. The fractional catabolic rate was expressed as 
pools per day and the synthetic rate as mg per kg of body weight.
In order to fit the plasma and urine radioactive decays these were modelled simultaneously 
using version 30 o f the Simulation, Analysis And Modeling (SAAM) computer program 
generated by Berman & Weiss (1974). This was distributed by the SAAM Institute, 
University of Washington, Seattle, USA with detailed instructions in the CONS AM Users 
Manual (1990). Further details of kinetic analyses are given in the appropriate chapters.
2.7 Ethical Implications
All subjects gave informed written consent to the studies which met with the requirements 
of the Ethics Committee o f each host institution ie Glasgow Royal Infirmary; Victoria 
Infirmary, Glasgow; Stobhill Hospital, Glasgow; Hairmyres Hospital, East Kilbride; 
Chelsea and Westminster Hospital, London and University College Hospital, London. All 
radioactive injections were carried out under the ARSAC licence of Professor James 
Shepherd and Dr Denis O’Reilly.
2.8 Statistical Analysis
Statistical analysis was carried out using the PC version o f Minitab version 10 (Minitab 
Inc, PA). All variables were tested for the presence of a normal distribution by drawing 
normality plots and in instances where they were not normally distributed, appropriate 
transformations were performed. Differences in mean values between groups were 
compared by Student’s unpaired t-tests using transformed data where appropriate. 
Differences between lipid, lipoprotein, compositional data and metabolic parameters at 
different time points in the same individuals were analysed by paired students t-test. 
Associations between variables were tested by calculating the Pearson correlation 
coefficient and the significance of association between pairs was determined by linear 
regression. Multivariate analysis was conducted using the analysis of variance General 
Linear Model (GLM) in Minitab which generated the coefficient o f determination (r2) 
related to the independent contribution o f variables.
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Chapter 3 Epidemiology of
Low Density Lipoprotein Subfractions
3.1 Introduction
Early studies with the analytical ultracentrifuge showed that LDL exhibited a range of 
flotation rates at the standard density of 1.063 g/ml (Lindgren et al, 1969). Later it was 
shown by Hammond & Fisher (1971) and Fisher et al (1983) that multiple peaks or 
polydisperse LDL patterns were present in subjects with hypertriglyceridaemia or diabetes 
mellitus. Subsequent studies have led to the recognition that the LDL flotation profile in 
most subjects represents overlapping distributions of several components and is 
appropriately described and analysed as a paucidisperse system.
A number of high resolution methods employing electrophoresis and ultracentrifugation 
have been developed to identify and characterise subfractions along the LDL density 
spectrum. Non denaturing gradient gel electrophoresis as described by Nichols et al 
(1986), using commercially available 2-16% polyacrylamide gels, is commonly employed 
to measure the mean particle diameter of isolated LDL. A variety o f ultracentrifugation 
methods have also been used. These have involved sequential separations at various 
densities (Hammond & Fisher, 1971), rate zonal ultracentrifugation (Patsch, 1986) and 
density gradient ultarcentrifugation (Krauss & Burke, 1982; Fisher et al, 1983, Lee & 
Downs, 1982, Marzetta et al, 1986, Swinkels et al, 1987, Chapman et al, 1988).
Analysis of LDL subclass distributions by both particle size and density has revealed 
marked variability among individual subjects, a large portion o f which is related to clinical 
and metabolic variables, including gender, age, adiposity, diet, hormonal status and drug 
use (Krauss 1991, McNamara et al, 1987). Many of these factors result in coordinate 
changes among LDL subclasses, notably a reciprocal variation in levels o f LDL I and LDL 
III (Krauss et al, 1988). These important effects on LDL subclass patterns may be 
amplified in disease states such as hypertriglyceridaemia (Hammond & Fisher, 1971; 
Nichols et al, 1986) and diabetes mellitus (Fisher 1983; Barakat et al, 1990).
The clinically most important variation in the LDL profile is a predominance of small 
dense LDL. It is an important feature in two metabolic disorders in which there is a 
clustering of risk factors - the insulin resistance syndrome (IRS) and the atherogenic 
lipoprotein phenotype (ALP). IRS, first proposed by Gerry Reaven in the 1988 Banting 
Lecture, is a plurimetabolic disorder linked to increased risk of CHD. It is associated with 
hypertriglyceridaemia, depressed HDL, central obesity, hypertension, impaired glucose 
metabolism and to this list Reaven et al added in 1993, increased proportions of small 
dense LDL. In 1990b, Austin et al identified in the general population a clustering of 
moderate hypertriglyceridaemia, low HDL and a predominance o f small dense LDL which 
she termed the ALP and linked to increased risk of myocardial infarction (Austin et al, 
1988).
The purpose of the present investigation was to develop a quantitative method of isolating 
LDL subfractions, to compare it with already published methods and to examine in detail 
the LDL subfraction distribution in normals, and subjects with coronary artery disease,
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hyperlipidaemia, familial hypercholesterolaemia, non insulin dependent diabetes mellitus 
and the nephrotic syndrome.
3.2 Methods
The techniques o f gradient gel electrophoresis, zonal ultracentrifugation and density 
gradient ultracentrifugation were explored in an attempt to develop a method to 
subfractionate LDL into discrete species.
3.2.1 Gradient gel electrophoresis
Non denaturing gradient gel electrophoresis on 2-16% Pharmacia gels as originally 
desribed by Nichols et al (1986) and in detail in 2.4.8 was employed to examine LDL (d 
1.019-1.063 g/ml) in an initial survey o f a mixed popultion o f 143 subjects. Based on 
these findings of a useful but limited resolution, attempts were made using home made gels 
to improve the separation o f LDL fractions by narrowing the gradient and by using linear 
and concave gradients from 2.5-5.4% and 2.5-7.8% polyacrylamide.
3.2.2 Zonal Ultracentrifugation
Zonal ultracentrifugation as described in 2.4.4 in a T il4 rotor (capacity 665ml, path length
5.3 cm) and a Ti 15 rotor (capacity 1800ml, path length 7.3 cm) was carried out as a 
preparative method to isolate different LDL species. The following gradients were formed 
with run times varying from 4 to 24 h and speeds from 30 to 40,000 rpm: linear and 
concave gradients d l .006-1.21 g/ml and d 1.006-|'1.3 'g/ml, and a stepwise gradient 
1.006:1.063:1.21 in the ratio 5.2:4.0:2.5, mimicking the density gradient ultracentrifugation 
of Marzetta et al (1986).
3.2.3 Density Gradient Ultracentrifugation
Initially, three o f the current published density gradient ultracentrifugation methods were 
evaluated. In the first (Krauss et al, 1981), 2 ml LDL (d 1.006-1.063 g/ml) adjusted to 
1.040 g/ml was layered between 2.5 ml d 1.054 g/ml solution and 2.5 ml d 1.028 g/ml 
solution and centrifuged for 40h at 40,000 rpm in a Beckman SW40 rotor. In the second 
(Swinkels et al, 1987), 3.4 mis of serum stained with coomassie blue at pH 4.5-5 was 
layered under 2.5 ml d 1.065 g/ml, 2.5 ml d 1.020 g/ml and 2.5 ml d 1.006 g/ml and 
centrifuged for 19.5 h at 40,000 rpm in a swinging bucket rotor. In the third (Marzetta et 
al, 1986), 4 ml LDL at d 1.006-1.063 g/ml was layered between 2.5 ml d 1.21 g/ml and 5.2 
ml d 1.006 and centrifuged for 24h at 40,000rpm.
3.2.4 Development o f  final LDL Subfractionation Method
With the knowledge of density intervals for each individual subfraction obtained from the 
above methods, various stepwise gradients in the density range 1.019-1.063 g/ml were 
devised and run initially with pre-isolated LDL (d 1.019-1.063 g/ml) to optimise 
conditions. However, as this LDL took 48h to prepare and may have suffered 
deterioration, it was decided in the final method, to minimise any opportunity for damage 
from prolonged centrifugations, to apply fresh plasma to the gradient. Various times 
(between 18h and 48h) and temperatures were tried to optimise conditions. The final
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method chosen is described in detail in chapter 2.4.9 and consisted of a stepwise gradient - 
3ml plasma at d 1.109g/ml, 1ml d 1.060g/ml, 1ml d 1.056 g/ml, 1ml d 1.045 g/ml, 2ml d 
1.034g/ml, 2ml d 1.024g/ml,lml d 1.019g/ml with ultracentrifiigation carried out at 40,000 
rpm and 23°C for 24 hours.
The density of the gradient formed in the centrifuge tube was measured using a Paar 
Scientific densitometer and the mean particle size o f isolated LDL was determined both by 
gradient gel electrophoresis on 2-16% polyacrylamide gradient gels as described in 2.4.8 
and that o f purified LDL subtractions by electron microscopy as described in 2.5. The 
lipoprotein content of each subfraction was analysed as in 2.4.6. The content of 
apoproteins B, E and CIII was analysed using radioimmunoassay at Professor Frucharf s 
laboratory in Lille, France. The stability of the LDL subfraction profile using this 
methodology was determined by comparing the subfraction distribution in fresh plasma 
(analysis beginning within 24 h of venepuncture) with that of stored plasma (48h, 4°C) and 
frozen plasma (2-3 weeks, -70°C). Recovery and reproducibility measurements were also 
carried out.
Aspects of this work were performed jointly with Dr Bruce Griffin, in particular the 
automation of the method using the Beckman fractionation system and data leader program 
and a few of the early structural studies.
Using this methodology LDL subfractions were quantified in a number of normals and 
subjects with coronary artery disease, primary moderate hyperlipidaemia, familial 
hypercholesterolaemia, non insulin dependent diabetes mellitus and nephrotic syndrome. 
During these studies all subjects maintained their normal habits of diet and exercise. 
Normolipaemic subjects were recruited from staff at Glasgow Royal Infirmary. None were 
taking medication known to affect lipid metabolism and none were obese. The remaining 
subjects were recruited from Lipid Clinics at Glasgow Royal Infirmary University/NHS 
Trust; Victoria Infirmary, Glasgow and Hairmyres Hospital, East Kilbride; the Menopause 
Clinic at Stobhill Hospital, Glasgow; the database of Department o f Cardiac Surgery, 
Glasgow Royal Infirmary; the Renal Unit, Glasgow Royal Infirmary; the Diabetic Clinic at 
Chelsea and Westminster Hospital, London and the FH register at the University College 
Hospital, London. Where appropriate, all subjects were screened for haematological, 
hepatic, endocrine or renal disorders by routine clinical laboratory testing. Except in the 
familial hypercholesterolaemia study, none of the subjects had clinical evidence of familial 
hypercholesterolaemia (FH) and none were taking any medication known to affect lipid 
metabolism
3.3 Results
3.3.1 Comparison o f  Methods
The four main types of subfraction profile observed in the gradient gel electrophoresis 
survey are shown in fig. 3.1. In all subjects 2 or 3 main fractions were evident. The 
profiles were classed according to mean particle diameter as pattern A or pattern B to 
correspond with the nomenclature of Krauss et al (1982). Table 3.1 shows that in profile 
A l LDL I was the main species and had the largest particle size, A2 profile had LDL II as 
the major species while in B3 and B4 there were increasing proportions of small LDL
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(LDL III). Most o f the 143 LDL profiles examined were classified as pattern A, with 52% 
o f the population exhibiting an A2 profile and LDL II being the major LDL species.
Table 3.1 Particle size distribution o f  LDL
mJI fail ft/JM IM
A l >26.0 LDL I>II + III 21
A2 25.5-26.0 LDLII>I + III 52
B3 24.7-25.5 LDLIII = 1 + 11 8
B4 <24.7 LDL III>I + II 18
* determined by comparison with high molecular weight standards and latex beads.
The concentrations o f LDL cholesterol and total plasma cholesterol were unrelated to LDL 
particle size. However there were significant associations between concentrations of 
plasma triglyceride and LDL particle size ( r= -0.60, p<0.0001), HDL cholesterol and LDL 
particle size ( r=0.44, p<0.005) and HDL cholesterol and plasma triglyceride ( r=-0.37, 
pcO.OOl).
■a 2.8
1.4
OJ 2.0
1.2
1.2
Peak
Diameter
(nm)
> 26.0 > = 25.5 < 25.5 < 24.7
B3A1 A2 B4
LDL Subfraction Patterns (GGE)
Fig.3.1 LDL Subfraction Patterns by Gradient Gel Electrophoresis
Pattern A l peak diameter >26.0 nm. (n=30), pattern A 2peak diameter >25.5 nm (n-75), pattern 
B3 peak diameter <25.5 (n=12), pattern B4 primary peak <24.7nm (n=26). Plasma triglyceride 
and HDL cholesterol measurements are in mmol/l.
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No apparent improvement was seen when the method was altered to give a narrow gradient 
on the gels. The separation between the subfractions was improved at the expense of 
resolution with banding becoming diffuse and irregular.
The zonal ultracentrifugation approach was encouraging and different profiles were 
observed in subjects with low and high plasma triglycerides and these were confirmed by 
gradient gel electrophoresis. However as a method o f isolation and purification of the 
subfractions, there was insufficient resolution compared to the final method, only 1 sample 
could be handled at a time and too much blood was required. It was decided not to explore 
this technology further.
O f the 3 density gradient ultacentifugation published methods attempted, that o f Marzetta 
et al looked most promising in our hands. However the modified gradient devised and 
described in 2.4.9 gave the best resolution and was adopted for the following studies.
3.3.2 Characteristics o f  fin a l Density Gradient Ultracentrifugation M ethod  
Isolated LDL subfractions were characterised by density, size and composition and the 
recovery and reproducibility o f the method and the stability o f the subfractions determined. 
Measurement o f the gradient in the centrifuge tube showed it to be continuous and 
curvilinear (fig. 3.2) with discrete LDL bands in the range d 1.025-1.060 g/ml. The LDL 
bands did not reach isopycnic equilibrium under conditions o f the run. Individual 
subfractions were harvested at d 1.025-1.034 g/ml (LDL I), d 1.034-1.044 g/ml (LDL II) 
and d 1.044-1.060 g/ml (LDL III).
1.070
1.060
1.050
E
££ 1.040
1.030
1.020
1.010
1 2 3 4 5 6 7 8 9 10 11 12
V olum e  (m is )
Fig.3.2 Density gradient form ed  in Swing-out Centrifuge Tube
Density in g/ml was measured on successive one ml fractions after an LDL gradient was centrifuged 
fo r  24h, 40,000 rpm, 23°C.
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Fig. 3.3 shows the relationship between density gradient ultracentrifugation profile and 
gradient gel electrophoresis particle size for LDL in 2 subjects.
DGUC
GGE
DGUC
GGE
29.5 P artic le  D iam eter (nm ) 24.2 
i l l  1
1.025 1.034 1.044 1.060
D ensity  (g/ml)
Fig.3.3 Relationship between Particle Size (GGE) and 
Density (DGUC) of LDL Subfractions
LDL Profiles by gradient gel electrophoresis (GGE) and density gradient ultracentrifugation 
(DGUC) on a female and male subject.
Fig. 3.4 shows a gradient gel of purified LDL subtractions from a normal subject. LDL I 
was the largest at 26.0nm, LDL II was 25.5 nm and LDL III was 24.7 nm.
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Fig.3.4 Gradient Gel o f  Purified LDL Subfractions
LDL I (26. Onm), LDL II (25.5nm) and LDL HI (24.7nm) and LDL (d 1.019-1.063 g/ml). Standards - 
latex beads at 38nm, and high molecular weight standards at 17 and 12.2nm.
Fig. 3.5 is electron micrograph photographs o f purified LDL subfractions in a single 
subject. LDL I was 23.6 nm, LDL II was 22.2 nm and LDL III was 20 nm. The size and 
density o f LDL obtained by these 2 methods is shown in table 3.2. Those measured by 
gradient gel electrophoresis were larger than sizes obtained with electron microscopy.
Table 3.2 Size and Density o f  LDL Subfractions
LDL I 1.025-1.034 26.0 23.6
LDL II 1.034-1.044 25.5 22.2
LDL III 1.044-1.060 24.7 20
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Fig. 3.5 Electron Micrograph Photographs o f  purified LDL I, LDL II  and LDL 
II I  fro m  a male subject
Purified LDL I, LDL II and LDL III from  a subject was photographed by negative contrast electron 
microscopy.
Apoproteins B, E and CIII content in LDL subtractions isolated from a young male and a 
young female are shown in table 3.3. In both subjects the majority o f  apoB was in LDL II 
followed by LDL I and approximately 17% was in LDL III. The majority o f CIII was in 
LDL I and the majority o f E in LDL III. In both subjects the CIII to E ratio was 2.8&2.9 
respectively in LDL I, 1.0 &0.6 in LDL II and 0.2 &0.6 in LDL III.
Table 3.3 Apoprotein Content o f  LDL Subfractions
Apo B
male 37 (37) 47 (47) 16.5(16)
female 39 (36) 51 (46) 20.0(18)
ApoCIII
male 120 (60) 57 (28) 25 (12)
female 80 (48) 32(19) 65 (33)
Apo E
male 44 (21) 54 (26) 110(53)
female 38(16) 74 (32) 120 (52)
* apo B in mg/100ml, apo C III in fig/100ml, apo E in yg/100 ml.
Values in brackets are apoprotein content in each subfraction as % total LDL apoprotein.
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Lipoprotein compositions for each subfraction isolated after one spin in a survey o f 37 
normal subjects is shown in table 3.4. LDL I was found to have lower percentage protein 
and higher percentage triglyceride content than the other subfractions whereas LDL II was 
enriched in cholesteryl ester. The highest protein to cholesterol ratio was found in LDL III 
mainly due to a lower percentage o f cholesteryl ester.
Table 3.4 Lipoprotein Composition o f  LDL Subfractions
.... .. \ ■ ■ -
LDL I 22.0 9.1 31.1 19.1 18.7
(SEM ) (0.6) (0.2) (0.9) (0.4) (1.2)
LDL II 24.1 9.2 37.5 18.6 10.5
(SEM ) (0.5) (0.2) (0.8) (0.5) (0.6)
LDL III 24.4 7.3 27.6 17.1 12.9
(SEM ) (0.7) (0.4) (1.0) (0.7) (0.8)
Specific extinction coefficients to relate optical density at 280nm (OD280) to lipoprotein 
concentrations were determined in 22 subjects. For LDL I, the OD280 for a 1 mg/ml 
solution o f lipoprotein was 0.38, for LDL II it was 0.34 and LDL III it was 0.51. In future 
studies where lipoprotein mass was to be quantitated, a specific extinction coefficient was 
applied to the absorbance at 280 nm. To correct OD280 for the amount o f lipoprotein in 
each fraction, LDL I is multiplied by 1/0.38 (=2.63), LDL II by 1/0.34 (-2 .94) and LDL III 
by 1/0.51 (=1.96). The distribution o f protein in each subfraction, as measured by OD280 , 
was calculated as % area under the curve using a computer aided package (Data Graphics, 
Beckman) and corrected for lipoprotein distribution using the extinction coefficients. The 
total lipoprotein mass in LDL (d 1.019-1.063 g/ml) was determined for each plasma sample 
as described in chapter 2. and the distribution o f the lipoprotein was apportioned 
accordingly. The unit o f LDL subfraction concentration is therefore mg lipoprotein /100ml 
plasma.
Recovery o f LDL protein was 102±14% (mean ±SD). The LDL fractions were free from 
contamination by plasma proteins as judged by polyacrylamide gel electrophoresis and 
immunological techniques. When gradient fractions were assayed for Lp(a) with a wide 
range o f plasma Lp(a) levels up to 150 mg/100 ml less than 6% o f Lp(a ) was found in the 
LDL III fraction. Lp(a) eluted from the gradient after the LDL III peak.
The analysis o f 6 replicate samples within the same rotor gave a coefficient o f variation of 
3.4%, 2.0% and 5.4% for LDL I, LDL II and LDL III respectively. Between batch 
coefficient o f variation was less than 6.5%, when 6 samples were analysed in 3 rotors run 
simultaneously.
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Storage o f plasma for 24 h at 4°C and at -20°C for 2-3 weeks resulted in the loss of 
resolution between LDL I and LDL II and was accompanied by a small increase in LDL III 
(fig. 3.6). A similar change was observed when LDL (d 1.019-1.063 g/ml) prepared over 
48h by sequential ultracentrifugation was subjected to density gradient ultracentrifugation.
1.025 1.034 1.044 
D ensity  (g/ml)
1.060
Fig. 3.6 Effect of Storage and Prolonged Centrifugation upon LDL Subfraction 
Profile
LDL subfraction profiles prepared by the density gradient centrifugation o f (a) and (d) fresh 
plasma, within 24h, (b) LDL (d 1.019-1.063 g/ml) derived from plasma a, (c) plasma a stored for 
24h at 4°C, (e) plasma d  storedfor 2 weeks at -20°C, (f) plasma d  stored for 3 weeks at -20°C.
3.3.3 LDL Subfraction Profiles in Normal and Hyperlipidaemc Subjects 
Normal subjects
Four groups of normal subjects were studied: (i) young males, (ii) premenopausal females 
with the same mean age, (iii) women who had undergone hysterectomy and bilateral 
oophorectomy at least 2 months previously and (iv) older males. Table 3.5 shows the lipid, 
lipoprotein and apoprotein values and comparisons in the groups.
Young males and females had similar total cholesterol and triglyceride concentrations , but 
the males had significantly higher VLDL cholesterol (p<0.01) and lower HDL cholesterol 
(p<0.01), the difference being in HDL2 subtraction. In the older group of men cholesterol, 
triglyceride, VLDL and LDL cholesterol were all significantly raised as was apoAI. When 
the premenopausal and post surgical menopausal women were compared, the older women 
had higher cholesterol and LDL cholesterol levels, but similar plasma triglyceride, VLDL
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and HDL cholesterol concentrations. These older women had lower triglyceride and higher 
HDL cholesterol levels than men o f similar age. In these groups o f normals, Lp(a) levels 
were lower in young males.
Table 3.5 Lipids, Lipoproteins and Apoproteins in Normal Subjects
IEH1
Age 32(2) 31 (2) 42(2) 48.3(1) b§, cf
Number 18 18 17 28
Cholesterol 5.06(0.25) 4.73(0.16) 5.62(1.42) 6.3(0.20) b j ,  c f
Triglyceride 1.05(0.10) 0.88(0.05) 1.17(0.54) 1.75(0.26) b*, d*
VLDL citol 0.54(0.04) 0.41(0.03) 0.44(0.24) 0.79(0.06) a t ,  b*, d t
LDL citol 3.3(0.23) 2.76(0.16) 3.54(1.00) 4.23(0.19) b t ,c * ,d *
HDL chol 1.21(0.06) 1.61(0.11) 1.64(0.28) 1.33(0.06) a t ,  d f
HDL2 47.6(6.0) 101(17.4) — a t
HDL3 238.5(14.4) 261(14.6) — —
Apo A l 114(3.7) 130(5.3) 162(18) 143(5.8) a* ,b § ,d *
Apo B 91(6.7) 72(3.8) 72(18) —
Lp(a) 7(0.8) 24(6.7) — 26.5(5.6) a*, b f
Values are mean (SEM). Cholesterol in plasma,VLDL,IDL and HDL and triglyceride values are in mmol/1 , 
HDL subfractions and apoproteins are in mg/100ml.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p values: 
*<0.02, +<0.01, f  <0.001, §<0.0001.
a young males versus premenopausal females, b young males versus older males, c premenopausal versus 
postmenopausal females, d postmenopausal females versus older males.
The LDL subfraction profile (table 3.6) demonstrated that in normals LDL II was the major 
species being 50-60% o f total LDL. However it was observed that in the young females 
(age <21 years) LDL I was the major species. The distribution o f the other 2 species was 
significantly different between males and females, LDL I being lower and LDL III being 
higher in males. There was a reciprocal relationship between LDL I and LDL III with LDL 
II concentrations remaining relatively constant at 160-190 mg lipoprotein /100ml plasma.
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Table 3.6 LDL Subfractions in Normal Subjects
.
' . . ■
8p s ;<V - i
H H H H H
mr* ' ■" i
V, '
- "
LD L mass 315(21.2) 273(14.6) 333(86) 284(35.6)
LD L I 44(6.1) 79(10.0) 110(41) 47(7.4) a t ,  dt
LD L IT 190(17.9) 162(13.4) 171(56) 162(21.7)
LD L I I I 82(23.6) 32(3.5) 52(30) 76(15.8) a*
% LD L I 14.8(2.2) 29.0(3.2) 33.0(9.8) 14.8(2.0) a t, dt
% LD L I I 61.8(4.6) 58.9(3.1) 51.4(6.0) 57.0(4.4)
% LD L I I I 23.4(5.5) 12.1(1.6) 15.6(9.5) 27.0(4.0) a*, d*
Values are mean (SEM). LDL subfractions masses are in mg lipoprotein/100ml plasma.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p values: 
*<0.02, t<0.01, $<0,001, §<0.0001.
a young males versus premenopausal females, b young males versus older males, c premenopausal versus 
surgical postmenopausal females, d surgical postmenopausal females versus older males.
Subjects with Coronary Artery Disease
Lipds, lipoproteins, apoprotein and lipoprotein subfractions were compared in four groups 
o f male subjects with coronary artery disease: (i) a group identified by coronary
angiography as having three-vessel disease, defined as 3 major epicardial arteries with at 
least 50% stenosis (denoted CAD+), (ii) a group identified by coronary angiography as 
having no major pericardial vessel with greater than 50% stenosis (denoted CAD-), (iii) 40 
men who had sustained a documented acute myocardial infarction in the previous 6- 
12months (denoted PMI) and (iv) 8 men who had undergone coronary artery bypass 
surgery between 3 and 12 months previously (denoted CABG). Although the mean ages 
were similar, the CAD+ group was older and this difference was significant when 
compared to the older group o f normal males and CAD- group. Comparisons were made 
between the 4 groups and the older male controls and with CAD+ and CAD -. The lipid, 
lipoprotein and apoprotein results are shown in table 3.7.
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Table 3.7 Lipids, Lipoproteins and Apoproteins in Subjects with Coronary Disease
f Ai ^ 4 ; £<■ A. %
Age 52.8(0.81) 46.8(1.8) 50.9(1.0) 50.9(1.6) a t ,  e t
Number 46 24 40 8
Cholesterol 6.10(0.11) 5.70(0.21) 6.31(0.16) 6.57(0.17)
Triglyceride 2.25(0.21) 1.45(0.11) 2.60(0.24) 1.87(0.14) c*,ef
VLDL chol 0.94(0.08) 0.59(0.06) 1.21(0.11) 0.84(0.07) b * ,c f ,e j ,
LDL chol 3.98(0.12) 3.77(0.16) 4.10(0.15) 4.56(0.20)
HDL 1.18(0.05) 1.32(0.06) 0.99(0.03) 1.10(0.02) c§, d f
Apo A l 116(5.0) 139(6.5) 122(2.6) a j ,  c f, ef
Apo B 104(5.0) 92(3.0) 123(4.2)
Lp(a) 33.6(4.7) 15(4.6) 15(2.8) 20(11) e t
Values are mean (SEM). Cholesterol and triglyceride units are mmol/1, HDL subfractions and apoproteins 
are in mg/ 100ml.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p values: 
*<0.02, +<0.01, JO .OOl, §<0.0001.
a CAD+ vs N older males, b CAD- vs N older males, c PMI vs N older males, d CABG vs N older males, e 
CAD+ vs CAD
All groups had similar total cholesterol and LDL concentrations as the group o f control 
subjects with LDL levels at 4.0-4.5 mmol/1. PMI subjects were distinguished from normals 
by significantly higher triglyceride (p<0.02) and VLDL cholesterol (p<0.01), lower HDL 
cholesterol (p<0.0001) and raised LDL III (p<0.0001, table 3.8). The major LDL species 
in these subjects was LDL III being 51% of the total compared to 27% in normals. When 
compared to CAD-, the CAD+ subjects had significantly raised triglyceride (p<0.01), 
VLDL cholesterol (p<0.001) and LDL III concentrations (p<0.001). There were significant 
alterations in the distribution o f the LDL species, LDL I and LDL II being in lower 
proportions and LDL III higher. CABG subjects were similar to control subjects with 
practically identical LDL subfraction distributions, the only difference being a significant 
decrease (p<0.01) in HDL cholesterol.
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Table 3.8 LDL Subfractions in Subjects with Coronary Disease
LDL mass 360(1 1.7) 368(14.4) 407(14.2) 413(32.6) c | ,  d*
LDL I 54.5(5.4) 77(9.0) 44(5.0) 74(8.5) b*
LDL I I 171(12.1) 205(12.0) 187(15.1) 222(16.4)
LDL I I I 135.2(12.3) 86(12.9) 176(15.6) 118(29.5) a t ,  c§, e t
% LDL I 15.3(1.6) 22.1(2.2) 10.3(1.1) 18.4(2.4) b*, e*
% LDL I I 39.9(2.5) 48.7(2.4) 39.6(3.0) 55.0(4.5) e t
% LDL I I I 45.2(3.7) 30.1(3.9) 51.3(3.9) 26.6(5.7) a t ,  c§, e t
Values are mean (SEM). LDL subfractions masses are in mg lipoprotein/100ml plasma.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p values: 
*<0.02, t<0.01, £<0.001, §<0.0001.
a CAD+ vs N older males, b CAD- vs N older males, c PMI vs N older males, d CABG vs N older males, e 
CAD+ vs CAD
Examination o f the frequency distribution o f LDL subfraction concentrations in the data set 
revealed unimodal distributions for LDL I and LDL II, but a bimodal distribution for LDL 
III with an inflection point at a concentration o f 100mg/ 100ml (fig. 3.7). The relative risk 
o f CAD associated with an LDL III in excess o f lOOmg/lOOml was estimated by the 
calculation o f odds ratios. This was compared with other potential predictors i.e. a plasma 
above the triglyceride level that appeared to be a threshold determinant o f LDL subfraction 
distribution (1.5 mmol/1) (Tan et al, 1995a), and a previously published coronary risk 
parameter (Castelli et a l, 1983) o f cholesterol: HDL cholesterol ratio o f >6.0. Table 3.9 
shows the significance o f these odds ratios determined by chi-square analysis with one 
degree o f freedom.
Table 3.9 Relative Coronary Risk associated with 
LDL II I  > lOOmg/lOOml,
Triglyceride > 1.5 mmol/l and  
CholesteroUH.DL cholesterol ratio >6.0
--------------------------------------------------------- --------- -
LDL III >100 mg/lOOml 4.5 <0.01 6.9 <0.001
Triglyceride >1.5 mmol/l 4.1 <0.01 6.1 <0.001
ChoIesteroLHDLchol >6.0 4.8 <0.05 7.2 <0.001
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Fig. 3.7 Frequency Distribution Plots of LDL Subfractions
Frequency for LDL I and LDL II are unimodal, whereas LDL III is bimodal, showing a change at 
100 mg/100ml. Data represent square-root transformed values.
A level of LDL III > lOOmg/ml was associated with a 4-fold risk of CAD (CAD+vs CAD-) 
and 7-fold increased risk of MI (PMI vs Controls). The odds ratio calculated for a plasma 
triglyceride > 1 .5  mmol/l was 4 for CAD and 6 for MI. A cholesterol:HDL cholesterol 
ratio of 6.0 gave relative risk estimates of 4.8 for CAD and 7.2 for MI. The relative risk 
associated with LDL III > lOOmg/lOOml was independent of plasma triglyceride, age, 
smoking and drug status whereas cholesterol :HDL cholesterol was dependent on 
triglyceride: odds ratio for MI being reduced to 6.4 after correction for triglyceride. LDL 
III measurement was therefore a reasonably sensitive and specific predictor o f risk.
60
Primary Moderate Hyperlipidaemia
Three groups o f patients with primary moderate hyperlipidaemia (moderate 
hypercholesterolaemia (HC), moderate hypertriglyceridaemia (HTG) and combined 
hyperlipidaemia (CHL)) were studied. The groups comprised males and postmenopausal 
females with a mean age o f 50 years. Comparisons were made with the older normal males 
in tables 3.5 and 3.6 and between the groups. Lipids, lipoproteins and apoproteins are in 
table 3.10 and LDL subfractions are in table 3.11.
The HC subjects had significantly raised cholesterol (p<0.0001), LDL cholesterol 
(p<0.0001) and elevated concentrations o f LDL I (p<0.0001) and LDL II (p<0.001), with 
the relative distribution o f LDL subfractions being similar when compared to normals. 
When compared to normals, the HTG group had raised plasma triglyceride (p<0.01), 
VLDL cholesterol (p<0.01) and lower HDL cholesterol (p<0.0001). Less than 10% of total 
LDL was LDL I and more than 70 % was LDL III. Two o f these subjects had no detectable 
LDL I and several exhibited the presence o f an LDL species o f density greater than that 
normally associated with LDL III. It can be termed ‘LDL IV ’ (Krauss & Burke, 1982) but 
has been included for the purpose o f this study in the LDL III subclass. Compared to 
normals, subjects with CHL had raised levels o f cholesterol (p<0.0001), plasma 
triglyceride (p<0.001), VLDL (p<0.001) and LDL III (p<0.01). The distribution o f LDL 
was such that there were approximately equal proportions o f LDL II and LDL III (43% and 
42% respectively).
Table 3.10 Lipids, Lipoproteins and Apoproteins in Subjects 
with Primary Moderate Hyperlipidaemia.
Age 55.6(1.6) 53.6(2.9) 48.6(2.1) a {
Number 31 19 19
Cholesterol 7.68(0.14) 6.1(0.24) 7.95(0.28) a§, c§, d§, f§
Triglyceride 1.55(0.06) 3.2(0.32) 2.99(0.17) bf, c}, d j ,  e§
VLDL c/tol 0.70(0.04) 1.46(0.15) 1.40(0.13) b f, c j ,  d j,  e§
LDL chol 5.60(0.15) 3.68(0.23) 5.44(0.20) a§, c§, d§, f§
HDL 1.35(0.04) 0.93(0.07) 1.11(0.09) b§, d§, e*
HDL2 70(6.5) 16(1.8) 53(12.1) d§,f*
HDL3 250(8.5) 245(20.7) 251(19.7)
Apo A l 126(3.5) 118(8.5) 126(5.0)
Apo B 137(5.1) 153(6.9) 147(9.2)
Lp(a) 42(8) 28(7.5) 61(14.9)
Values are mean (SEM). Cholesterol and triglyceride units are m m ol/l, HDL subfractions and apoproteins 
are in mg/100ml. P refers to the significance of difference between groups as determined by student’s
unpaired t-test. p values: *<0.02, t<0.01, JO .OOl, §<0.000l.a  moderate hypercholesterolaemia vs Nmales, 
b moderate hypertriglyceridaemia vs N males, c combined hyperlipidaemia vs N males, d moderate 
hypercholesterolaemia vs moderate hypertriglyceridaemia, e moderate hypercholesterolaemia vs combined 
hyperlipidaemia, f  moderate hypertriglyceridaemia vs combined hyperlipidaemia.
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When the group o f HC individuals was compared with the group o f CHL subjects, there 
were similar concentrations o f total cholesterol, LDL cholesterol and total LDL mass but 
lower plasma triglyceride (pO.OOOl), VLDL cholesterol (pO.OOOl) and higher HDL 
cholesterol (p<0.02) in the former group. The main difference in LDL profile was a 
halving o f the concentration o f LDL I and a doubling o f LDL III in CHL. When HTG and 
CHL subjects were compared, the former group had lower cholesterol (pO.OOOl), LDL 
cholesterol (pO.OOOl), lower LDL I (pO .02), lower LDL II (pO.OOOl) but similar: LDL 
III.
Table 3.11 LDL Subfractions in Subjects 
with Primary Moderate Hyperlipidaemia.
LDL mass
LDL I  
LDL I I
LDL I I I  
% LDL I  
% LDL I I  
% LDL I I I
Moderate
¥ VHyper­
cholesterolaemia
468(20.1)
129(17.5)
262(14.8)
77(13.1)
26.5(2.8)
56.8(2.4)
16.7(2.8)
Hyper­
triglyceridaemia
279(21.1)
23(4.3)
57(12.0)
198(23.5) 
8.6(4.4) 
20.7(4.4) 
70.7(5.6)
lipidaemiu
392(16.4)
61(10.9)
171(17.9)
160(20.3)
14.7(2.8)
43.0(3.7)
42.4(5.9)
a§, cf, d§, e f ,n
a§, d§, e f, f* 
a t  b j, d§, e t
f§
b t  c t ,  d t  e t  
a t ,  d§, e t  
b j,  d§, e t ,  f t  
b§, d § ,e t  f t
Values are mean (SEM). LDL subtractions masses are in mg lipoprotein/100ml plasma.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p values: 
*<0 .02, +<0 .01, £<0 .001, §<0 .0001.
a moderate hypercholesterolaemia vs N males, h moderate hypertriglyceridaemics vs N males, c combined 
hyperlipidaemia vs N males, d moderate hypercholesterolaemia vs moderate hypertriglyceridaemia, e 
moderate hypercholesterolaemia vs combined hyperlipidaemia, f  moderate hypertriglyceridaemia vs 
combined hyperlipidaemia.
Familial Hypercholesterolaemia
37 subjects with heterozygous familial hypercholesterolaemia (FH), defined as LDL 
cholesterol >4.9 mmol/l plus similar raised cholesterol in a 1st or 2nd degree relative, plus 
either a family history o f MI below 50 o f age in 1st or 2nd degree relative, or tendon 
xanthoma or family history o f such xanthoma in 1st or 2nd degree relative, were studied. 
The group consisted o f 19 men (mean age 51 years) and 18 females (mean age 43 years). 
Also examined was a group o f 14 subjects with familial defective apo B100 (FDB). Five 
had the classic R3500Q mutation in which arginine had been replaced by glutamine, 4 were 
the recently discovered FDB variant R3500W (Gaffney et al, 1995) in which arginine was 
replaced by tryptophan and 5 were FDB subjects who had an arginine to cysteine change at
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amino acid 3531 (Pullinger et al, 1995). The lipids and lipoproteins are in table 3.12 and 
LDL subfractions in table 3.13
Table 3.12 Lipids, Lipoproteins and Apoproteins in Subjects 
with Familial Hypercholesterolaemia.
-
Age 46.8(2.8)
Number 37 14
Cholesterol 6.9(0.2) 6.7(0.39) b t
Triglyceride 1.32(0.14) 1.75(0.35)
VLDL chol 0.54(0.11) 0.82(0.23)
LDL chol 5.1(0.20) 4.46(0.44)
HDL 1.24(0.05) 1.28(0.12)
HDL 1.24(0.05) 1.28(0.12)
Values are mean (SEM). Cholesterol and triglyceride units are m m ol/l, HDL subfractions and apoproteins 
are in mg/lOOml. P refers to the significance of difference between groups as determined by student’s 
unpaired t-test. p value: t<0.01. b Familial Hypercholesterolaemia vs moderate hypercholesterolaemia
When compared to normal males, FH subjects had higher masses o f LDL I (PO.OOOl) and 
LDL II (P O .O l) with a higher proportion o f LDL I and FDB subjects had higher LDL II 
concentrations. FH and FDB groups were similar to HC in plasma lipid levels and LDL 
profile and to each other.
Table 3.13 LDL Subfractions in Subjects 
with Familial Hypercholesterolaemia.
LDL mass 410(15.7) 408(22.9) a t ,  c f
LDL I 110(10.0) 83(14.1) a§
LDL I I 229(12.9) 242(21.7) a t ,  c*
LDL I I I 71(10.4) 81(24.8)
%o LDL I 26.7(2.1) 20.9(4.1) a§
% LDL I I 55.5(2.0) 61.2(5.0)
% LDL II I 17.8(2.5) 19.3(4.3)
Values are mean (SEM). LDL subfraction masses are in mg lipoprotein/100ml plasma. P refers to the 
significance of difference between groups as determined by student’s unpaired t-test. p values: *<0.02, 
t<0.01, §<0.000 La Familial Hypercholesterolaemia vs older normal males, c Familial Defective apoBlOO vs 
older normal males
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Secondary Hyperlipidaemia
Two groups o f subjects with secondary hyperlipidaemia were investigated. The first was a 
group o f 24 subjects (14 males, 10 females) with non insulin dependent diabetes mellitus 
(NIDDM) who were treated with diet alone or with an oral hypoglycaemic drug. 
Comparisons were made with the older male population. The second group which 
consisted o f 12 patients (10 males and 2 females) with nephrotic syndrome who had 
primary glomerular disease with serum creatinine <300pmol/l and urinary albumin 
excretion >2.5g/24h. Comparisons were made with 23 age and sex matched controls with 
no history o f CAD. The results are shown in tables 3.14 and 3.15. Male and female 
NIDDM subjects had similar plasma lipid and lipoprotein levels except for plasma 
triglyceride (p<0.01) which was 2.69 (0.37, SEM) mmol/l in males and 4.08 (0.28, SEM) 
mmol/l in females.
Table 3.14 Lipids, Lipoproteins and Apoproteins in Subjects 
with Secondary Hyperlipidaemia
Age 62.7(1.5) 46(16) 44(14) a§, c§
Num ber 24 12 23
Cholesterol 7.32(0.21) 6.5(1.4) 5.3(1.1) a+
Triglyceride 3.23(0.28) 3.2(2.7) 1.2(0.4) a j ,b +
VLDL chol 1.66(1.27) 0.48(0.22) b f
LDL chol 4.7(0.17) 3.72(1.43) 3.62(1.06)
HDL 1.12(0.04) 1.08(0.48) 1.19(0.26) a+
Values are mean (SEM). Cholesterol and triglyceride units are mmol/l.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p 
values: +<0.01, +<0.001, §<0.0001.
a NIDDM vs normals, b Nephrotics vs aged and sex matched controls, c NIDDM vs Nephrotics
The group o f NIDDM subjects were the oldest group studied and had higher cholesterol 
(p<0.01), higher triglyceride (p<0.001), lower HDL cholesterol (p<0.01) and similar LDL 
cholesterol concentrations when compared to normals. LDL III was half o f the total LDL 
and the concentration o f this subfraction was significantly higher than normal (p<0.001). 
Nephrotic syndrome patients had raised plasma triglyceride (p<0.01) and VLDL 
cholesterol (p<0.001) when compared with age and sex matched controls. In the majority 
LDL III was the major LDL species and the presence o f LDL IV was observed in 3 
subjects. When compared with controls, the total LDL mass was slightly lower (non 
significant), the concentration o f LDL I was lower (p <0.02) and LDL III significantly 
higher (p<0.01). There were similarities between these 2 groups o f secondary
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hyperlipidaemia in levels o f all lipids and lipoproteins and concentrations and distribution 
o f the LDL subfractions.
Table 3.15 LDL Subfractions in Subjects 
with Secondary Hyperlipidaemia— ■ mZuSm* w m  m m m m
LDL mass 366(16) 285(97) 334(88)
LDL I 38(5.2) 32(23.6) 62(26.4) b*
LDL II 142(16.7) 121(80) 193(80.1)
LDL III 182(21.2) 135(64.3) 75(71.3) a}, b j
% LDL I 10.5(1.5) 9.3(1.8) 19.5(10.3)
%  LDL II 38.6(4.1) 40.3(6.5) 57.8(17.3)
% LDL III 50.9(5.0) 50.4(7.4) 21.4(17.8) a j, b t
Values are mean (SEM). LDL subfractions masses are in mg lipoprotein/100ml plasma.
P refers to the significance of difference between groups as determined by student’s unpaired t-test. p values: 
*<0.02, t< 0 .01 , $<0,001, §<0.0001.
a NIDDM vs normals, b Nephrotics vs age and sex matched controls
3.3.4 Regulation o f  LDL Concentration, Composition and Subfractions 
The data from all the subjects described above was pooled to give a cohort o f 304 
individuals with plasma cholesterol from 3.25-10.4 mmol/l, plasma triglyceride from 0.45- 
8.65 mmol/l and LDL cholesterol from 1.5 - 7.6 mmol/l. In this group LDL cholesterol 
rose significantly with age ( r = 0.33, p <0.0001) and was significantly correlated with LDL 
II subfraction ( r =0.51, pO.OOOl). VLDL cholesterol was positively associated with the 
mass o f  LDL III ( r = 0.52, pO.OOOl). HDL was negatively associated with triglyceride ( r 
= -0.41, pO.OOOl) and LDL III (r = - 0.45, pO.OOOl) and positively with LDL I ( r = 0.40. 
pO.OOOl). The HDL associations were with HDL2 subfraction and not HDL3. There were 
no associations between LDL subfraction concentrations and apo E phenotype or BMI. 
Plasma triglyceride was negatively correlated with LDL I ( r = - 0.34, pO.OOOl) and LDL 
II ( r = - 0.35, pO.OOOl) and positively with LDL III ( r = 0.64, pO.OOOl). Plasma 
triglyceride concentration was negatively associated with % free cholesterol in LDL ( r = - 
0.52, pO.OOOl) and positively with % LDL triglyceride ( r = 0.54, pO.OOOl).
Fig. 3.8 shows the relationship o f the 3 LDL subfractions with plasma triglyceride. At low 
levels o f plasma triglyceride LDL I levels are at their highest and they fall to reach a 
baseline value o f about 50 mg/100ml. Over the plasma triglyceride range 0.5-1.5 mmol/l, 
LDL II concentrations rise and then fall off above a plasma triglyceride o f 1.5 mmol/l, 
whereas LDL III concentrations are flat and then rise sharply. This is in agreement with an 
observation in normal individuals in a separate paper from our laboratory (Tan et al, 
1995a), who showed that the point o f inflection where the LDL II/III changes take place
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was at a plasma triglyceride concentration o f 1.5 mmol/l. Table 3.16 shows the lipid, 
lipoprotein and LDL subtraction concentrations when the data set was divided at this level 
o f plasma triglyceride.
Fig.3.8 Relationship o f Plasma Triglyceride with LDL I, LDL 11 and LDL III
At low plasma triglyceride < 1.5 mmol/l LDL II and LDL III are positively associated with 
triglyceride (p<0.01) and at triglcerude >1.5 LDL II is negatively associated with triglyceride and 
LDL III positively (p<0.0001)
Table 3.16 Comparison o f Low and High Triglycerides
Vu •. ' yl '
-
—
  : - _ _ _ _
Number 137 166
Triglyceride 1.05 (0.02) 2.76 (0.10)§
Cholesterol 5.86 (0.11) 6.92 (0.08)§
VLDL cholesterol 0.49 (0.02) 1.16 (0.05)§
LDL cholesterol 4.04(0.11) 4.57 (0.08)§
HDL cholesterol 1.34 (0.03) 1.11 (0.02)§
HDL2 81 (6.0) 45 (4.2)§
HDL3 255 (7.5) 260 (9.1)
LDL I 88 (5.3) 52 (3.7)§
LDL II 207 (7.1) 171 (7.3)**
LDL III 54 (3.5) 164 (4.2)§
Values are mean (SEM). Triglyceride, cholesterol, VLDL cholesterol and HDL cholesterol are in mmol/l. 
HDL and LDL subfractions are in mg/IOOml. **p<0.0005, § p<0.0001.
f -0,007
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f 0,25§
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Fig.3.8b Relationship o f Plasma Triglyceride with LDL I, LDL II and LDL III
At low plasma triglyceride <1.5  mmol/l, LDL 11 and LDL III are positively associated with triglyceride 
(p<0.01) and at triglyceride > 1.5 mmol/l, LDL II is negatively associated and LDL III positively
(p<0.0001)
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There were highly significant differences between the groups in all parameters except for 
HDL3. Plasma triglyceride > 1.5 mmol/l was associated with raised cholesterol, raised 
VLDL cholesterol, raised LDL cholesterol, reduced HDL cholesterol this being due to the 
HDL2 fraction, lower concentrations o f LDL I and LDL II and higher concentrations of 
small dense LDL III. Table 3.17 shows the Pearson correlations between triglyceride, 
cholesterol, HDL cholesterol and the LDL subfractions.
Table 3.17 Correlations with LD L Subfractions
__________
IIWfJWSEM
----------------------------------------
Triglyceride - 0.007 0.2551* 0.2341* - 0.389§ - 0.539§ 0.5 5 7 §
Cholesterol 0.550§ 0.602§ -0.001 0.320 § 0.429§ -0.116
HDL cholesterol 0.208 -0 .126 - 0.209 0.475§ 0 .312§ - 0.462§
h d l 2 0.348t -0 .238 - 0 .224t 0.622§ 0.445§ - 0.414§
fp<0.01, §p<0.0001
Plasma triglyceride <1.5 mmol/l showed a significant positive relationship with LDL 
cholesterol ( r = 0.34, pO.OOOl) and no significant relationship when above this value ( r= 
0.098). Cholesterol was positively associated with LDL I and LDL II at all concentrations 
o f plasma triglyceride. Below 1.5 mmol/l, plasma triglyceride was weakly positively 
correlated with LDL II and LDL III but when the concentration o f the lipid was raised 
above this level, correlations with the LDL subfractions were very strong P(<0.0001), LDL 
I and LDL II being negatively and LDL III positively associated. HDL cholesterol and 
HDL2 in particular, at the higher triglyceride concentration was associated positively with 
LDL I and LDL II and negatively with LDL III. The determinants o f LDL subfraction 
concentration were assessed in an analysis o f variance general linear model (table 3.18).
Table 3.18 Determ inants o f  LDL Subfraction Concentration
w m m , S ITEfgxS-...
Age 17.8§ 16.0 J J 1.3
S ex 2.0 1.3 1.2
B M I 4.0*f 1.2 0.4
A po E  phenotype 0 0 0.8
Triglyceride 3.2 0.8 30.1*1*
VLDL cholesterol 1.5 0 0
H D L 2 16.6§ 1.9 0.4
values are r2. p *t<0.05, <0.005, §<0.0001
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In the multivariate model, age and HDL2 were significant independent predictors of LDL I, 
age was the only significant independent predictor of LDL II and triglyceride was the 
significant independent predictor of LDL III accounting for 30% of the variability of this 
subfraction.
3.4 Discussion
Of the published methods none met the objective o f a rapid quantitative LDL 
subfractionation assay which could be easily used to investigate the causes of altered LDL 
profiles in hyperlipidaemia and coronary artery disease. Further, it was recognised early on 
in this project that gradient gel electrophoresis was not sufficient to generate the data 
necessary to understand the origin and control o f heterogeneity in LDL but it was a 
standard to which other techniques had to be compared.
Thus the objective was to devise a density gradient ultracentifugation which generated 
profiles comparable to those obtained by gradient gel electrophoresis. A successful 
gradient was developed based on that o f Marzetta et al (1986) and the use of fresh plasma 
gave improved resolution. Density gradient ultacentrifugation separation of LDL produced 
clear banding in the centrifuge tube and there was a high reproducibility of peaks in the 
eluting profile. Gradient gel electrophoresis (fig. 3.3) and electron microscopy (fig. 3.5) of 
the purified subfractions produced evidence for the existence of discrete LDL species. The 
density and size of LDL I, LDL II and LDL III were identical to those obtained by Krauss 
et al (1982) and so direct comparisons can be made with the investigations carried out on 
subjects identified as having LDL phenotype A or B profiles. Size by gradient gel 
electrophoresis was larger than that obtained by electron microscopy and Kahlon et al 
(1982) when using sedimentation equlibrium observed a systematic bias in gradient gel 
electrophoresis towards a larger molecular size. The application of specific coefficients of 
extinction for each subfraction allowed concentration distribution to be inferred from the 
OD280 profiles. This alleviated the necessity for the collection and analyses of individual 
lipoproteins in each specific fraction, and so minimised the cost and time involved.
The LDL subfraction distribution profile was characterised in normals, a number of 
dyslipidaemic states and CAD as summarised in fig. 3.9. In agreement with other methods 
o f subfractionation (McNamara et al, 1987, Swinkels et al, 1989), differences were 
observed in normals between young males and females, particularly in LDL I and LDL III 
which had a reciprocal relationship, LDL I being higher in females and LDL III higher in 
males. This may be partly due to the sex difference in plasma triglyceride in the general 
population but in these subjects plasma triglyceride levels were similar and so the 
differences must be attributed to other factors. In a companion study (Tan et al, 1995a) in 
normals (the results of which have not been included in this thesis) we also found this 
pattern o f subfraction distribution in young normal males and females. Gender differences 
were attributal, as described below, to variations in HL activity which is known to be 
influenced by sex hormones.
In the CAD case control study, LDL III was found to be a powerful predictor of coronary 
risk and was independent of age, plasma triglyceride, BMI, smoking and drug status 
(Griffin et al, 1994). This was in agreement with Austin et al (1988) who observed that a 
preponderance of pattern B LDL phenotype (small dense LDL ) was associated with a
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three-fold increase in the risk of MI independently of gender, age or body weight. In the 
present study it was clear that a concentration of small dense LDL III in excess of 
lOOmg/lOOml gives rise to a greatly increased risk o f CHD independent o f total circulatory 
LDL mass.
LDL I LDL II LDL
fem ale
m ale
CAD
HC
CHL
HTG
Fig 3.9 LDL Subfraction Profiles
LDL profiles by density gradient ultracentrifugation in a female, a male, subjects with coronary 
artery disease (CAD), hypercholesterolaemia (HC), combined hyperlipidaemia (CHL) and 
hypertriglyceridaemia (HTG).
LDL profile was examined in a number o f dyslipidaemic states and across all there was a 
clear link between plasma triglyceride and LDL III as can be seen in the combined data 
(fig.3.8). Moderate hypercholesterolaemia and familial hypercholesterolaemia are 
associated with an elevation of large LDL I and LDL II and when these were accompanied 
by a raised triglyceride in the combined hyperlipidaemic group, there was double jeopardy 
with raised total LDL mass and raised LDL III. This observation goes some way to 
explaining why the combined hyperlipidaemic subjects are at greater risk when compared
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to normotriglyceridaemics with the same LDL cholesterol level (Assmann & Schute, 1992, 
Frick et al, 1987). There is a debate at present as to whether the CHD risk is increased in 
hypertriglyceridaemics with normal LDL cholesterol levels. The data presented in table 
3.10 indicating the presence o f low HDL2 and high concentrations o f LDL III would indeed 
suggest that such subjects were at greater coronary risk.
Despite the different methodologies employed to determine the LDL profile, these 
observations in hyperlipidaemic subjects are entirely in agreement by those reported by de 
Graaf et al (1993) for FH , Innerarity et al, 1990 for FDB, Francheschini et al (1994) for 
FH and type Ha hyperlipidaemia, Chapman et al (1996) and Guerin et al, (1996) for 
combined hyperlipidaemia and Kleinman et al (1985) and Lahdenpera et al, (1995) in 
hypertriglyceridaemia.
The secondary hyperlipidaemic subjects studied with NIDDM and nephrotic syndrome 
showed similar lipid and lipoprotein profiles (tables 3.14) despite differing aetiology. The 
similarity in LDL profiles (table 3.15) was likely to be driven by the raised plasma 
triglyceride concentrations. These two groups of subjects exhibited an ALP profile and 
were considered at high CHD risk because of the accelerated atherosclerosis found in these 
conditions (Steiner et al, 1985, Ordonez et al, 1993). The findings in NIDDM patients 
were in agreement with numerous investigations (Barakat et al, 1990, Feingold et al, 1992, 
Tan et al, 1995b, Lahdenpera et al, 1996) but to date there have no reports in the literature 
o f LDL size in the nephrotic syndrome.
The primary determinant of LDL concentration was plasma triglyceride and the complex 
association of this plasma lipid with the individual LDL subtractions (fig. 3.8) suggested 
that there was a threshold for the formation of LDL III from LDL II. These findings are in 
agreement with the observations in normal subjects reported separately (Tan et al, 1995a) 
in which a model was proposed to account for the formation of small dense LDL (fig.3.10). 
It was suggested that in individuals with elevated plasma concentrations of triglyceride rich 
lipoproteins there was an enhanced transfer of triglyceride into LDL II via the action of 
CETP. LDL in turn lost cholesteryl ester in the exchange process and become triglyceride 
enriched so forming an ideal substrate for HL. The enzyme acts on LDL II to hydrolyse the 
triglyceride enriched core and generate LDL III. If HL activity is low, LDL II remains the 
major species despite being relatively triglyceride enriched. The HL activities from the 
young male and female subjects in this present study are reported in Watson et al, 1994 
and, in agreement with those reported by Tan et al (1995a), HL levels in females are lower 
than males. Thus the data presented here are consistent with this model since at 
triglyceride concentrations <1.5 mmol/l there is a positive correlation between plasma 
triglyceride and LDL II and at plasma triglyceride concentrations >1.5 mmol/l there is a 
negative correlation (table 3.16). Total LDL mass is conserved across the plasma 
triglyceride range.
HDL, in particular HDL2, was found to be an important predictor o f LDL I mass. This may 
also be explained by HL which is also known to strongly influence the size and density of 
HDL and hence HDL2 concentrations (Patsch et al, 1987) by mechanisms similar to that 
proposed for LDL.
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C hylom icrons 
^ VLDL ^
Fig, 3,10 Proposed Modelfor Formation o f LDL III
LpL lipoprotein lipase, HL hepatic lipase, CETP cholesterol ester transfer protein, CE cholesteryl 
ester, TG triglyceride, PL phospholipid.
CETP mediates exchange o f cholesteryl ester for triglyceride, forming an LDL II particle rich in 
trigylceride which is an ideal substrate for HL. Hydrolysis o f the trigycerude results in the 
formation o f a small LDL III particle enriched in cholsteryl ester.
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Chapter 4 Modification of LDL Subfractions by
Hypolipidaemic Agents
4.1 Introduction
The pharmacological management of patients with dyslipidaemia has benefited from major 
advances in the last decade. Safe and effective drug therapies that have been thoroughly 
validated in clinical trials are available. However it is recognised in all guidelines (the 
second report o f the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATPII), 1993; 
the European Atherosclerosis Society (EAS) , International Task Force, 1992; the British 
Hyperlipidaemia Association (BHA), Betteridge et al, 1993) that lifestyle and diet 
modification is essential as a first step in correcting hyperlipidaemia.
Hypolipidaemic drugs may be classified by their predominant therapeutic effect although 
they alter more than one lipid fraction. Cholesterol lowering agents are the bile-acid 
sequestrants and HMG-CoA reductase inhibitors, whereas circulating levels of triglyceride 
are decreased by nicotinic acid and fibric acid derivatives.
The bile-acid sequestrants have a long history o f clinical use and the two currently 
available agents are cholestyramine and colestipol, both of which are highly charged 
polycationic resins which interrupt the intrahepatic circulation o f bile acids. As a 
consequence the activity of 7-a-hydroxylase is increased, resulting in increased conversion 
of sterols into bile acids. This leads to a decrease in hepatic cholesterol and up regulation 
o f the LDL receptor. In patients with an underlying metabolic propensity for 
hypertriglyceridaemia, triglyceride synthesis and VLDL production is promoted by resins 
although the mechanism of this effect remains obscure. Usually LDL cholesterol decreases 
by 15-30% and HDL cholesterol increases by 3-5% while triglyceride is unaffected but 
may be increased in a few patients.
The HMG-CoA reductase inhibitors or statins, the most recent class of hypolipidaemic 
agent, have had a major impact in terms of efficacy and tolerability. The currently 
available statins are lovastatin, simvastatin, pravastatin, fluvastatin and atorvastatin. HMG- 
CoA reductase is the enzyme which modulates the reduction of HMG-CoA to mevalonate. 
It acts as the pacemaker enzyme in the cholesterol biosynthetic pathway. Statins 
competitively inhibit HMG-CoA reductase and thereby decrease cholesterol synthesis. The 
content of cholesterol in key regulatory pools is diminished and so there is activation of the 
LDL receptor via the mediation o f the sterol regulatory element binding protein (SREBP), 
a positive transcription factor for the receptor gene. Clearance of all circulating apoB/E 
containing lipoproteins (ie VLDL, IDL and LDL) from the circulation is increased by 
statins. Typical plasma changes are an LDL cholesterol decrease by 20-40%, an HDL 
cholesterol increase by 5-15% and triglyceride decreases o f 10-20%. The drugs are the 
most intensively studied lipid lowering compounds in large clinical trials for example the 
Scandinavian Simvastatin Survival Study (4S) with simvastatin and the West of Scotland 
Coronary Prevention Study (WOSCOPS) with pravastatin.
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Nicotinic acid is a B vitamin which acts as a coenzyme in intermediary carbohydrate 
metabolism and when given in large doses (2-5g/d) it has a substantial lipid lowering 
effect. The nicotinic acid derivative acipimox is available as a hypolipidaemic agent in the 
UK. Nicitonic acid suppresses free fatty acid mobilisation from peripheral adipocytes and 
inhibits VLDL and triglyceride production in the liver. It lowers LDL cholesterol by 10- 
25%, raises HDL cholesterol 15-30% and lowers triglyceride 20-50%.
The parent fibrate compound (clofibrate) was introduced in 1962 and second and third 
generation fibric acid derivatives gemfibrozil, bezafibrate, ciprofibrate and fenofibrate are 
now available. Fibrates are believed to act by stimulating (possibly through binding) 
peroxisome proliferator activated receptors (PPAR) in the liver. These members of the 
steroid hormone nuclear receptor family regulate a number o f genes including apo CIII and 
LPL. Fibrates suppress apo CIII synthesis in the liver as a result. Plasma apoCIII 
concentration falls and since this protein acts to inhibit the receptor-mediated uptake of 
triglyceride rich lipoproteins there is increased chylomicron/VLDL uptake by the liver and, 
due to the further action o f the drug, there is promotion o f lipolysis by stimulation of 
lipoprotein lipase. The effect on LDL cholesterol is variable depending on the initial 
concentration. If it is high, LDL cholesterol is decreased bylO-15% but if  low, as in 
hypertriglyceridaemia, the LDL cholesterol is increased by therapy. Plasma triglyceride is 
reduced 20-40% and HDL cholesterol is increased by 10-15%.
In the previous chapter the LDL subfraction profile was examined in normal and various 
dyslipidaemic states. It was demonstrated that the concentration and distribution of the 
LDL species was not only dependent on plasma cholesterol, but that plasma triglyceride 
was a major determinant of the distribution as was the role o f the lipolytic enzymes LPL 
and HL. In this chapter the perturbation of the LDL subfraction profile by hypolipidaemic 
drugs was observed to be predictable depending on their actions on lipoprotein and hepatic 
lipase, plasma triglyceride levels and LDL receptors. Drugs that lower plasma triglyceride 
shift the spectrum towards less dense particles and those that activate LDL receptors will 
reduce the larger species due to increased receptor-mediated clearance.
4.2 Method
4.2.1 Protocol
Except in the case of normal subjects, treatment with hypolipidaemic agents took place for 
the specified time periods after a three month standard cholesterol reducing diet. 
Measurements were taken before and after therapy for fasting lipids, lipoproteins, 
apolipoproteins and lipoprotein subfractions analyses as described in chapter 2.
4.2.2 Subjects
Normolipaemic subjects were recruited from staff at Glasgow Royal Infirmary. None were 
taking medication known to affect lipid metabolism and none were obese. The remaining 
subjects were recruited from Lipid Clinics at Glasgow Royal Infirmary University/NHS 
Trust; Victoria Infirmary, Glasgow; Hairmyres Hospital, East Kilbride; the Menopause 
Clinic at Stobhill Hospital, Glasgow; the database of Department of Cardiac Surgery, GRI
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and the Diabetic Clinic at Chelsea and Westminster Hospital, London. All subjects were 
screened for haematological, hepatic, endocrine and renal dysfunction to exclude secondary 
causes o f hyperlipidaemia. None o f the subjects had clinical evidence o f familial 
hypercholesterolaemia (FH) and none were taking any medication known to affect lipid 
metabolism. During the study, all subjects maintained their normal habits o f diet and 
exercise.
4.3 Results
4.3.1 Bile-acid Sequestrants
Treatment with cholestyramine was investigated in a group o f normal individuals and 
treatment with colestipol in a group o f subjects who had undergone coronary artery bypass 
grafting (CABG).
Cholestyramine
Nine normolipaemic subjects, 4 males and 5 females aged 25-37, mean age 32 years, 
received cholestyramine resin at 16g/day for 4 weeks. The effect on lipids and lipoproteins 
is shown in table 4.1.
Table 4.1 Effect o f  Cholestyramine on Lipids in Normal Subjects
Baseline
mean 4.57 0.82 0.41 2.69 1.48
(SEM)
Cholestyramine
(0.86) (0.80) (0.25) (0.84) (0.32)
mean 3.79 0.80 0.34 1.84 1.61
(SEM) (0.80) (0.26) (0.14) (0.74) (0.50)
P <0.001 NS NS <0.001 NS
In response to cholestyramine treatment for 4weeks, 9 normal subjects showed a significant 
reduction in plasma cholesterol (17%, p<0.001) that was attributed to a decrease in LDL 
cholesterol (32%, p<0.001). Plasma triglyceride was unaffected whereas HDL showed a 
9% (NS) increase.
The effect o f 4 weeks treatment with cholestyramine on LDL subfractions is shown in table 
4.2.
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Table 4.2 Effect o f Cholestyramine on LDL Subfractions in Normal Subjects
‘ - W tm t  gMSS-S# . - ,v'< ' V i //JFH/Jw
Baseline
mean 253 57 162 34
(SEM) (81) (20) (85) (14)
Cholestyramine
mean 150 32 75 43
(SEM) (65) (29) (30) (41)
P NS <0.05 <0.005 NS
The total lipoprotein mass o f LDL was decreased as a result o f a significant reduction of 
the large LDL I (44%, p<0.05) and LDL II (54%, p<0.005). The concentration o f small, 
dense LDL III was increased in five subjects but showed a variable response in the 
rem ainder o f the group. This resulted in an apparent enrichment in LDL III which was 
28% o f  total LDL compared to 13% in the control phase even though the increase o f 26% 
in the mass o f LDL III was non-significant. There was no change in the lipoprotein 
com position o f  total LDL (d 1.019-1.063 g/ml).
Colestipol
Seven male subjects aged 44-64 with initial cholesterol level >6.0 mmol/l and triglyceride 
< 3 .0  mmol/l were treated with colestipol for 10 weeks, rising to a dose o f 20 g/day after 7- 
10 days. All had undergone coronary artery bypass grafting (CABG) between 3 and 12 
months previously. The changes in lipids and lipoproteins are in table 4.3.
Table 4.3 E ffect o f  Colestipol on Lipids in CABG Subjects
Baseline
mean 6.58 1.84 0.82 4.59 1.09
(SEM) (0.20) (0.16) (0.08) (0.23) (0.02)
range 6.02-7.27 1.32-2.65 0.73-1.12 3.70-5.50 1.03-1.23
Colestipol
mean 5.62 2.01 0.89 3.57 1.17
(SEM) (0.13) (0.18) (0.08) (0.11) (0.06)
range 5.35-6.40 1.33-2.69 0.57-1.93 3.07-4.15 0.97-1.32
P <0.005 NS NS <0.005 NS
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Colestipol treatment reduced cholesterol by 15% (p<0.005). This was due to a 22% fall in 
LDL cholesterol (p<0.005), while VLDL cholesterol and HDL cholesterol were unchanged. 
There was a variable response in plasma triglyceride with no change overall. The effect on 
LDL subfractions is shown in table 4.4.
Table 4.4 Effect o f  Colestipol on LDL Subfractions in CABG Subjects
> ills T ' V ff.
Baseline
mean 410 73 232 105
(SEM) (37) (9.8) (15.3) (30.9)
range 305-584 45-107 154-285 24-216
Colestipol
mean 269 45 144 81
(SEM) (15) (7.4) (13.1) (17)
range 220-322 24-71 98-202 26-143
P <0.01 <0.05 <0.005 NS
There was inter-individual variation in the LDL subfraction profile but the mass o f LDL III 
both on and o ff colestipol was significantly associated with plasma triglyceride level (r= 
0.64, p<0.02). The mass o f total LDL was decreased by 34% (p <0.01) on drug, the most 
significant change being due to a 38% decrement in the major LDL II species (p<0.005) 
and a 38% reduction in LDL I (p <0.05). There was a variable response in LDL III 
resulting in an overall reduction in mass o f 23%. There were no changes in Lp(a) or in the 
lipoprotein composition o f LDL (d 1.019-1.063 g/ml).
4.3.2 HMG-CoA Reductase Inhibitors
Simvastatin therapy was investigated in 2 groups o f subjects with moderate 
hypercholesterolaemia and combined hyperlipidaemia and atorvastatin therapy in a group 
of subjects with combined hyperlipidaemia.
Simvastatin in Moderate Hypercholesterolaemia
Six subjects (4 men and 2 postmenopausal females) aged from 36-64 year were treated with 
simvastatin at 20mg nocte for 10 weeks, rising to this dose after 4 weeks at an initial dose 
of lOmg nocte. The subjects had moderate hypercholesterolaemia with LDL cholesterol 
>4.5 mmol/l and plasma triglyceride <2.3 mmol/l. The lipid and lipoprotein results are in
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table 4.5. Treatment reduced plasma cholesterol by 29% (pO.OOl). The decrement was 
due to a 40% (pO.OOOl) fall in LDL cholesterol while VLDL and HDL cholesterol 
remained unchanged. Triglyceride was not significantly affected although there was a 15% 
reduction.
Table 4.5 Effect o f  Simvastatin on Lipids in Moderate Hypercholesterolaemia
■  ■
Baseline
mean 7.20 1.63 0.63 5.13 1.35
(SEM) (0.17) (0.19) (0.08) (0.11) (0.07)
range 6.5-7.6 1.0-2.25 0.35-0.85 4.75-6.0 1.1-1.6
Simvastatin
mean 5.10 1.39 0.63 3.09 1.36
(SEM) (0.26) (0.16) (0.08) (0.23) (0.05)
range 4.2-6.0 0.95-1.95 0.35-0.90 2.42-4.10 1.20-1.55
P 0 .0 0 1 NS NS 0.0001 NS
Table 4.6 documents the changes observed in the lipoprotein subfractions. There was a 
37% reduction (p 0 .0 5 )  in LDL mass. While the subfraction profile exhibited 
considerable variation, LDL II was the major subfraction in each subject. Quantitative 
analysis revealed that there was a 40% decrement in this species (p O .0 5 ) while there was a 
31% reduction in LDL I and 36% in LDL III. There was a tendency for LDL III to remain 
unchanged in those subjects in whom the mass was low and be reduced in those subjects in 
which the baseline mass was >100mg/100ml. HDL2 was increased significantly (p 0 .0 0 5 )  
by 73%, while HDL3 was unaffected.
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Table 4.6 E ffect o f  Simvastatin on Lipoprotein Subfractions 
in Moderate Hypercholesterolaemia
■■ ' ’ :
#/ Jfji
. . . . . . .  .. •
Baseline
mean 382 62 231 90 40 254
(SEM) (53) (7.9) (35) (25.9) (3.7) (7.3)
range 283-640 30-88 163-392 17-182 28-53 236-286
Simvastatin
mean 239 43 138 58 70 274
(SEM ) (35.9) (9.0) (15.0) (15.6) (5.5) (17.7)
range 170-412 16-74 102-206 33-132 51-90 211-326
P <0.05 NS <0.05 NS <0.005 NS
There were no changes to Lp(a). The lipoprotein composition o f LDL (d 1.019-1.063 g/ml) 
was altered. The percentage o f free cholesterol fell from 10.5 to 8.0 , a reduction o f 24% 
(p<0.05) while that o f triglyceride was increased by 34% (p<0.05).
Simvastatin Treatment in Combined Hyperlipidaemia
Five subjects, 4 male and 1 postmenopausal female with combined hyperlipidaemia 
(plasma cholesterol > 6.0 mmmol/1 and plasma triglyceride >2.3 mmol/l) were treated with 
simvastatin 40mg/d for 8 weeks. The lipid and lipoprotein levels attained are summarised 
in table 4.7.
Table 4.7 Effect o f  Simvastatin on Lipids in Combined Hyperlipidaemia
I » fflg&K 4y * - .fs \  ~ ^
'
Baseline
mean 6.55 2.90 1.13 4.53 0.90
(SEM) (0.11) (0.32) (0.17) (0.06) (0.06)
range 6.4-7.0 2.25-4.10 0.75-1.70 4.35-4.70 0.70-1.05
Simvastatin
mean 3.93 1.82 0.70 2.26 0.95
(SEM) (0.22) (0.21) (0.08) (0.13) (0.07)
range 3.2-4.4 1.35-2.60 0.60-1.00 1.9-2.7 0.7-1.1
P <0.001 <0.05 NS <0.0001 NS
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Simvastatin had profound reducing effects on plasma cholesterol (40%, p<0.001), plasma 
triglyceride (37%, p<0.05), VLDL cholesterol (38%, NS) and LDL cholesterol (50%, 
pO.OOOl), with a 5% non-significant increase in HDL cholesterol. Apo B (table 4.8) was 
reduced by 33% (p 0 .0 0 0 5 ) while Apo Al was unaffected.
Table 4.8 E ffect o f  Simvastatin on LDL Subfractions and Apoproteins 
in Combined Hyperlipidaemia
■f: .■
...........
■ W U M I M
ITT!
m f $
Baseline
mean 342 36 127 179 112 149
(SEM) (35) (9.1) (23.1) (27.7) (9.1) (7.6)
range 222-434 6.4-55.6 65-204 112-278 80-133 128-168
Simvastatin
mean 189 35.9 105 49 108 83
(SEM) (16.0) (9.0) (16.3) (14.3) (5.6) (4.1)
range 142-240 13.5-58 67-151 17-79 87-117 70-92
P <0.02 NS NS <0.01 NS <0.0005
The LDL subfractions shown in table 4.8 were altered by therapy. At baseline, LDL III 
levels were high and accounted for 52% of the total LDL mass. Treatment with simvastatin 
decreased the levels o f all 3 subfractions, the greatest fall being 73% (pO .O l) in LDL III. 
In all subjects concentration o f this species was > lOOmg/lOOml at baseline and less than 
this value on treatment. The relevant percentages o f LDL I, LDL II and LDL III on statin 
were 20%, 54% and 25% respectively, compared with 11%, 36% and 52% at baseline. 
LDL II and LDL III were negatively correlated with each other (r = -0.838, p<0.002) and 
LDL I and LDL III were also similarly associated (r= -0.788, p<0.01). There were no 
changes to Lp(a) or the lipoprotein composition o f LDL (d 1.019-1.063 g/ml).
Atorvastatin in Combined Hyperlipidaemia
Four subjects, 3males and 1 postmenopausal female with combined hyperlipidaemia 
(plasma cholesterol > 6.0 mmmol/1 and plasma triglyceride >2.3 mmol/l) were treated with 
atorvastatin at 40mg/day for 8 weeks. The lipid and lipoprotein levels attained are 
summarised in table 4.9.
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Table 4.9 Effect o f Atorvastatin on Lipids in Combined Hyperlipidaemia
...
■
Baseline
mean 6.84 2.84 1.18 4.71 0.95
(SEM ) (0.36) (0.28) (0.27) (0.14) (0.04)
range 6.4-7.9 2.25-3.55 0.75-1.90 4.45-5.10 0.90-1.05
Atorvastatin
mean 3.86 1.75 0.61 2.18 1.08
(SEM ) (0.16) (0.10) (0.03) (0.14) (0.01)
range 3.45-4.15 1.55-1.95 0.55-0.70 1.8-2.5 1.05-1.10
P 0 .0 0 2 0 .0 5 NS 0 .0001 0 .0 5
Treatm ent with atorvastatin had dramatic effects on the lipids and lipoproteins. There were 
reductions in plasma cholesterol (42%, p<0.002), plasma triglyceride (38%, p<0.05), 
V LD L cholesterol (48%, NS) and LDL cholesterol (54%, pO.OOOl) with a small but 
significant increase in HDL cholesterol (13%, pO .05). Table 4.10 summarises the effect 
o f  treatm ent on the LDL subfraction profile and the apolipoproteins. Apo Al was unaltered 
by atorvastatin but apo B was significantly reduced (47%, p 0 .0 0 5 ).
Table 4.10 Effect o f  Atorvavastatin on LDL Subfractions and Apoproteins
in Combined Hyperlipidaemia
H U B
Baseline
m ean 368 38 142 188 118 145
(SEM ) (26.1) (11-0) (22.2) (31.1) (5.6) (8.4)
range 316-434 6.4-55.6 99-204 146-278 106-133 128-168
Atorvastatin
mean 188 23.1 94.1 71 116 77
(SEM ) (11.0) (5.7) (8.0) (11.1) (2.1) (2.9)
range 164-214 7.5-34.7 71-108 46-92 110-120- 71-84
P 0 .0 0 5 NS NS 0 .0 5 NS 0 .0 0 5
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The mass o f LDL (table 4.10) was halved on atorvastatin therapy (p<0.005) and this was 
due to reductions in levels o f all 3 LDL species. LDL I fell by 39% (NS), LDL II by 34% 
(NS) and LDL III by 62% (p<0.05). All subjects had LDL III levels<100mg/ml on 
treatment. There was a switch in the distribution o f LDL II and LDL III, at baseline this 
was 39:51 and on atorvastatin it was 58:37. LDL I and LDL III were inversely associated ( 
r = -0.71, p<0.05). There were no changes to Lp(a) or the lipoprotein composition o f LDL 
(d 1.019-1.063 g/ml).
4.3.3 Nicotinic A cid  Derivatives
Acipimox treatment was investigated in normal, moderate hypercholesterolaemic and 
combined hyperlipidaemic groups o f subjects.
Acipimox Therapy in Normals
Nine normolipaemic subjects, 5 males and 4 premenopausal females aged 25-37, mean age 
31 years, received acipimox at 750mg/day for 4 weeks. The effect on lipids and 
lipoproteins is shown in table 4.11.
Table 4.1 J Effect o f  Acipimox on Lipids in Normal Subjects
Baseline
mean 5.23 1.20 0.61 3.09 1.51
(SEM) (1.59) (0.99) (0.51) (1.23) (0.31)
Acipimox
mean 4.59 0.77 0.36 2.68 1.55
(SEM) (0.70) (0.22) (0.25) (0.73) (0.32)
P NS NS NS NS NS
Treatment with acipimox for 4 weeks resulted in a 36% decrease in plasma triglyceride and 
slight but non-significant alterations in cholesterol, VLDL cholesterol and HDL 
cholesterol. The LDL subfraction data is shown in table 4.12.
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Table 4.12 Effect o f  Acipimox on LDL Subfractions in Normal Subjects
. mS B jfo ? 'f&g]
Baseline
mean 269 62 147 59
(SEM) (88) (29) (64) (14)
Acipimox
mean 270 68 161 41
(SEM) (58) (16) (51) (14)
P NS NS NS NS
While total LDL mass was unaffected by acipimox therapy, its component subfractions 
showed a tendency to redistribute towards larger more buoyant species (LDL I + 10%, LDL II 
+ 10%, LDL III - 31%). The change in LDL III correlated significantly with the fall in plasma 
triglyceride ( r= 0.75, p<0.05). There were no changes in the lipoprotein composition of 
LDL (d 1.019-1.063 g/ml).
Acipimox Therapy in Moderate Hypercholesterolaemia
Five subjects (3 males and 2 postmenopausal females) aged from 36-60 years were treated 
with acipimox at 1250 mg/day for 10 weeks. The subjects had moderate 
hypercholesterolaemia with LDL cholesterol >4.5 mmol/l and plasma triglyceride <2.3 
mmol/l. The lipid and lipoprotein results are in table 4.13. Treatment reduced plasma 
cholesterol by 18% (p<0.01). This decrement was due to a significant 21% fall in LDL 
cholesterol (p< 0.005) with a nonsignificant fall o f 26% in VLDL cholesterol and a mild 
3% increase in HDL cholesterol. There was also a non-significant fall in triglyceride of 
12%. The lipoprotein subfraction changes are shown in table 4.14.
Table 4.13 E ffect o f  Acipimox on Lipids in Moderate Hypercholesterolaemia
im
Baseline
mean 7.98 1.72 0.85 5.91 1.23
(SEM) (0.19) (0.12) (0.12) (0.21) (0.09)
range 7.5-8.6 1.32-2.02 0.45-1.17 5.34-6.60 1.00-1.57
Acipimox
mean 6.54 1.52 0.63 4.65 1.27
(SEM) (0.29) (0.23) (0.12) (0.22) (0.10)
range 5.9-7.4 1.12-2.28 0.42-1.05 4.03-5.33 1.08-1.57
P <0.01 NS NS <0.005 NS
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LDL II was the major species in these subjects and there was a moderate 11% decrease 
with therapy. There was a redistribution of the other LDL subfractions with a 76% rise in 
LDL I and a 37% decrease in LDL III. None o f these responses to acipimox therapy were 
significant. The HDL2/HDL3 ratio increased by 37% due to a 25% rise in HDL2 and an 
11% fall in HDL3. Triglyceride was inversely related to LDL I (r=-0.822, p< 0.005). On 
treatment LDL I and LDL III were negatively associated (r= -0.90, p<0.05) as were LDL I 
and LDL II (r= -0.96, p<0.01).
Table 4.14 Effect o f  Acipimox on Lipoprotein Subfractions 
in Moderate Hypercholesterolaemia
Baseline
mean 404 58 224 122 59 241
(SEM) (57) (15.8) (49.4) (66.4) (13.0) (25.6)
range 280-597 14-99 73-385 32-381 22-94 193-335
Acipimox
mean 378 102 199 77 74 221
(SEM) (25.3) (27.6) (17.2) (33.1) (14.5) (14.3)
range 309-466 18-154 164-248 12-200 34-107 191-261
P NS NS NS NS NS NS
There were no changes in the concentration o f Lp(a) or in the lipoprotein composition of 
LDL (d 1.019-1.063 g/ml).
Acipimox Therapy in Combined Hyperlipidaemia
One male subject aged 49 and one postmenopausal female aged 47 were treated with 
acipimox at 1250 mg/day for 10 weeks. The subjects had moderate combined 
hyperlipidaemia with LDL cholesterol >4.5 mmol/1 and plasma triglyceride >2.3 mmol/1. 
The lipid and lipoprotein results are in table 4.15. Treatment with acipimox in these two 
subjects had a favourable effect on all the lipids and lipoproteins. Cholesterol was reduced 
by 11% and 15% respectively in subjects Acipl and Acip2, triglyceride by 20% and 19%, 
VLDL cholesterol by 34% and 20% , LDL cholesterol by 12% and 18% and HDL 
cholesterol was increased by 23% and 10%.
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Table 4.15 Effect o f  Acipimox on Lipids in Combined Hyperlipidaemia
■ H
Baseline
Acip 1 7.9 2.72 1.25 5.73 0.95
Acip2 7.2 2.80 1.33 4.95 0.90
Acipimox
Acip 1 7.0 2.17 0.83 5.02 1.17
Acip 2 6.1 2.27 1.07 4.07 1.00
LDL mass (table 4.16) was reduced in both subjects by 10% and 29%. In Acipl there was 
a redistribution o f LDL subfractions towards larger and lighter species. At baseline, 82% 
was LDL III with a complete absence of LDL I. Acipimox decreased LDL III by 84%, 
increased LDL II by 145% and LDL I species was present. The percentages o f LDLI, LDL 
II and LDL III on treatment were 23, 66 and 11 respectively. At baseline LDL II was the 
major species in subject Acip 2. On treatment there was a 34% reduction in LDL II and a 
moderate 6% reduction in LDL III, resulting in a decrement of 29% in total LDL mass. 
There were similar alterations in HDL subfractions with a 24% rise in the ratio of 
HDL2:HDL3 in Acip 1 and 18% in Acip 2.
Table 4.16 E ffect o f  Acipim ox on Lipoprotein Subfractions 
in Combined Hyperlipidaemia
■ 1 1 I B l
K m
Baseline
Acip 1 430 0 79 351 31 179
Acip 2 460 64 299 97 29 213
Acipimox
Acip 1 474 107 311 56 55 257
Acip 2 327 42 194 91 33 205
There were no changes in the concentration of Lp(a) or in lipoprotein composition of LDL 
(d 1.019-1.063 g/ml).
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4.3.4 Fibrates
Two second generation fibrates were studied. Fenofibrate therapy was given to a group of 
subjects with moderate hypercholesterolaemia and a group o f subjects with non-insulin 
dependent diabetes mellitus. Ciprofibrate was given to a group o f subjects with moderate 
hypercholesterolaemia and another group with moderate hypertriglyceridaemia.
Fenofibrate in Moderate Hypercholesterolaemia
One male and 5 postmenopausal females aged 48 to 63 were treated with fenofibrate 
(lOOmg t.i.d.) for 8 weeks. The subjects had moderate hypercholesterolaemia with fasting 
LDL cholesterol >4.5 mmol/1 and plasma triglyceride <2.3 mmol/1. Plasma lipid, 
lipoprotein and apolipoprotein levels are shown in table 4.17.
Table 4.17 E ffect o f  Fenofibrate on Lipids and Apoproteins 
in Moderate Hypercholesterolaemia
Cliol Triglyceride VLDl
Choi Choi Choi
nmiol/l oig/IOIIml
Baseline
mean 8.29 1.64 0.64 6.27 1.38 131 142
(SEM) (0.27) (0.14) (0.12) (0.32) (0.07) (4.1) (6.6)
range
Fenofibrate
7.7-9.5 1.2-2.1 0.3-1.0 5.4-7.6 1.2-1.6 118-146 119-161
mean 5.83 1.06 0.42 3.90 1.50 132 96
(SEM) (0.31) (0.10) (0.05) (0.30) (0.08) (7.6) (3.8)
range 5.3-7.3 0.9-1.5 0.3-0.7 3.4-5.3 1.2-1.8 109-158 87-109
P <0.0002 <0.01 NS <0.0005 NS NS <0.0005
Treatment with fenofibrate significantly lowered plasma cholesterol by 30% (p<0.0002) 
and plasma triglyceride by 35% (p<0.01). The fall in VLDL cholesterol paralleled that of 
plasma triglyceride (34%). Fenofibrate reduced LDL cholesterol by 38% (p<0.0005) and 
apoB by 33% (p<0.0005, table 4.18). There was no change in the concentration o f HDL 
cholesterol or apo AI concentration. However there was a non-significant decrease o f 36% 
in HDL2:HDL3 ratio (table 4.18).
LDL II was the major subfraction (table 4.18) in most individuals. Fenofibrate therapy 
induced a 32% (p<0.02) fall in LDL mass, an 11% reduction in LDL I, a 44% reduction in 
LDL II (p<0.002) and a 44% non-significant reduction in LDL III. Where LDL III was 
present in small concentrations there was no change, but when it was in larger 
concentrations >100mg/100ml, there were dramatic reductions so that all subjects had LDL 
III concentrations < 50 mg/100ml.
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Table 4.18 E ffect o f  Fenofibrate on Lipoprotein Subfractions 
in Moderate Hypercholesterolaemia
m w jm IBf Jf 11 ,11111 
' * '■ , - N
Baseline
mean 526 170 297 60 66 249
(SEM) (43.2) (50.1) (24.0) (19.7) (17.9) (18.4)
range 374-651 58-385 233-365 20-152 30-144 181-294
Fenofibrate
mean 355 151 166 34 50 294
(SEM) (19.5) (19.5) (17.5) (5.6) (11.8) (20.7)
range 275-405 94-221 98-227 14-46 24-106 222-358
P <0.02 NS <0.002 NS NS NS
There were no changes in the concentration o f Lp(a) or in the lipoprotein composition of 
LDL (d 1.019-1.063 g/ml).
Fenofibrate in Non Insulin Dependent Diabetes Mellitus (N1DDM)
Ten patients, six men and 4 postmenopausal women, with stable NIDDM treated with 
either diet alone or in combination with an oral hypoglycaemic drug were treated with 
micronised fenofibrate for 12 weeks. The subjects were aged beteen 56 and 72 with mean 
BMI 27.4 (SEM 1.85). Table 4.19 shows a summary o f the lipids, lipoproteins and 
apoproteins.
Table 4.19 Effect o f  Fenofibrate on Lipids, Lipoproteins and Apoproteins 
in Non Insulin Dependent Diabetes Mellitus
Baseline
; V ' . m  * 
:
| |  6 ;
mean 7.29 3.06 1.14 4.94 136 153
(SEM) (0.22) (0.48) (0.07) (0.27) (3.1) (7.3)
range
Fenofibrate
6.1-8.2 0.7-5.2 0.9-1.7 3.8-6.2 120-150 100-180
mean 6.22 2.1 1.37 3.81 142 125
(SEM) (0.28) (0.34) (0.06) (0.17) (4.1) (7.8)
range 4.8-8.0 1.1-4.8 1.1-1.7 2.7-4.6 120-160 100-180
P <0.01 NS <0.05 <0.005 NS <0.02
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Treatment significantly lowered cholesterol (15%, p<0.01), LDL cholesterol (23%, 
p<0.005), Apo B (18%, p<0.02) and raised HDL cholesterol (20%, p<0.05). The reduction 
o f 31% in plasma triglyceride was not significant as 2 o f the 10 subjects had higher levels 
on fenofibrate. As was noted in NIDDM patients in chapter 3, there was a significant 
difference (p=0.024) in triglyceride between males and females. At baseline the mean 
(SEM) values in mmol/1 were 2.23(0.50) for males and 4.30(0.52) for females, but this was 
lost in treatment (males 1.85(0.28)mmol/l, females 2.48(1.56)mmol/l). ApoAI was 
unchanged.
Table 4.20 Effect o f  Fenofibrate on LDL Subfractions 
in Non Insulin Dependent Diabetes Mellitus
Ipilp • ^ , : r  y: a; V  * ' ; ,  .‘A ; ' T  ?
Baseline
mean 361 38 134 177
(SEM) (26.1) (7.3) (24.5) (28.1)
range 256-502 0-65 62-315 14-289
Fenofibrate
mean 340 64 200 76
(SEM) (23.1) (6.9) (14.6) (22.8)
range 253-459 35-111 148-268 32-269
P NS <0.02 <0.05 <0.02
LDL mass o f lipoproteins (table 4.20) did not alter after fenofibrate therapy, however there 
were significant changes in the distribution o f the LDL subfractions. At baseline 53% of 
LDL was small and dense LDL III. On fenofibrate, the mass o f this species was decreased 
by 60% (p<0.02) so that it comprised 21% of the total LDL mass. LDL I was increased by 
68% (p<0.02) becoming 19% o f total LDL and LDL II was increased by 49% (p<0.05) on 
treatment becoming the major LDL species at 60%. In these subjects, plasma triglyceride 
was highly correlated with the percentage o f all 3 subfractions 
(LDL I: r =-0.66, p<0.002; LDL II: r= - 0.731, p<0.0001; LDL III: r = 0.75, p<0.0001) 
and the subfractions were related to each other: LDLI and LDL II: r = 0.759, p<0.0001, 
LDL I and LDL III: r= -0.876, p<0.0001, LDL II and LDL III: r = -0.979, p<0.0001.
There were no changes in the concentration o f Lp(a) or in the lipoprotein composition of 
LDL (d 1.019-1.063 g/ml).
Ciprofibrate in Moderate Hypercholesterolaemia
Ciprofibrate therapy (lOOmg/d) was given to 9 subjects (6 men and 3 postmenopausal 
females ), aged 37-68 for 8 weeks. In these moderate hypercholesterolaemic subjects
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ciprofibrate favourably altered the lipid and lipoproteins (table 4.21). The 18% decrease in 
plasma cholesterol (p <0.005 ) was due to a 38% fall in VLDL cholesterol (p <0.005) and a 
24% fall in LDL cholesterol (p <0.01), while there was a 14% non-significant rise in HDL 
cholesterol. There was a marked 38% fall in plasma triglyceride (p <0.0005). Apo AI was 
unaffected by ciprofibrate, whereas apo B concentration was decreased by 33% (p <0.005).
Table 4.21 Effect o f  Ciprofibrate on Lipids, Lipoproteins and Apoproteins 
in Moderate Hypercholesterolaemia
Baseline
mean 7.46 1.38 0.71 5.32 1.39 140 130
(SEM) (0.29) (0.09) (0.05) (0.29) (0.08) (10.0) (6.9)
range 6.5-9.1 1.1-2.0 0.5-1.0 4.4-6.1 1.1-1.7 88-186 110-165
Ciprofibrate
mean 6.01 0.85 0.43 4.05 1.58 131 87
(SEM) (0.26) (0.07) (0.04) (0.32) (0.09) (7.8) (6.3)
range 5.1-7.4 0.6-1.2 0.3-0.6 2.9-5.6 1.3-2.0 107-171 59-118
P <0.005 <0.0005 <0.0005 <0.01 NS NS <0.0005
Analysis o f LDL and HDL subfractions are shown in table 4.22. There was no change in 
HDL3 with a slight decrease in HDL2. The mass o f total LDL was significantly reduced by 
22% (p< 0.01). The changes in the individual subfractions were not significant, however 
both LDL II and LDL III fell 31%. In subjects with higher LDL III concentrations these 
were greatly reduced.
Table 4.22 Effect o f  Ciprofibrate on Lipoprotein Subfractions 
in Moderate Hypercholesterolaemia
-
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Baseline
mean 492 163 272 56 99 259
(SEM) (25.3) (20.2) (29.2) (13.8) (11.5) (23.5)
range 410-618 97-252 181-451 22-141 34-158 175-392
Ciprofibrate
mean 381 157 186 39 84 266
(SEM) (27.7) (13.3) (22.8) (6.9) (15.8) (25.5)
range 253-493 108-224 102-298 15-79 33-166 153-339
P <0.01 NS NS NS NS NS
LDL I and LDL III were negatively associated ( r= -0.67, p <0.05), whereas triglyceride 
was associated with % LDL I (r = - 0.59, p <0.02) and positively with LDL II (r = 0.58, p< 
0.02). There were no changes in the concentration o f Lp(a) or in the lipoprotein 
composition o f LDL (d 1.019-1.063 g/ml).
Ciprofibrate in Moderate Hypertriglyceridaemia
Ten men, aged 34-65, with moderate hypertriglyceridaemia were treated with ciprofibrate 
at lOOmg/day for 10 weeks. There was a slight non-significant fall in plasma cholesterol 
(table 4.23) and a slight non-significant rise in LDL cholesterol (table 4.23 ). HDL 
cholesterol was also raised non-significantly (11%). The major change was a 36 % 
decrement in plasma triglyceride (p <0.02), which was reflected in a 44% fall in VLDL 
cholesterol (p <0.002). The apoproteins reflected these alterations in plasma lipoproteins 
with no change in apo AI and a 19% (p <0.05) fall in apo B.
Table 4.23 Effect o f  Ciprofibrate on Lipids, Lipoproteins and Apoproteins 
in Moderate Hypertriglyceridaemia
Baseline
mean 6.05 3.12 1.48 3.64 0.88 115 148
(SEM) (0.24) (0.36) (0.14) (0.23) (0.03) (7.7) (7.6)
range 5.2-
7.1
5.67
2.0-5.2 1.0-2.1 2.6-4.5 0.8-1.1 90-166 116-180
Ciprofibrate
mean 2.0 0.83 3.87 0.98 120 120
(SEM) (0.30) (0.18) (0.09) (0.25) (0.06) (5.1) (11.0)
range 4.2- 1.1-2.7 0.4-1.3 2.6-4.7 0.7-1.2 96-137 62-164
P
6.9
NS <0.02 <0.002 NS NS NS <0.05
Table 4.24 summarises the response o f the lipoprotein subfractions to ciprofibrate 
treatment. There were small non-significant changes in HDL subfractions and no change in 
LDL mass. However, there were dramatic alterations to the distribution o f the individual 
LDL subfractions. At baseline the distribution of LDLI: LDLII: LDL III was 8:20:71 and 
13:46:38 on treatment. The masses o f LDL I and LDL II were increased by 67% (p <0.05) 
and 124% (p < 0.001) respectively, whereas the mass o f LDL III was decreased by 40% (p 
<0.05).
There were no changes in the concentration o f Lp(a) or in the lipoprotein composition of 
LDL (d 1.019-1.063 g/ml).
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Table 4.24 E ffect o f  Ciprofibrate on Lipoprotein Subfractions 
in Moderate Hypertriglyceridaemia
LDL 111 
mg/100ml
Baseline
mean 279 23 57 198 17 248
(SEM) (21.2) (4.3) (12.0) (23.5) (1.9) (18.4)
range 191-356 0-42 0-112 130-354 10-26 176-374
Ciprofibrate
mean 319 39 144 125 27 297
(SEM) (20.9) (5.6) (17.1) (24.3) (5-9) (16.2)
range 207-396 10-61 37-220 16-260 11-70 234-401
P NS <0.05 <0.001 <0.05 NS NS
4.3.5 Combination Therapies
The combinations o f acipimox and cholestyramine and colestipol and simvastatin were 
exam ined in subjects with moderate hypercholesterolaemia.
Acipim ox and Cholestyramine Combination in M oderate Hypercholesterolaemia 
A com bination therapy o f 12g/day o f cholestyramine: and 1250 mg/day o f acipimox was 
given to 5 subjects with moderate hypercholesterolaemia. The subjects were 3 males and 2 
postmenopausal females, aged 36-60. Table 4.25 indicates that combination therapy 
reduced plasma cholesterol by 25% (p<0.001) while plasma triglyceride fell by a non­
significant 8%. There was a 19% (NS) fall in VLDL cholesterol, a 29% (p <0.002) fall in 
LDL cholesterol and a non-significant 10% increase in HDL cholesterol.
Table 4.25 E ffect o f  Acipimox and Cholestyramine in Combination 
on Lipids in Moderate Hypercholesterolaemia
- > ' W' "j tS>N
p Iflf §§11 j
Baseline
mean 7.98 1.72 0.85 5.91 1.23
(SEM) (0.19) (0.12) (0.12) (0.21) (0.09)
range 7.5-8.6 1.3-2.0 0.45-1.17 5.34-6.60 1.00-1.57
Acipimox + cholestyramine
mean 6.02 1.58 1.68 4.17 1.36
(SEM) (0.27) (0.26) (0.10) (0.28) (0.09)
range 5.5-7.0 1.0-2.4 0.48-1.03 3.42-4.85 1.08-1.60
P <0.001 NS NS <0.002 NS
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There were no significant changes in the lipoprotein subfractions (table 4.26). The 
individual HDL subfractions were slightly raised and LDL I decreased by 11%, and LDL II 
and LDL III both decreased by 27%. This resulted in a 22% non-significant decrease in 
LDL mass. There were no changes in the concentration o f Lp(a) or in the lipoprotein 
composition o f LDL (d 1.019-1.063 g/ml).
Table 4.26 E ffec t o f  A cipim ox and Cholestyramine in Combination  
on Lipoprotein Subfractions in M oderate H ypercholesterolaemia
Baseline
IIM | IK , ^
mean 404 58 224 122 59 241
(SEM) (57.1) (15.8) (49.4) (66.4) (13.0) (25.6)
range
Acipim ox + 
cholestrvr amine
280-597 14-99 73-385 32-381 22-94 193-335
mean 314 52 161 89 66 253
(SEM) (24.8) (10.9) (20.4) (28.1) (16.2) (6.4)
range 261-378 18-83 124-239 26-159 23-101 236-272
P NS NS NS NS NS NS
Colestipol and Simvastatin Combination in Moderate Hypercholesterolaemia  
Simvastatin (20mg nocte) and colestipol (20g/d) were given in combination for 10 weeks to 
a group o f 7 male subjects with cholesterol >6.0 mmol/1 and plasma triglyceride < 3 . 0  
mmol/1. They were aged between 45 and 64 years. Plasma lipid and lipoprotein levels are 
displayed in table 4.27. Combined treatment reduced plasma cholesterol by 37% 
(p<0.0001), while plasma triglyceride fell by 8% (NS). This decrement was due to a 48% 
fall in LDL cholesterol (p< 0.0001) and a 19% fall in VLDL cholesterol (NS). HDL 
cholesterol was significantly (p<0.05) raised by 11%.
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Table 4.27 Effect o f Colestipol and Simvastatin in Combination
on Lipids in Moderate Hypercholesterolaemia
B |B |
$s pH'
UjH
Baseline
mean 6.68 1.95 0.88 4.6 1.10
(SEM) (0.16) (0.14) (0.06) (0.22) (0.03)
range 6.02-7.27 1.52-2.65 0.70-1.12 3.7-5.5 1.03-1.23
Colestipol +
simvastatin
mean 4.19 1.79 0.71 2.25 1.23
(SEM) (0.15) (0.26) (0.11) (0.13) (0.05)
range 3.78-4.80 0.97-3.03 0.40-1.25 1.95-2.78 1.10-1.48
P <0.000 1 NS NS <0.0001 <0.05
Table 4.28 shows the effect o f colestipol and simvastatin in combination on the lipoprotein 
subfractions. There were modest, non-significant rises in HDL subfractions with no 
alteration in HDL2/HDL3 ratio. There was a marked fall in total LDL mass (54%, p 
<0.001), which could be explained by profound decreases in both o f the larger, more 
buoyant species LDL I and LDL II (72%, p<0.0005 and 59%, p<0.0005 respectively). 
Despite a 33% reduction in the mean value o f LDL III, the overall effect was not 
significant. At baseline the distribution o f LDL I: LDL II :LDL III was 6:53:27 and on 
therapy it was 11:46:42.
Table 4.28 Effect o f  Colestipol and Simvastatin in Combination 
on LDL Subfractions in Moderate Hypercholesterolaemia
■ n r ?
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Baseline
mean 420 77 218 125 47 226
(SEM) (36.8) (9.1) (18.5) (33.1) (12.6) (9.1)
range 305-584 45-107 154-285 24-216 23-102 199-260
Colestipol +
simvastatin
mean 194 21 89 84 63 281
(SEM) (10.7) (5.2) (7.6) (16.8) (9.3) (24.8)
range 154-232 0-44 69-121 30-154 16-89 217-379
P <0.001 <0.0005 <0.0005 NS NS NS
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There were no changes in the concentration of Lp(a) or in the lipoprotein composition o f 
LDL(d 1.019-1.063 g/ml).
4.3.6 Influence o f  Triglyceride on LDL III
Triglyceride showed no relationship with LDL III until > 1 . 5  mmol/1 when there was a 
positive association at baseline (fig 4.1). On treatment with fibrates this association was 
retained (baseline r = 0.63, p<0.001, on fibrate r=0.67, p<0.001). On statins, in particular 
in the combined hyperlipidaemic subjects, this association between LDL III and plasma 
triglyceride became negative (baseline r = 0.42, p=0.12 and on statin r = -329, p=0.231).
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Fig. 4.1 Plasma Triglyceride and LDL III on Statin and Fibrate Therapy
LDL III concentrations before (black) and after(red) therapy with fibrates (left) and statins (right). 
Closed cicles are combined hyperlipidaemic subjects on statin.
4.4 Discussion
Application o f a quantitative procedure for LDL subfractionation to the study o f the 
mechanisms o f the action of drugs permits a closer insight into their effects compared to a 
simple evaluation of particle size or lipid composition o f the particle. This is demonstrated 
repeatedly in the present studies where the influence of various drugs on the actual 
concentration of small dense LDL could be determined.
The resins colestipol and cholestyramine were observed to selectively decrease the mass of 
the larger more buoyant LD11 and LDL II species in both normal and CABG subjects.
LDL III concentration was relatively unaffected resulting in an apparent enrichment in 
small dense LDL III. This finding is in agreement with previous observations in miniature
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pigs (Huff et al, 1989), guinea pigs (Witzum et al, 1985) and in humans (Young et al, 
1989). When resin- and control-LDL were compared in vitro and in vivo, the control LDL 
had a higher affinity for the LDL receptor and a higher fractional catabolic rate. This 
suggests that resins by stimulating the LDL receptor induce selective clearance of an LDL 
species with high affinity (LDL I/II) leaving behind an LDL relatively enriched in small 
dense particles which have lower affinity for receptors (fig.4.2).
L D L  I L D L  II LDLIII
Pattern A Pattern B
o.
receptors
Fig. 4.2 Pharmacological Regulation of LDL Subfractions
Trig triglyceride, LpL lipoprotein lipase, HL hepatic lipase.
When hepatic lipase activity or plasma triglyceride concentrations are high, small LDL III is formed 
and the LDL distribution profle shifts towards a pattern B phenotype Large LDL is more activly 
taken up by the receptor-mediated process compared to the smaller LDL III. Drugs that lower 
plasma triglyceride or stimulate the activity o f lipoprotein lipase (such as the fibrates) result in a 
reduction in small LDL III and a shift in LDL subfraction profile from pattern B to pattern A so 
producing a better ligandfor receptors.. Drugs such as statins up regulate the LDL receptor and 
result in increased removal of larger LDL particles.
Therapy with HMGCoA inhibitors in moderate hypercholesterolaemia significantly 
reduced plasma cholesterol, LDL cholesterol and the quantities o f larger LDL, with a 
variable effect on LDL III. Where this last subfraction was present at high concentration (> 
lOOmg/ 100ml) it was reduced. These changes in LDL I and II are consistent with the 
observation by Witzum et al (1985) noted above that larger LDL is removed selectively by 
the LDL receptor. In combined hyperlipidaemia, both simvastatin and atorvastatin gave
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approximately 40% reductions in plasma cholesterol and plasma triglyceride ( tables 4.7 
and 4.9). This resulted in reductions in the larger LDL subtractions but even greater 
reductions in LDL III. The influence o f statins on the LDL profile may be due to the 
removal of precursors of small dense LDL from the circulation by stimulated receptors. In 
support of this suggestion Gaw et al (1995) reported that in hypercholesterolaemics, 
simvastatin stimulated direct removal of apo B in Sf 12-400 range resulting in a decreased 
LDL production rate. Furthermore stable isotope metabolic studies from this laboratory in 
the subjects in tables 4.7 to 4.10. have shown that there was increased clearance of VLDLx 
on treatment with simvastatin (Forster et al, 1996a) and atorvastatin (Forster et al, 1996b). 
This action reduced the amount of VLDL! remnants passing through the IDL-LDL cascade 
resulting in lower levels of LDL III. The effect of statins on LDL III is in clear distinction 
to that of the resins which tend to increase triglyceride and VLDL! levels (Packard & 
Shepherd, 1982).
Since plasma triglyceride is a major determinant o f LDL III concentration, triglyceride 
lowering drugs would be predicted to have a major impact on the LDL subtraction profile. 
The influence o f an isolated triglyceride lowering is seen in normal subjects who when 
treated with acipimox showed no overall change in LDL mass but a redistribution of the 
profile towards LDL I and LDL II. In hyperlipidaemic subjects there was a reduction in 
plasma cholesterol with a modest reduction in triglyceride, greater reductions being 
observed in those subjects with triglyceride > 2.3 mmol/1. As in normals, there was a 
modest decrement in LDL mass but there was a substantial redistribution of the LDL 
profile resulting in an increase in LDL II and a decrease in LDL III to below 100 
mg/100ml. One subject in this study reduced LDL III mass from 351 to 97 mg/100ml. In 
one of the few studies published on the effects of nicotinic acid, Franceschini et al (1990) 
observed structural change in LDL in patients with hypertriglyceridaemia when larger more 
buoyant LDL appeared on treatment with an increased affinity for the LDL receptor in 
vitro. In 1992, Superko et al observed a change from pattern B (small LDL) by gradient 
gel electrophoresis to pattern A (larger LDL) in subjects treated with nicotinic acid when 
plasma triglyceride fell below 1.6 mmol/1. This in line with the idea of a threshold 
triglyceride level for B to A transition.
In all forms of dyslipidaemia investigated - moderate hypercholesterolaemia, moderate 
hypertriglyceridaemia and non insulin dependent diabetes - the fibrates had a profound 
effect on triglycerides as well as the LDL subtraction profile. The concentration of LDL III 
was reduced but there was a variable response in the larger subtractions which were 
increased in diabetes and moderate hypertriglyceridaemia and reduced in moderate 
hypercholesterolaemia. These observations are in agreement with studies carried out by 
Chapman et al (1996) using ciprofibrate and Guerin et al (1996) using micronised 
fenofibrate in combined hyperlipidaemia. In 1984, Homma et al observed reductions in 
small dense LDL in subjects with type II and IV hyperlipidaemia. In an elegant study in 
1987, Kleinman et al showed that LDL in hypertriglyceridaemia was small and enriched in 
triglyceride and protein when compared to normal LDL and showed defective binding to 
LDL receptors of normal cultured fibroblasts. These structural and functional defects were 
reversed with bezafibrate treatment and the improvement was related to altered disposition
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o f apo B epitopes on LDL as measured by monoclonal antibodies, indicating a 
conformational change in this LDL protein.
There have been recent advances in the knowledge of the molecular mechanisms that 
underlie the lipid lowering action of fibrates. The fibrates activate a group of transcription 
factors belonging to the superfamily of nuclear hormone receptors, the peroxisome 
proliferator-activated receptors (PPAR) (Gottlicher et al, 1992). Upon activation, these 
receptors bind to the response elements of target genes and thus regulate their expression. 
Fenofibrate and bezafibrate have been observed to down regulate the apo C III gene (Staels 
et al, 1995; Haubenwallner et al, 1995) and upregulate the lipoprotein lipase gene (Staels et 
al, 1992; Schoonjans et al, 1995). These actions will enhance both the intravascular 
lipolysis of triglyceride-rich lipoproteins and the binding of VLDL to LDL receptors due to 
reduced amount of CIII relative to E on the particle. Studies in transgenic mice have 
shown that over-expression of apo CIII alone causes hypertriglyceridaemia by reducing 
clearance (Aalto-Setala et al, 1992), while the absence of CIII expression by gene knockout 
induces rapid clearance of triglyceride and very low plasma triglyceride levels (Maeda et 
al, 1994). The net effect of both these fibrate actions is the elimination of raised plasma 
triglyceride levels and hence reduced capacity for neutral lipid exchange. This has 
predictable consequences for the LDL subtraction pattern as outlined in chapter 3. 
However since like the statins, fibrates promote direct catabolism o f triglyceride rich 
VLDL, then it may be that less apo B is channelled into the production o f small dense LDL 
on such treatment also.
Combination therapy of acipimox and cholestyramine reduced plasma triglyceride and 
LDL cholesterol more than expected. There were reductions in all 3 subfractions. 
Acipimox therapy favours the formation of receptor-active LDL I and LDL II whereas 
cholestyramine enhances receptor expression and so these species are quickly removed. On 
the basis of previous discussion this is due to the formation of a receptor-active from a 
receptor-inactive species. The combination o f colestipol and simvastatin was highly 
effective in reducing all 3 LDL species as well as inducing favourable changes in the lipids 
and lipoproteins. Metabolic studies by Gaw et al (1996) indicate that these reductions are 
due to increased IDL and LDL clearance. It is postulated that addition o f a statin overcame 
the resin effect on LDL III.
These drug induced alterations in the LDL subtraction profile can be explained by 
consideration o f the putative model o f LDL subtraction metabolism proposed in chapter 3 
and supported by the observations of Tan et al (1995a). Plasma triglyceride is the major 
controlling factor being positively associated with LDL III and negatively with LDL I. The 
activities of the lipolytic enzymes are important - a high level of hepatic lipase in the male 
range being required to lipolyse triglyceride-rich LDL II to LDL III. CETP mediated 
transfer of triglyceride from triglyceride-rich VLDL for cholesteryl ester in LDL forms a 
triglyceride-rich LDL which is a better substrate for hepatic lipase.
Reduction in triglyceride by stimulation of LPL (fibrates) or increased VLDL catabolism 
(fibrates, statins) reduces the extent o f conversion of LDL II to LDL III and favours the 
retention of larger LDL particles which in turn are removed more rapidly by receptors. Fig.
4.2 shows that drugs that lower plasma triglyceride levels shift the spectrum towards less
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dense particles especially if  plasma triglycerides fall below 1.5 mmol/1. Activation of LDL 
receptors by resins or statins reduces LDL I and LDL II due to increased receptor-mediated 
clearance. It was interesting to note an apparent break in the link between plasma 
triglyceride level and LDL III in the group of combined hyperlipidaemic patients treated 
with simvastatin and atorvastatin in which there had been the observation that the drugs 
induced a rapid removal o f large triglyceride-rich VLDL! (Forster et al, 1996a, 1996b).
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Chapter 5 Metabolic Heterogeneity of
Low Density Lipoprotein in Normals
5.1 Introduction
Low density lipoprotein (LDL), the major cholesterol transporter in human plasma, is 
generated by the stepwise delipidation of very low density lipoprotein (VLDL). In 1981 
Phillips et al observed a strong positive link between plasma triglyceride and LDL 
cholesterol levels within the normal range for these parameters. This relationship persists 
after correction for age and weight and was confirmed in the Glasgow arm (Townhead 
Screening Study) of a UK epidemiological survey (Mann et al, 1988) carried out in the mid 
1980s. Fig 5.1 demonstrates this relationship in 1843 men and 1881 women. As plasma 
triglyceride rose from 0.5 to 1.5 mmol/1 there was a 33% increase in LDL cholesterol but 
when plasma triglyceride exceeded 2.0 mmo/1 there was a gradual reduction in LDL levels. 
Above 5 mmol/1 i.e. in severe hypertriglyceridaemia very low LDL cholesterol 
concentrations are found (Shepherd et al, 1985).
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Fig. 5.1 Relationship between LDL Cholesterol and Plasma Triglyceride
The measurements were carried out in 1843 men and 1881 women. LDL cholesterol was calculated 
by the Friedwald equation
In order to examine more closely the link between plasma triglyceride levels and LDL 
metabolism, a study was designed to investigate LDL kinetics in a group of young men 
and women with normal lipid levels. Although early investigations o f LDL metabolism in 
normolipaemic subjects assumed structural and metabolic homogeneity (Langer et al, 
1972), there is evidence that LDL exists in the plasma of all individuals as a group of
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discrete subfractions as has been described fully in Chapter 3. In the present study, a 
previously defined multicompartmental modelling procedure (Boston et al, 1982) was used 
to analyse LDL catabolism from plasma and the appearance and disappearance of its 
products from urine.
5.2 Methods
5.2.1 Protocol
Each subject took part in a two week study period during which they underwent 
measurements of lipids, lipoproteins and lipoprotein subfractions and determination of the 
kinetics of native and 1,2-cyclohexanedione-treated, radiolabelled LDL tracers as described 
in 2.6. The metabolic studies were conducted on an outpatient basis with standard dietary 
advice provided to all participants, based on the American Heart Association (AHA) Step 1 
diet, being reinforced by interviews during the study period. The clinical aspects of the 
work were undertaken by Professor J Shepherd, Dr J Series and Dr B Yip.
5.2.2 Subjects
Volunteers, 21 males and 4 females, aged 19-39 years (mean 26 years) were recruited from 
individuals attending a local coronary screening programme. All were healthy and, on the 
basis of clinical laboratory investigations, were free from hepatic, renal, endocrine or 
haematological dysfunction. None was on medication, including oral contraceptive 
therapy, nor were any of the females pregnant. All subjects were within 15% of their ideal 
body weight and had normal lipid levels (plasma cholesterol <6.5 mmol/1 and plasma 
triglyceride <2.3 mmol/1). The characteristics of the subjects are shown in table 5.1.
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Table 5.1 Summary o f Subjects Characteristics
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. V :: 
...............................................................................................................................
N 1 M 32 56 3/4
N 2 M 31 65 3/3
N 3 M 30 57 3/4
N 4 M 30 67 3/3
N 5 F 26 55 2/3
N 6 M 21 61 3/4
N 7 M 20 65 3/3
N 8 F 33 53 3/3
N 9 M 22 55 3/3
N 10 M 20 70 3/3
N 11 F 27 64 2/2
N 12 F 39 66 3/3
N 13 M 21 79 3/3
N 14 M 25 83 3/4
N 15 M 22 60 3/3
N 16 M 20 65 3/3
N 17 M 30 71 2/3
N 18 M 19 73 3/4
N 19 M 19 69 3/4
N 20 M 21 73 3/3
N 21 M 21 88 3/4
N 22 M 27 73 3/4
N 23 M 35 68 3/3
N 24 M 30 83 3/4
N 25 M 21 78 4/4
5.2.3 Kinetic Analysis
The kinetics o f plasma apo-LDL was first analysed by a simple curve-peeling procedure 
and secondly plasma and urine data were analysed together by multicompartmental 
modelling.
Curve-peeling Kinetic Analysis
The kinetics o f LDL turnover were first analysed by the standard Matthews (1957) 
approach used in the classic study o f Langer et al (1972). When the daily plasma 
radioactivities were plotted on semi-logarithmic graph paper, the curves obtained were 
biexponential and indicative o f a model with an extra-vascular and an intra-vascular plasma 
pool o f apo-LDL. The curve (fig 5.2) was biexponential and was described by the equation
b i t  . b 2 ty=C[e- + C2e-
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where Cj and C2 are the intercepts on the y-axis, and b l and b2 are the slopes o f the two 
exponentials. If  the tracer is homogeneous and catabolised solely from the plasma 
compartment then a number of kinetic parameters may be determined by Matthews 
mathematical approach. The fractional catabolic rate (FCR) is described by the equation:
FCR=l/(C1/bl+C2/b2) 
and the intravascular pool (IV) by the equation:
\V=(Cylb\+C2lb 2 f  / (C ,/(bl)2 + C2/(b2)2)
Practically the plasma data was plotted to determine visually the start o f the second, slow 
exponential. Simple regression was used to provide a line of best fit to this exponential, 
yielding b l and Q . The exponential was then extrapolated to the y-axis and these 
projected values were then subtracted from the plasma curve at suitable intervals (0.5, 1.0,
1.5 and 2 days) in the LDL turnover in order to calculate the first exponential. Linear 
regression was used to derive b2 and C2. Absolute catabolic rates (ACR) were calculated 
as the product o f the FCR and the mass of apo-LDL in the circulation. Plasma volume was 
usually calculated by isoope dilution or as 4% of body weight (both being in good 
agreement).
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Fig. 5.2 Matthews Analysis of Plasma Radioactivity Curve
The biexponential curve is resolved into two monoexponentials defined by the parameters bj and b2 
(slopes) and Cj and c2 (intercepts).
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Multicompartmental Modelling
When urine and plasma radioactivities were combined together using the 
multicompartmental procedure in SAAM 29, two plasma apo-LDL compartments were 
required to provide a satisfactory fit (fig 5.3).
synthesismgfd
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Fig. 5.3 Two pool Model of LDL Kinetics
There are two plasma compartments with two points o f input and pool B is allowed extravascular 
exchange.
One represented LDL with a rapid catabolic rate and high affinity for the receptor pathway 
(pool A) while the other defined a lipoprotein which was more slowly catabolised (pool B) 
by mechanisms involving a reduced level of receptor activity. Pool B was allowed to 
exchange with an extravascular pool o f apo-LDL. Using this model it is possible to 
interpret U/P ratios obtained for the subjects in the study, seen in fig 5.4. If plasma apo- 
LDL was limited entirely to pool A, then there would be a constant U/P ratio of about 0.5 
for quintile 1 (Q l), 0.34 for quintile 2 (Q2) and 0.29 for quintile 3 (Q3) throughout the 14 
days of the turnover. On the other hand, if  all the material was in pool B, there would be a 
constant U/P ratio of about 0.23. The fall-off in the U/P ratios from day 2 to day 12 reflects 
the heterogeneous mix of apo-LDL in the plasma. Individuals with lower apo-LDL mass 
(Q l) show a high ratio of pool A to pool B. As the more rapidly catabolised pool A species 
is cleared from the plasma, the U/P ratio decreases until all subjects achieve approximately 
the same U/P value which is determined by slowly metabolised pool B apo-LDL. The U/P 
ratio for cyclohexanedione modified LDL was constant at 0.2 pools/day.
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Fig. 5.4 Urine to Plasma Radioactivity Ratios
Urine to plasma radiactivity ratios in native LDL for quintiles 1,2 and 3 (Q 1-3) and for 
cyclohexanedione modified LDL (CHD).
In this model, the overall FCR for apo-LDL can be perturbed by changing either the FCR 
from pool A or the distribution between the pools A and B. The influence of these 
parameters was examined on daily U/P ratio in a series of simulations (fig. 5.5). Changes 
in the elimination rate from pool A affect the shape of U/P curve in a manner that is distinct 
from that which occurs when the initial mass is shifted from poool A to pool B. Hence 
these parameters can be derived unambigously during the fitting process.
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Panel A - altered mass distribution between pools A and B. a mass o f pool A = mass o f pool B, b 
mass of pool A > mass o f pool B,ratio A:B = 0.6, c mass o f pool A < mass o f pool B, ratio A:B = 
0.4. Panel B - altered elimination rates from pool A. d  rate = 0.55, e rate = 0.69, f  rate = 0.85.
5 3  Results
For ease o f presentation, the 25 subjects were ranked according to their total circulating 
apo-LDL mass (table 5.2) which varied from 1.41 to 4.21 g and divided into quintiles. 
Apo-LDL concentration was calculated as described previously (Packard et al, 1976) from 
the cholesterol: protein ratio of LDL (d 1.019-1.063 g/ml) and the plasma LDL cholesterol 
concentration determined by lipoprotein quantitation. This includes a small contribution 
from IDL (d 1.006-1.019 g/ml). The mass o f apo-LDL was the product o f the 
concentration and plasma volume.
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Table 5.2 Characteristics Summarised by Quintile
I v\ A >y.
■
I 29.8 4/1 60.0 2/3=1 1671
(1.0) (2.5) 3/3=2
3/4=2
(75)
II 23.2 4/1 60.8 3/3=4 2036
III
(2.5)
2.6.8 3/2
(3.1)
70.4
3/4=1
2/2=1
(94)
2477
(3.2) (4.5) 3/3=3
3/4=1
(35)
IV 21.8 5/0 70.2 2/3=1 2640
(2.1) (1.5) 3/3=2
3/4=2
(36)
V 26.8 5/0 78.0 3/3=1 3371
(2.7) (3.5) 3/4=1
4/4=1
(273)
Values are m ean (SEM )
There were no significant age differences between the groups, nor did exclusion o f the 4 
females make any difference to the subsequent interpretation o f the data. Nineteen of the 
subjects were aged 30 or below and only one was over 35 years. Increasing apo-LDL mass 
was associated with higher body weights (r=0.69, p<0.001).
5.3.1 Lipids, Lipoproteins and Apolipoproteins
The individual lipids, lipoproteins and HDL subfractions are shown in Appendix tables 1 
and 2 ,with the mean (SEM) lipid and lipoprotein levels in these groups presented in tables
5.3 and 5.4.
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Table 5.3 Plasma Lipid and Lipoproteins by Quintile
WfRL ----------------------------%'?-1!* %£ - , •' ■- ' :
.1,''.:.. ..............
I 4.46 0.82 0.38 2.56 1.54
(0.25) (0.15) (0.07) (0.14) (0.14)
II 4.56 1.14 0.36 2.54 1.66
(0.21) (0.14) (0.10) (0.13) (0.10)
III 4.70 1.10 0.44 2.82 1.42
(0.33) (.007) (0.02) (0.34) (0.12)
IV 5.34 1.22 0.62 3.04 1.58
(0.38) (0.08) (0.09) (0.14) (0.14)
V 5.90 1.54 0.64 3.78 1.50
(0.15) (0.18) (0.07) (0.14) (0.09)
Values are m ean (SEM )
In this group o f normolipaemic individuals, plasma triglyceride ranged between 0.5 and 1.9 
mmol/1, plasma cholesterol from 3.8 to 6.6 mmol/1 and LDL cholesterol from 2.0 to 4.2 
mmol/1. There were significant correlations between plasma triglyceride and plasma 
cholesterol (r=0.71, p<0.001) and between plasma triglyceride and LDL cholesterol 
(r=0.57, p<0.01). Body weight was related to the concentration o f triglyceride (r=0.51, 
p<0.01) but not to LDL cholesterol (r=0.26, NS). VLDL cholesterol was related to plasma 
triglyceride (r=0.71, p<0.0001) total cholesterol (r=0.64, p<0.001), LDL cholesterol 
(r=0.49, p=0.013) and LDL mass (r=0.56, p<0.005).
Table 5.4 Apo-LDL and HDL Subfraction Concentrations by Quintile
I 69.8 ........... 65 .... 221
(3.8) (17) (30)
II 82.8 80 230
(4.3) (18) (13)
III 87.2 37 182
(6.2) (5) (14)
IV 94.2 81 223
(1.9) (16) (24)
V 108 61 206
(8.7) (9) (21)
Values are m ean (SEM )
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Neither HDL cholesterol nor the concentrations o f HDL subfractions differed across the 
quintiles. Apo-LDL concentration rose 50% across the quintiles and the total circulating 
mass o f the apoprotein in quintile V was double that in quintile I. Apo-LDL concentration 
and pool size correlated strongly with plasma cholesterol (r=0.67, p<0.001; r=0.64. 
p<0.001, respectively) and with plasma triglyceride levels (r=0.52, p<0.01; r=0.70, p<0.001 
respectively).
There was no significant influence o f apoE phenotype on plasma lipid and lipoprotein 
levels although there was a tendency for the E4 allele to be associated with increased 
circulating apo-LDL mass.
The composition o f LDL (Appendix table 3 and table 5.5) did not differ between the 
quintiles, indicating that the variation observed in LDL cholesterol concentration was 
associated with an altered number o f lipoprotein particles in the circulation.
Table 5.5 Compostion o f  LDL by Quintile
7 26.2 12.2 32.3 7.6 21.6
(1.2) (0.8) (1.3) (0.8) (1.1)
u 25.3 11.4 34.6 7.3 21.4
(0.3) (1.2) (1.3) (0.9) (0.9)
i n 24.9 9.8 34.7 8.1 22.6
(1.1) (0.4) (0.6) (0.7) (0.8)
IV 25.6 10.5 36.2 7.2 20.6
(0.8) (0.5) (0.9) (0.9) (0.3)
V 24.8 11.0 35.8 7.6 20.9
(0.6) (0.7) (0.4) (0.3) (0.3)
Values are m ean (SEM )
5.3.2 Receptor-mediated and Receptor-independent Apo LDL Metabolism
Apo-LDL kinetic parameters derived from by Matthews analysis for individual subjects are
given in Appendix table 4 and by quintiles in table 5.6.
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Table 5.6 Matthews Kinetic Parameters by Quinti/e
.
w&gMm
fS m M
■ %. . . . . . .
mBBmimu wit I *. •MHMW m M m
m s m m m
^ H
I 0.45 0.21 0.24 12.4 6.0 7.1
(0.01) (0.01) (0.02) (0.9) (0.4) (1.0)
II 0.38 0.22 0.16 12.7 7.4 5.4
(0.02) (0.02) (0.01) (1.1) (0.9) (0.4)
III 0.36 0.19 0.17 12.3 6.5 5.8
(0.02) (0.02) (0.01) (1.4) (0.8) (0.6)
IV 0.35 0.20 0.14 13.1 7.7 5.4
(0.02) (0.02) (0.03) (0.7) (0.8) (1.2)
V 0.32 0.17 0.14 13.4 7.9 5.5
(0.02) (0.02) (0.02) (1.0) (1.0) (0.8)
Values are m ean (SEM ). FCR-fractional catabolic rate; Rl - receptor independent ie clearance from 
cyclohexanedione modified LDL; RM - receptor mediated calculated as the difference between native and 
chd modified apo-LDL; synthetic rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in 
mg divided by the body weight in kg; ACR is the absolute catabolic rate and is the product o f  either receptor 
independent or the receptor mediated FCR and the apo-LDL pool size divided by the body weight. Under 
steady stale conditions synthetic rate and catabolic rate should be equal.
The rate o f apo-LDL production was similar to that observed in similar studies (Packard et 
al 1976, 1983), and varied little between the quintiles. Thus the increase in mass o f apo- 
LDL across the quintiles derived from the reduction observed in its total FCR which fell by 
30%. Apo-LDL FCR was significantly associated with plasma cholesterol (r = -0.44, 
p<0.05), plasma triglyceride (r = -0.54, p<0.01), LDL cholesterol (r = -0.54, p<0.01) and 
body weight (r = -0.53, p<0.01). When catabolism was divided between the receptor- 
mediated and receptor-independent pathways, it was observed that the increase in 
circulating mass o f apo-LDL was strongly related to a reduction in the receptor-mediated 
catabolism (r=-0.55, p<0.01) and not to any change in the FCR via receptor-independent 
pathways (r=-0.30, p=0.143). The relationships between these kinetic parameters using 
Pearson correlation are given in table 5.7.
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Table 5 .7 .Relationships between Plasma Lipids, Lipoproteins, 
Body Weight and Apo-LDL Kinetic Parameters
Apo-LDL
concentration
0.67 J 0.524t 0.79J -0.234 0.25
Apo-LDL
pool
0.636J 0.704J 0.730J -0.227 0.68J
Apo-LDL
FCR
-0.436*f -0.5351 -0.539t 0.185 -0.534-
Apo-LDL
synthesis
0.131 0.017 0.255 -0.157 -0.256
p  values: *f<0.05, f  <0.01, /  <0.001
Categorisation o f the subjects by apoE phenotype (table 5.8) indicated that in these subjects 
there was no impact on plasma apo-LDL concentration or kinetics.
Table 5 .8  Effect o f  ApoE Phenotype on LDL Kinetic Parameters
ApoE  phenotype Apo-LDL mass Apo-LDL Apo-LDL
Synthetic rate FCR
3/3 87 13.3 0.39
2/3 (3.7) (0.6) (0.01)
3/4 90 12.2 0.35
4/4 (7.0) (0.6) (0.02)
p ___________________ NS_________________ NS__________________ NS
Values are mean (SEM)
Examination of the urinary radioactivity excretion data (fig.5.6) and calculation o f the daily 
urine:plasma (U/P) ratio indicated that the kinetics o f apo-LDL metabolism were more 
complex than the Matthews analysis had first suggested. In virtually all the subjects the 
U/P for native LDL (fig 5.4) fell from a peak value at 2-4 days post injection to a much 
lower value by days 10-12. The fall-off was graded across the quintiles being steeper for 
those subjects in quintile I with the lowest apo-LDL mass. On the other hand, the U/P ratio 
observed for cyclohexanedione-modified LDL was constant over the 14 days o f the study,
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indicating that the increased catabolism in the early stages o f the turnover was due to a 
receptor-mediated process. These data are incompatible with a simple one-compartment 
model in which LDL has a constant catabolic rate. They point to the presence o f metabolic 
heterogeneity and so detailed kinetic analysis followed using a multicompartmental 
analysis approach.
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Decay curves fo r native ,25I-LDL plasma (upper) and urine (lower) in black, cycloexanedione- 
modified Iill-LDL in red.
5.3.3 Two compartmental Model o f  Apo LDL Metabolism
Kinetic parameters and pool sizes for apo-LDL in pools A and B in the individual subjects 
are given in Appendix tables 5 and 6 and by quintile in tables 5.9 and 5.10.
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Table 5.9 Kinetic Parameters o f Pool A Apo-LDL by Quintile
S ill jp jj£
■
: , Id-■ . t
v 4 ' m li ^  f  
L : ■ ■ ■'
— $ ............
I 1058 599 0.57 0.26 0.30
(67) (53) (0.03) (0.02) (0.04)
II 936 735 0.69 0.34 0.35
(87) (43) (0.03) (0.03) (0.03)
III 1553 837 0.53 0.28 0.25
(151) (105) (0.02) (0.03) (0.02)
IV 1401 680 0.49 0.23 0.26
(154) (94) (0.04) (0.02) (0.03)
V 1491 639 0.45 0.24 0.21
(190) (88) (0.07) (0.04) (0.05
Values are m ean (SEM ). FCR-fractional catabolic rate; RI - receptor independent ie clearance from  
cyclohexanedione modified LDL; RM - receptor mediated calculated is the difference between native and chd 
modified apo-LDL
In these normal subjects, 70% (SEM 1.66) o f the receptor-mediated catabolism o f apo-LDL 
was from pool A and the amount o f apo-LDL in pool A rose approximately 50% in 
quintiles IV and V compared to quintiles I and II. This was due to a 25% reduction in the 
FCR from this compartment which was significantly inversely related to apo-LDL pool A 
mass (r = -0.55, p<0.01). Synthesis of apo-LDL into pool A was relatively constant.
Table 5.10 Kinetic Parameters o f  Pool B Apo-LDL by Quintile
]
I 510 155 0.25 0.13 0.12
(95) (12) (0.01) (0.01) (0.01)
II 1044 248 0.23 0.13 0.10
(110) (37) (0.01) (0.01) (0.01)
III 924 199 0.21 0.09 0.12
(145) (36) (0.01) (0.01) (0.004)
IV 1239 291 0.23 0.13 0.10
(163) (52) (0.01) (0.01) (0.01)
V 1880 491 0.26 0.14 0.12
(196) (66) (0.02) (0.03) (0.01)
Values are m ean (SEM). FCR-fractional catabolic rate; R l - receptor independent ie clearance from  
cyclohexanedione modified LDL; RM - receptor mediated calculated as the difference between native and 
chd modified apo-LDL
Much greater changes were seen in the circulating mass o f pool B apo-LDL. It rose more 
than three-fold as a result o f an increase in synthesis (r = 0.95, p<0.0001 ). The FCR from 
this compartment did not change with increasing apo-LDL mass, in line with the 
observation that the U/P ratio fell to the same limiting value in all subjects.
Thus as total apo-LDL mass increased in these normal subjects, the ratio o f pool A to pool 
B material fell from 2.1 in quintile I to 0.79 in quintile V. A stronger relationship was 
observed between the total apo-LDL mass and pool B mass (r = 0.83, p<0.0001) than 
between apo-LDL mass and pool A mass ( r = 0.61, p<0.01). Apo-LDL mass was also 
related to pool A FCR ( r= -0.55, p<0.01).
Pearson correlation coefficients describing the relationships between body weight, plasma 
lipid levels and apo-LDL kinetics in pools A and B are given in table 5.11.
Table 5.11 Relationships between Plasma Lipids, Lipoproteins, Body weight 
and Kinetic Parameters o f  Pools A and B Apo-LDL
,Kf VS * BHmm
Cholesterol 0.282 ..-0 455*1*... -0.195 0.581 + 0 166
______
Triglyceride 0.334 -0.336 -0.067 0.602+ 0.209 0.641 +
VLDLchol 0.267 -0.335 -0.146 0.547+ 0.346 0.542+
LDLchol 0.396*+ -0.540+ -0.192 0.611 + 0.190 0.626+
HDLchol -0.293 0.233 0.046 -0.108 -0.200 -0.078
W eight 0.349 -0.448*+ -0.039 0.633+ 0.027 0.545+
p values: *t<0.05, f<0.01 . {<0.001
In univariate analysis, the FCR from pool A was negatively correlated with LDL 
cholesterol (r = -0.54, p<0.01), total cholesterol (r = -0.46, p<0.05) and body weight (r = - 
0.45, p<0.05) while the mass o f apo-LDL in pool A showed a weak correlation with LDL 
cholesterol (r = 0.40, p<0.05). On the other hand, both mass and synthesis o f apo-LDL in 
pool B were strongly positively correlated with cholesterol (r = 0.58, p<0.01; r = 0.60, 
p<0.01), triglyceride (r = 0.60, p<0.001; r = 0.64, p<0.001), VLDL cholesterol (r = 0.55, 
p<0.01; r = 0.54, p<0.01), LDL cholesterol ( r = 0.61, p<0.001; r = 0.63, p<0.001) and body 
weight (r = 0.63, p<0.01; r = 0.55, p<0.01).
A General Linear Model (GLM) was employed to adjust for the effects o f covariates and to 
identify the best combination o f explanatory variables for mass o f circulating apo-LDL. 
Synthesis o f apo-LDL in pool B was the most important predictor explaining about 50% of 
the variation, followed by the FCR from pool A (18%) and the synthesis o f pool A (16%).
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5.7 Discussion
The results of this kinetic study were analysed first by the standard curve peeling approach 
of Matthews (1957) used previously for LDL turnovers (Langer et al, 1972; Packard et al, 
1976). This showed that the rise in apo-LDL was associated with a fall in its catabolic rate. 
However the urine data indicated that a more complex phenomenon was occurring in these 
subjects. The curves that were observed reflect the earlier findings o f Boston et al (1982), 
who first postulated, on the basis o f a falling urine/plasma ratio over time that LDL was 
metabolically heterogeneous. Matthews analysis fails in this situation since its basic 
assumption is that the kinetics describe clearance o f a homogeneous tracer by a single 
catabolic mechanism. In the face of tracer heterogeneity, the Matthews procedure cannot 
identify whether the activity o f the removal mechanism is altered or the relative 
subcomponents o f the compartment are changed.
The minimal model required to satisfy both the urine and plasma radioactivity curves 
necessitated the presence of two circulating pools of apo-LDL with differing kinetic 
characteristics. Foster el al (1986) described a number of two-compartment models that 
were all capable o f accommodating urine and plasma radioactivity data. One of these 
(Model B in Foster et al, 1986) was adopted for this study because it was compatible with 
the LDL subsystem in a much larger model developed in the Department of Pathological 
Biochemistry, Glasgow Royal Infirmary (Packard et al, 1984; Demant et al, 1991, Gaw et 
al 1995) during investigations of apoB transport through the VLDL-IDL-LDL delipidation 
cascade. In those studies, the presence of parallel pathways o f LDL transport and 
catabolism was demonstrated. Small VLDL (Sf 20-60) gave rise to a species of LDL that 
was cleared rapidly, with an FCR of 0.3-0.5 pools/day, similar to the rate seen in pool A. 
Large VLDL (Sf 60-400) on the other hand, when lipolysed, produced LDL that was 
removed more slowly with an FCR of about 0.2 pool/day, equivalent to the rate seen for 
pool B material. An alternative, such as model C of Foster et al (1986), in which pool A is 
converted to pool B by lipolysis would increase pool B formation as lipolysis increases. 
The model employed in this study has certain features that appear to have physiological 
significance. First,the FCR of pool A (fig.5.3) is a key variable in controlling the rate of 
LDL catabolism. Second, overall LDL clearance is also influenced by the distribution of 
mass between pools A and B. This in turn is dependent on their relative synthesis rates and 
possibly on the nature of the VLDL precursor made by the liver. Third, the FCR of pool B 
is constant. This is a reflection of the observation that parallel terminal exponentials appear 
after 8-10 days in both the plasma and urine radioactivity decay curves which give a U/P 
ratio of about 0.2 pool/day. Clearance of pool B material in our model is by both receptor- 
mediated and receptor-independent pathways although Malmendier et al (1989) restricted 
this to the receptor-independent pathway. This is consistent with in vitro observations of 
Kleinman et al (1987), Nigon et al, (1991) and Campos et al, (1996) that LDL from 
virtually all subjects has the ablilty to react with LDL receptors, but the affinity varies 
depending on the plasma triglyceride level and the density of the LDL subtraction.
It is concluded that in these young normolipidaemic individuals as the plasma triglyceride 
rose from 0.82 to 1.54 mmol/1, the mass of the apo-LDL circulating pool doubled 
principally due to an increase in pool B synthesis. The basis of this kinetic heterogeneity in 
LDL is unknown but is linked to the origin of the particle and is not due to the apoE
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phenotypes of the subjects studied. It is likely that the metabolic heterogeneity observed is 
linked to underlying structural heterogeneity as previous chapters (3 and 4) have shown 
that LDL structure is strongly influenced by plasma triglyceride level. Furthermore there is 
increasing evidence (Chen et al, 1994, Galeano et al, 1994) that the binding affinity of LDL 
to the LDL receptor is reduced with increasing plasma triglyceride and density of LDL 
such that the LDL becomes smaller in size and is due to conformational changes in the apo 
B100. Further kinetic studies on the individual LDL subfractions are required to test this 
hypothesis.
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Appendix to Chapter5
Table 1 Individual Lipid and Lipoprotein Levels
in Normal Subjects
---------------------------------------------------
#-f .ilj
N 1 4.8 1.0 0.6 2.7 1.5
N 2 4.1 0.6 0.2 2.3 1.6
N 3 4.1 0.7 0.5 2.6 1.1
N 4 4.0 0.5 0.3 2.2 1.5
N 5 5.3 1.3 0.3 3.0 2.0
N 6 4.6 1.1 0.2 2.5 1.9
N 7 4.4 1.0 0.2 2.3 1.9
N 8 5.2 1.5 0.6 3.0 1.6
N 9 3.9 0.7 0.2 2.3 1.4
N 10 4.7 1.4 0.6 2.6 1.5
N 11 5.2 0.9 0.4 3.7 1.1
N 12 5.1 1.0 0.4 2.9 1.8
N 13 3.8 1.1 0.5 2.1 1.2
N 14 4.0 1.3 0.5 2.0 1.5
N 15 5.4 1.2 0.4 3.4 1.5
N 16 4.9 1.1 0.6 2.8 1.5
N 17 5.8 1.1 0.7 3.5 1.6
N 18 4.7 1.3 0.7 2.7 1.4
N 19 4.7 1.1 0.3 3.1 1.3
N 20 6.6 1.5 0.8 3.1 2.1
N 21 5.9 1.8 0.8 3.5 1.6
N 22 5.3 0.9 0.4 3.5 1.4
N 23 6.1 1.4 0.6 3.7 1.8
N 24 6.1 1.7 0.7 4.2 1.4
N 25 6.1 1.9 0.7 4.0 1.3
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Table2 Individual Apo-LDL and HDL Subfraction Concentrations
in Normal Subjects
fiN BH ■ V : • ; " mm
N 1 63
N 2 63 70 149
N 3 73 21 267
N 4 67 66 194
N 5 83 103 274
N 6 76 128 199
N 7 71 44 228
N 8 88 61 262
N 9 95 - -
N 10 84 85 229
N 11 94 38 128
N 12 86 42 205
N  13 77 18 193
N 14 72 48 184
N 15 107 40 201
N 16 99 103 189
N 17 91 81 178
N 18 89 55 267
N 19 97 37 293
N 20 95 128 188
N 21 82 81 173
N 22 100 42 243
N 23 108 77 266
N 24 115 68 158
N 25 135 37 188
M il
116
Appendix to Chapter 5
Table 3 Lipoprotein Composition o f Apo-LDL in Normal Subjects
.
N 1
N 2 25.1 14.3 34.5 6.0 20.0
N 3 27.3 11.5 30.6 9.7 20.9
N 4 30.0 12.3 29.7 7.1 20.5
N 5 22.3 10.6 34.6 7.6 24.9
N 6 26.0 14.4 31.2 8.8 19.5
N 7 25.5 11.9 34.8 5.0 22.8
N 8 24.4 9.6 37.4 8.4 20.1
N 9 - - - - -
N 10 25.4 9.5 35.1 7.0 23.1
N i l 20.9 10.4 36.2 7.0 25.5
N 12 24.3 10.7 35.4 8.1 21.6
N 13 27.2 8.9 33.0 10.0 20.9
N 14 27.0 8.6 33.7 9.0 21.8
N 15 25.3 10.2 35.1 6.4 23.0
N 16 26.7 9.4 33.4 10.5 20.1
N 17 22.4 11.8 39.3 6.0 20.7
N 18 26.3 9.3 35.8 7.4 21.1
N 19 26.4 10.7 36.6 5.7 21.2
N 20 26.4 11.4 36.0 6.3 19.7
N 21 23.2 13.3 36.3 6.8 20.5
N 22 24.8 10.9 35.9 7.3 21.1
N 23 23.8 9.8 36.4 8.3 21.6
N 24 25.5 11.6 34.2 7.7 21.0
N 25 26.7 9.3 36.0 7.9 20.1
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Table 4 Kinetic Parameters by Matthews Analysis
in Normal Subjects
IIP
N 1 1414 0.41 0.20 0.21 10.4 5.1 ~5~3
N 2 1638 0.42 0.25 0.17 10.3 6.2 4.3
N 3 1664 0.47 0.21 0.26 13.7 7.6 9.5
N 4 1814 0.48 0.20 0.28 13.0 5.4 7.6
N 5 1826 0.45 0.18 0.27 14.8 5.8 9.0
N 6 1839 0.43 0.26 0.16 12.9 7.9 5.0
N 7 1846 0.34 0.20 0.14 9.6 5.6 4.0
N 8 2051 0.35 0.18 0.17 12.3 6.4 5.9
N 9 2090 0.43 0.26 0.17 16.6 10.6 6.6
N 10 2352 0.36 0.19 0.16 12.0 6.5 5.5
N 11 2406 0.31 0.16 0.14 11.5 6.2 5.4
N 12 2422 0.34 0.16 0.17 11.6 5.6 5.9
N 13 2433 0.40 0.23 0.17 12.2 6.9 5.3
N 14 2556 0.32 0.16 0.16 9.1 4.6 4.5
N 15 2568 0.41 0.22 0.19 17.3 9.2 8.1
N 16 2577 0.33 0.17 0.15 12.9 6.9 6.0
N 17 2584 0.35 0.16 0.19 12.6 5.6 7.0
N 18 2599 0.40 0.22 0.18 14.3 7.7 6.6
N 19 2677 0.28 0.26 0.02 10.9 10.2 0.6
N 20 2765 0.39 0.21 0.18 14.9 8.1 6.8
N 21 2870 0.32 0.13 0.19 10.3 6.1 4.2
N 22 2920 0.31 0.14 0.17 12.3 5.6 6.7
N 23 3024 0.37 0.22 0.15 16.0 9.6 6.4
N 24 3830 0.32 0.16 0.15 14.5 7.5 7.0
N 25 4212 0.26 0.20 0.06 14.0 10.8 3.2
FCR-fractional catabolic rate; Rl - receptor independent ie clearance from  cyclohexanedione modified LDL; 
RM - receptor mediated calculated as the difference between native and chd modified apo-LDL; synthetic 
rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in mg divided by the body weight in 
kg; ACR is the absolute catabolic rate and is the product o f  either receptor independent or the receptor 
mediated FCR and the apo-LDL pool size divided by the body weight. Under steady state conditions 
synthetic rate and catabolic rate should be equal.
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Table 5 Kinetic Parameters o f Mathematical Pool A
in Normal Subjects
---------
II * 1
. \ ■ : ' ■
inraif iH
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H I
N 1 795 421 0.53 0.29 0.24
N 2 1121 549 0.49 0.28 0.21
N 3 1156 630 0.55 0.25 0.30
N 4 1073 690 0.64 0.29 0.35
N 5 1143 707 0.62 0.21 0.41
N 6 1026 630 0.61 0.37 0.24
N 7 616 891 0.69 0.30 0.39
N 8 1115 725 0.65 0.26 0.39
N 9 1029 740 0.72 0.38 0.34
N 10 895 691 0.77 0.38 0.39
N 11 1152 555 0.48 0.29 0.19
N 12 1579 839 0.53 0.26 0.27
N 13 1825 1095 0.60 0.35 0.25
N 14 1278 655 0.51 0.20 0.31
N 15 1930 1041 0.54 0.30 0.24
N 16 918 519 0.57 0.20 0.37
N 17 1594 698 0.44 0.20 0.24
N 18 1719 1036 0.60 0.31 0.29
N 19 1614 598 0.37 0.21 0.16
N 20 1158 551 0.48 0.22 0.26
N 21 1183 473 0.40 0.27 0.13
N 22 1284 627 0.49 0.16 0.33
N 23 1536 956 0.62 0.36 0.26
N 24 1241 658 0.53 0.27 0.26
N 25 2211 482 0.22 0.15 0.07
FCR-fractional catabolic rate; RI - receptor independent ie clearance from  cyclohexanedione modified LDL; 
RM - receptor mediated calculated as the difference between native and chd modified apo-LDL; synthetic 
rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in mg divided by the body weight in 
kg-
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Table 6 Kinetic Parameters o f  Mathematical Pool B
in Normal Subjects
f f* ■'* @8
a 1
' I .
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WhnwWi
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N 1 619 152 0.25 0.15 0.10
N 2 517 119 0.23 0.13 0.10
N 3 508 147 0.29 0.12 0.17
N 4 740 188 0.25 0.14 0.11
N 5 168 168 0.25 0.12 0.13
N 6 813 153 0.19 0.11 0.08
N 7 953 226 0.24 0.14 0.10
N 8 936 219 0.23 0.12 0.11
N 9 1061 265 0.25 0.17 0.08
N 10 1457 378 0.26 0.13 0.13
N 11 1254 281 0.23 0.10 0.13
N 12 843 169 0.20 0.07 0.13
N 13 608 128 0.21 0.08 0.13
N 14 1278 290 0.23 0.12 0.11
N 15 639 125 0.20 0.08 0.12
N 16 1656 438 0.26 0.16 0.10
N 17 990 204 0.21 0.09 0.12
N 18 880 216 0.25 0.12 0.13
N 19 1063 200 0.19 0.13 0.06
N 20 1607 397 0.25 0.16 0.09
N 21 1687 369 0.22 0.10 0.12
N 22 1636 391 0.24 0.12 0.12
N 23 1488 393 0.26 0.15 0.11
N 24 2589 673 0.26 0.10 0.16
N 25 2000 631 0.32 0.24 0.08
FCR-fractional catabolic rate; RI - receptor independent ie clearance from  cyclohexanedione modified LDL; 
RM - receptor mediated calculated as the difference between native and chd modified apo-LDL; synthetic 
rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in mg divided by the body weight in 
kg-
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Chapter 6 Fibrates and LDL Metabolism 
in Moderate Hypercholesterolaemia
6.1 Introduction
The fibrates are a family of hypolipidaemic drugs that lower plasma triglycerides by 
promoting the lipolysis of triglyceride-rich particles through activation of lipoprotein lipase 
(Wolfe et al, 1983) by stimulating VLDL catabolism and by the inhibition of VLDL 
synthesis and secretion as a result o f decreased free fatty acid flux to the liver (Kissebah et 
al, 1974). In addition it has been suggested that they are able to supress hepatic cholesterol 
synthesis (Bemt & Gaumert, 1978) and stimulate LDL receptor activity (Stewart et al, 
1982). The effect fibrates have on LDL varies and depends on the initial plasma 
triglyceride level. In severely hypertriglyceridaemic subjects, LDL particles are small and 
dense, and the low level of LDL in this condition is due to hypercatabolism of this species 
probably by receptor-independent pathways (Shepherd & Packard, 1986: Sigurdsson et al, 
1976). Shepherd et al (1985) found previously that fibrate treatment supressed this high 
rate of clearance, and we attributed this effect to a reduction in the amount of LDL 
degraded by the receptor-independent pathway, whereas LDL catabolism into the receptor 
route was increased. The overall impact of these changes was to increase the initially low 
levels of plasma LDL cholesterol, alter LDL composition, and increase the average particle 
size. Conversely in hypercholesterolaemic, normotriglyceridaemic subjects, initially 
elevated LDL cholesterol levels are decreased by fibrate therapy. In a previous 
investigation o f the mechanism of action of bezafibrate (Stewart et al, 1982) in type II 
hyperlipidaemia, the LDL lowering effect was ascribed to increased clearance via the LDL 
receptor pathway. At that time it was surmised that the drug operated to supress hepatic 
cholesterol synthesis and so activate clearance of LDL by receptors. However in the light 
o f the present knowledge o f the metabolic and structural heterogeneity of LDL, it is 
pertinent to ask whether it was the receptor or the ligand itself that changed during fibrate 
therapy. It is arguable that the drug, by changing LDL composition and size, increased the 
propensity of the particles for degradation by the receptor mechanism. In the present study 
second generation fibrates (fenofibrate and ciprofibrate) were used to treat two groups of 
subjects with primary hypercholesterolaemia and normotriglyceridaemia. The study was 
designed to test this hypothesis examining in detail the receptor-mediated and receptor- 
independent pathways of apo-LDL metabolism and also assessing the kinetic heterogeneity 
o f LDL using the two-pool model of LDL metabolism proposed for normolipaemic 
individuals in chapter 5.
Identical protocols with the same subject inclusion criteria were used for each of the drugs, 
however as there was an eighteen month time difference in administration and as there may 
be subtle differences in the mechanism of action, the results for each drug will be described 
separately. FF refers to the fenofibrate study and Ciprol refers to the ciprofibrate study.
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6.2 Protocol
The study was carried out in three phases. The first was a three month preliminary 
screening period in which a standard cholesterol-reducing diet was advised and each patient 
was screened for cardiological, haematological, hepatic, endocrine, renal and metabolic 
disease by routine clinical laboratory testing. The baseline phase lasted for two weeks in 
which the subjects underwent measurements o f lipids, lipoproteins and lipoprotein 
subfractions and determination o f native and 1,2-cyclohexanedione-treated, radiolabelled 
LDL turnover. The LDL was prepared by zonal ultracentrifugation and labelled as 
described in chapter 2.6.1. The active treatment period followed immediately after the 
baseline measurement o f apo-LDL metabolism. One group o f patients was commenced on 
fenofibrate therapy at a dose o f 100 mg t.i.d and the other on ciprofibrate at a dose o f 100 
mg/d. Patients remained on this dose for 8 weeks, the final 2 weeks o f which each patient 
underwent a second turnover investigation with lipid, lipoprotein and lipoprotein 
subfraction measurements.
6.3 Recruitm ent and Conduct of the Study.
Recruitment took place at Lipid Clinics at Glasgow Royal Infirmary by Dr A Gaw, Victoria 
Infirmary, Glasgow by Dr D Wosornu and at Hairmyres Hospital, East Kilbride by Dr B 
Vallance. Dr Gaw was responsible for the clinical aspects o f the study. The patients were 
visited at home each day for venepuncture by nurses namely Moira Devine and Grace 
Lindsay, whose contribution by encourageing the patients to adhere to the protocol was 
invaluable.
6.4 Subjects
All subjects showed persistent type Ila hyperlipidaemia with initial fasting plasma 
cholesterol > 7mol/l and triglyceride < 2.3 mmol/1. They did not have clinical evidence of 
familial hypercholesterolaemia (FH) ie no history o f premature heart disease in first degree 
relatives or the presence o f tendon xanthomas on clinical examination. None o f the 
subjects was receiving drug therapy known to affect lipoprotein metabolism, including 
hormone replacement therapy. The women were all post-menopausal. The characteristics 
o f the subjects are shown in tables 6.1 and 6.2.
Table 6.1 Fenofibrate Study Patient Characteristics
I E
FF 1 M 63 77.5 3/3
FF 2 F 64 60.0 3/3
FF 3 F 66 68.0 3/3
FF 4 F 65 59.5 3/3
FF 5 F 53 78.5 3/3
FF 6 F 63 64.5 3/4
FF 7 F 48 58.0 2/3
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Table 6.2 Ciprofibrate Study Patient Characteristics
C iprol 1 M 37 24.1 3/3
C ip ro l2 M 58 24.4 3/3
C ip ro l3 F 62 25.0 4/3
C ip ro l4 F 53 27.9 4/3
C ip ro l5 F 61 23.8 3/3
C ip ro l6 M 46 26.2 3/3
C ip ro l7 M 63 25.8 3/3
C ip ro l8 M 63 23.0 3/3
C ip ro l9 M 40 27.8 3/3
C iprol 10 M 68 23.4 3/3
6.5 Fenofibrate
Eight subjects, one man and seven post menopausal women, aged from 48 to 66 years took 
part in the study.
6.5.1 Lipids and Lipoproteins and Apoproteins
Plasma lipid, lipoprotein and apolipoprotein levels are shown in tables 6.3 and 6.4. All 
were hypercholesterolaemic due to an elevation in LDL and had normal levels o f plasma 
triglyceride and VLDL cholesterol. Treatment with fenofibrate significantly lowered 
plasma cholesterol and triglyceride levels by 29% and 35% respectively, (p<0.001). The 
fall in cholesterol content o f VLDL paralleled that o f plasma triglycerides (36%; p<0.01) 
and there was no change in the VLDL cholesterol to plasma triglyceride ratio (0.39) before 
and during therapy. Fenofibrate induced a decrease in LDL cholesterol from 6.0 (0.39) to 
3.86 (0.25) mmol/1; p<0.001), whereas plasma apoB fell by 33% (p<0.001). There were no 
changes in the concentrations o f HDL cholesterol, HDL2, HDL3 or apo Al. Fenofibrate 
therapy for 8 weeks also produced no significant changes in Lp(a) levels (86(22), range 11- 
141 mg/lOOml baseline; 91(18), range 12-140 mg/100ml on fenofibrate).
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Table 6.3 Lipids and Lipoproteins o f  Subjects on Fenofibrate Therapy
m
Baseline
FF 1 8.00 1.74 0.75 5.70 1.55
FF 2 8.20 1.30 0.35 6.45 1.38
FF 3 7.89 2.10 0.79 5.86 1.24
FF 4 6.33 1.63 0.67 4.28 1.38
FF 5 8.50 1.59 0.61 6.58 1.28
FF 6 9.50 1.20 0.30 7.60 1.62
FF 7 7.67 1.88 1.04 5.40 1.20
mean 8.01 1.63 0.64 6.00 1.38
(SEM ) (0.39) (0.12) (0.10) (0.39) (0.06)
Fenofibrate
FF 1 6.04 0.91 0.45 3.89 1.70
FF 2 5.30 0.89 0.29 3.59 1.40
FF 3 5.54 1.19 0.45 3.71 1.38
FF 4 5.33 1.10 0.31 3.62 1.39
FF 5 5.60 0.96 0.34 3.50 1.73
FF 6 7.26 0.88 0.34 5.34 1.59
FF 7 5.26 1.51 0.66 3.39 1.21
mean 5.71 1.06 0.41 3.86 1.49
(SEM ) (0.27) (0.09) (0.09) (0.25) (0.07)
P <0.001 <0.001 <0.01 <0.001 NS
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Table 6.4 Apoproteins and HDL Subfractions o f Subjects on Fenofibrate Therapy
Baseline
FF 1 132 129 11 47 222
FF 2 123 142 109 46 294
FF 3 130 158 141 37 286
FF 4 134 126 34 62 256
FF 5 118 161 140 92 228
FF 6 138 143 140 144 181
FF 7 146 119 28 30 281
mean 132 140 86 65 250
(SEM) (3.5) (6) (22) (15) (15.6)
Fenofibrate
FF 1 150 109 12 47 358
FF 2 126 88 103 37 330
FF 3 128 101 135 24 273
FF 4 111 83 67 66 291
FF 5 158 89 130 37 322
FF 6 119 102 140 106 222
FF 7 109 87 49 46 261
mean 129 94 91 52 294
(SEM) (7.1) (3.7) (18) (10.2) (17.5)
P NS <0.001 NS NS NS
Analysis o f the composition o f LDL (table 6.5) showed' no effect o f fibrate therapy, 
indicating that the reduction in LDL cholesterol was due to a diminished number of 
particles in the circulation.
Table 6.5 LDL Composition in Subjects on Fenofibrate Therapy
Baseline
mean 25.06 11.89 34.66 6.50 21.90
(SEM) (0.82) (0.47) (1.00) (0.47) (0.28)
Fenofibrate
mean 25.96 12.00 33.00 6.92 22.10
(SEM) (0.33) (0.56) (0.88) (0.34) (0.40)
P NS NS NS NS NS
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There was some inter-individual variation in the LDL pattern observed with subject FF3 
having 152 mg/100ml o f small dense LDL III as well as the highest triglyceride level o f 2.1 
mmol/1. Table 6.6 shows that the decrement in mass o f LDL lipoproteins (30 %, p<0.005) 
was largely due to reduction o f the major LDL II species (42 %, p<0.001). The largest 
most buoyant LDL I was unaltered, while the mean level o f small dense LDL III fell by 46 
%. This was not significant but there was a trend in reduction o f LDL III which was 
particularly noticeable in subjects FF 3 and FF 4 where values fell from 152 to 
46mg/100ml and from 108 to 52 mg/100ml respectively.
Table 6.6 LDL Subfractions on Fenofibrate Therapy
.............................
Baseline
FF 1 546 110 365 71
FF 2 374 80 248 46
FF 3 569 58 359 152
FF 4 501 70 323 108
FF 5 594 236 320 38
FF 6 651 385 233 33
FF 7 424 150 254 20
mean 523 156 300 67
(SEM) (37) (45) (21) (18)
Fenofibrate
FF 1 374 153 174 20
FF 2 322 94 186 42
FF 3 374 101 227 46
FF 4 417 144 221 52
FF 5 382 175 162 45
FF 6 405 221 148 36
FF 7 275 163 98 14
mean 364 150 174 37
(SEM) (19) (17) (17) (19)
P <0.005 NS <0.001 NS
6.5.2 Receptor-mediated and Receptor-independent Metabolism o f  LDL 
The influence o f fenofibrate therapy on apo-LDL metabolism was examined at baseline and 
on drug using dual-tracer, native and cyclohexanedione modified apo-LDL turnover studies 
as described in section 2.6. The kinetic parameters o f apo-LDL metabolism derived from 
simple Matthews kinetic analysis are presented in table 6.7.
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Table 6.7 Matthew's Kinetic Parameters o f Apo-LDL on Fenofibrate Therapy
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Baseline
FF 1 4092 0.239 0.100 0.139 978 410 568
FF 2 3696 0.248 0.127 0.121 916 469 447
FF 3 3993 0.242 0.145 0.097 966 579 387
FF 4 2332 0.319 0.144 0.175 744 336 408
FF 5 2662 0.239 0.109 0.130 636 290 346
FF 6 3431 0.204 0.114 0.090 670 361 309
FF 7 2747 0.295 0.143 0.152 810 392 418
mean 3279 0.255 0.126 0.128 817 420 412
(SEM) (264) (0.015) (0.019) (0.011) (53) (42) (31)
Fenofibrate
FF 1 2790 0.444 0.140 0.304 1239 391 848
FF 2 2108 0.379 0.168 0.211 799 349 450
FF 3 2439 0.524 0.185 0.339 1278 451 827
FF 4 2142 0.508 0.180 0.328 1088 385 703
FF 5 1995 0.361 0.148 0.213 720 295 425
FF 6 3149 0.292 0.147 0.145 920 463 457
FF 7 1562 0.448 0.154 0.294 700 241 459
mean 2312 0.422 0.160 0.263 963 368 596
(SEM) (200) (0.031) (0.018) (0.028) (91) (30) (72)
P <0.005 <0.0005 <0.001 <0.002 NS NS <0.05
FCR-fractional catabolic rate; RI - receptor independent ie clearance from  cyclohexanedione modified LDL ; 
RM - receptor mediated calculated as the difference between native and chd modified apo-LDL; synthetic 
rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in mg divided by the body weight in 
kg; ACR is the absolute catabolic rate and is the product o f  either receptor independent or the receptor 
mediated FCR and the apo-LDL pool size divided by the body weight. Under steady state conditions 
synthetic rate and catabolic rate should be equal.
Fenofibrate therapy was associated with a 65% increase in the fractional catabolic rate o f 
apo-LDL. This change was apparently responsible for the 30% decrement in the 
concentration o f LDL in plasma, as fenofibrate did not significantly affect the total apo- 
LDL synthesis. When LDL catabolism was divided into receptor-mediated versus 
receptor-independent pathways, it was observed that the fractional catabolic rate o f the 
former was increased by 105%, 0.263(0.028) pools/d on fenofibrate versus 0.128 (0.011) 
before drug; p<0.002 and the latter by 27%, 0.160 (0.018) pools/d on fenofibrate versus 
0.126(0.019) pools/d before drug; p<0.001. Furthermore, the amount o f apo-LDL degraded
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by the receptor route rose by 45% (p<0.05), whereas that removed by the receptor- 
independent pathway was unchanged.
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Fig 6.1 Plasma and Urine Radiactive Decay Curves at Baseline and on 
Fenofibrate
Plasma and urine radioactive decay curves for subject FF2 at baseline (upper curves) and on 
fenofibrate.
Visual examination of the plasma decay curves in conjunction with the daily urinary 
radioactivity excretion rates, shown for subject FF 2 in fig 6.1, revealed that fenofibrate 
perturbed LDL metabolism in a more complex fashion than that suggested by Matthew’s 
analysis o f the plasma data only. During the control turnover, the amount of radioactivity 
excreted in the urine each day was a relatively constant proportion of the radioactivity 
present in plasma. The calculated urine : plasma ratio (fig 6.2), a daily index of catabolic 
potential, fell only slightly from a peak value o f 0.34 at 2-4 days after injection to 0.26 by 
days 10-12. On fenofibrate, however, the relation between the urine and plasma decay 
curves was altered. During the first 5 days of the turnover, the plasma curve showed more 
rapid decay than during the control phase. This change was due to a catabolic event rather 
than enhanced extravascular exchange because there was a concominant increase in urinary 
radioactivity excretion. The urine : plasma ratio ratio in this patient was initially high
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(0.60), and showed a substantial fall during the turnover period to approximately the same 
value as the control phase. As in chapter 5, this is evidence that LDL was not behaving in a 
kinetically homogeneous fashion.
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Fig. 6.2 Urine to Plasma Radioactivity Ratios at Baseline and on Fenofibrate
Ratio o f radioactivity in native LDL for subject FF 2 at baseline (lower) and on fenofibrate (upper).
6.5.3 Two Compartment Model o f  Apo B Metabolism
The effects o f fenofibrate on apo-LDL metabolism were further studied by subjecting the 
plasma and urine radioactivities to more detailed analysis using the multicompartmental 
model which divides plasma LDL into 2 compartments (A and B) that are permitted to 
differ in their elimination rates as is described in Chapter 5.
The kinetic behaviour of pools A and B in the hypercholesteraemic subjects at baseline and 
on fenofibrate therapy are shown in table 6.8. In the control situation, pool A accounted for 
1,200 mg, or approximately one third, o f the circulating mass o f apo-LDL. Its mean 
synthetic rate was 400 mg/day with a fractional catabolic rate o f 0.39 pools/day. The 
majority o f apo-LDL was in pool B which had a mean mass o f approximately 2,000 mg. 
Its fractional catabolic rate was half o f that of pool A (0.2 pools/day), but the rate of 
production was similar (422 mg/day). Fenofibrate significantly increased the synthetic rate 
o f pool A by 77% (p<0.005) and at the same time significantly decreased the synthetic rate 
o f pool B by 39% (p<0.02%). The overall result was no difference in the transport o f total 
apo-LDL in agreement with Matthew’s analysis shown in table 6.7. The fractional 
clearance rate o f pool B was not altered, whereas that of pool A rose by 69% on 
fenofibrate. The net effect of these changes was that while the computed mass o f apo-LDL
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in pool A remained constant, that of pool B was reduced by approximately 50%. The effect 
on LDL overall FCR observed in Matthews analysis has been shown to be the switch from 
pool B to A in this model.
Table 6.8 Kinetics o f  Pools A  and B Apo-LDL on Fenofibrate Therapy
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Baseline
FF 1 2471 0.2.6 642 1621 0.203 329
FF 2 2064 0.29 595 1632 0.200 321
FF 3 1525 0.30 458 2468 0.210 518
FF 4 583 0.67 391 1749 0.200 353
FF 5 222 0.47 104 2440 0.220 532
FF 6 695 0.28 197 2736 0.180 502
FF 7 853 0.49 415 1894 0.210 396
mean 1202 0.39 400 2077 0.200 422
(SEM) (315) (0.06) (74) (174) (0.005) (35)
Fenofibrate
FF 1 939 0.87 817 1851 0.230 426
FF 2 1441 0.47 672 667 0.190 126
FF 3 938 0.98 919 1501 0.240 360
FF 4 1254 0.69 863 890 0.250 226
FF 5 916 0.53 482 1079 0.220 238
FF 6 1646 0.39 638 1503 0.190 283
FF 7 795 0.69 550 767 0.195 150
mean 1133 0.66 706 1180 0.220 258
(SEM) (120) (0.08) (62) (168) (0.009) (41)
P NS <0.05 <0.005 <0.005 NS <0.02
FCR-fractional catabolic rate; synthetic rate (SR) is the product o f  FCR in pools/d and the plasma pool o f  
apo-LDL in mg.
6.6 C iprofibrate
Ten subjects, 7 men and 3 postmenopausal women, aged from 37 to 69, took part in the 
study.
6.6.1 Lipids, Lipoproteins and Apolipoptoteins
The plasma lipids, lipoproteins and apolipoproteins are shown in tables 6.9 and 6.10.
130
Table 6.9 Lipids and Lipoproteins o f Subjects on Ciprofibrate Therapy
m
-------------------------- ■ b w m m m
Baseline
Ciprol 1 6.5 1.25 0.64 4.78 1.06
Ciprol 2 7.2 1.10 0.60 4.72 1.72
Ciprol 3
oo6^ 1.20 0.65 4.41 1.68
Ciprol 4 7.4 1.24 0.51 5.54 1.30
Ciprol 5 7.3 1.40 0.70 5.10 1.55
Ciprol 6 7.5 1.42 0.75 5.50 1.26
Ciprol 7 8.6 1.36 0.81 6.60 1.15
Ciprol 8 6.7 2.00 1.02 4.47 1.17
Ciprol 9 8.9 2.35 0.88 6.06 1.93
Ciprol 10 9.1 1.45 0.69 6.80 1.58
mean 7.6 1.48 0.73 5.40 1.44
(SEM) (0.3) (0.12) (0.05) (0.27) (0.09)
C iprofibrate
Ciprol 1 6.1 0.66 0.40 4.33 1.40
Ciprol 2 5.4 0.68 0.42 2.95 2.00
Ciprol 3 5.1 0.61 0.40 2.89 1.79
Ciprol 4 6.3 0.79 0.36 4.45 1.44
Ciprol 5 6.0 0.69 0.39 3.66 1.93
Ciprol 6 6.1 0.88 0.55 4.04 1.53
Ciprol 7 7.4 1.18 0.55 5.60 1.25
Ciprol 8 5.3 1.10 0.57 3.35 1.38
Ciprol 9 8.0 1.18 0.62 5.52 1.82
Ciprol 10 7.0 1.07 0.27 5.20 1.48
mean 6.3 0.88 0.45 4.20 1.60
(SEM) (0.3) (0.07) (0.04) (0.32) (0.08)
P <0.001 <0.001 <0.001 <0.001 <0.02
Treatment with ciprofibrate significantly affected all parameters o f the lipid profile. 
Plasma cholesterol was reduced by 17% (p<0.001). This decrement was due to a 38% fall 
in VLDL cholesterol (p<0.001), and a 22% fall in LDL cholesterol (p<0.001). There was 
also a marked reduction in plasma triglyceride of 41% (p<0.001) and a rise in HDL 
cholesterol o f 11% (p<0.02). No significant changes were observed in HDL2, HDL3 or 
Lp(a), range 1-100 mg/ 100ml at baseline and range 8-72 mg/100ml on ciprofibrate.
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Table 6.10 Apoproteins and HDL Subfractions o f Subjects on Ciprofibrate Therapy
;
Baseline
C iprol 1 36 34 175
C ip ro l2 7 107 392
C ip ro l3 17 158 239
C ip ro l4 51 92 229
C ip ro l5 46 132 229
C ip ro l6 14 81 219
C ip ro l7 48 102 209
C ip ro l8 1 81 290
C ip ro l9 76 134 361
C iprol 10 100 102 348
mean 40 102 269
(SEM) (10) (11) (23)
C iprofibrate
C iprol 1 35 39 202
C ip ro l2 8 118 335
C ip ro l3 15 166 194
C ip ro l4 62 85 336
C ip ro l5 51 141 153
C ip ro l6 15 72 321
C ip ro l7 43 43 199
C ip ro l8 18 33 314
C ip ro l9 72 81 441
C iprol 10 67 63 339
mean (SEM) 39 84 283
(8) (14) (29)
P NS NS NS
Analysis o f the overall composition o f LDL (table 6.11) showed that ciprofibrate therapy 
had no effect, suggesting that the fall in LDL cholesterol observed was due to a reduction 
in the number o f circulating LDL particles.
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Table 6.11 -LDL Composition in Subjects on Ciprofibrate Therapy
m m
'
Baseline
mean 26.9 12.4 35.3 5.7 19.8
(SEM ) (0.6) (0.4) (0.7) (0.5) (0.5)
Ciprofibrate
mean 25.8 11.6 36.3 6.3 19.8
(SEM ) (0.6) (0.8) (1.0) (0.5) (0.6)
P NS NS NS NS NS
Results o f qualitative analysis o f the LDL subfraction profiles are in table 6.12. Again 
there was some inter-individual variation in the patterns, but only one subject (Ciprol 7) 
had a concentration o f LDL III > lOOmg/lOOml. On ciprofibrate therapy, the decrement 
(28%, p<0.01) in the major LDL II species was the most significant change in these 
subjects. LDL I, the largest fraction, was unaffected by therapy, while the mean level of 
small dense LDL III fell by 30%. Again this was not significant.
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Table 6.12 LDL Subfractions in Subjects on Ciprofibrate Therapy
m
___
Baseline
Ciprol 1 410 147 227 36
Ciprol 2 429 141 202 86
Ciprol 3 434 230 181 22
Ciprol 4 536 241 269 27
Ciprol 5 471 252 195 24
Ciprol 6 484 107 328 49
Ciprol 7 598 116 341 141
Ciprol 8 442 97 253 92
Ciprol 9 447 181 223 43
Ciprol 10 618 139 451 28
mean 487 165 267 55
(SEM) (23) (18) (27) (12)
C iprofibrate
Ciprol 1 448 161 224 63
Ciprol 2 253 114 102 38
Ciprol 3 302 143 130 29
Ciprol 4 428 192 214 22
Ciprol 5 351 224 112 15
Ciprol 6 367 176 164 27
Ciprol 7 493 116 298 79
Ciprol 8 318 108 163 47
Ciprol 9 552 129 257 28
Ciprol 10 473 180 263 29
mean 399 154 193 38
(SEM) (30) (12) (22) (6)
P <0.02 NS <0.01 NS
6.6.2 Receptor-mediated and Receptor-independent Metabolism o f  LDL
The influence o f ciprofibrate therapy on apo-LDL metabolism was examined at baseline
1 2 5 * 131and on drug using dual tracers (I -native and I -CHD modified LDL). The results from 
Matthews kinetic modelling are shown in table 6.13. In two turnovers, Ciprol 4 drug and 
Ciprol 7 baseline, the decay curves for native and CHD-modified LDL were 
superimposable suggesting that there was either damage to native apo-LDL before 
reinjection or that modification was incomplete. Examination o f the decay curves and 
calculated kinetic parameters indicated that the former was most probable. These two 
subjects have been excluded from analysis o f the paired data.
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Table 6.13 Matthew's Kinetic Parameters o f  Apo-LDL on Ciprofibrate Therapy
WilTsJmfJTi
ImmMmwM
WjFmnfLwM IT1 o f  ifiiff
Baseline
Ciprol 1 105 0.41 0.17 0.23 18.4 7.8 10.6
C ip ro l2 108 0.30 0.14 0.16 12.8 6.0 6.7
Ciprol 3 126 0.33 0.16 0.11 16.7 8.2 8.5
C ip ro l4 101 0.21 0.12 0.10 8.6 4.7 3.9
Ciprol 5 133 0.42 0.22 0.20 22.0 11.7 10.3
Ciprol 6 141 0.35 0.18 0.17 19.8 10.3 9.5
Ciprol 7 171 - 0.16 - 10.7
Ciprol 8 121 0.33 0.17 0.16 16.2 8.2 8.0
C ip ro l9 110 0.23 0.11 0.12 11.9 5.7 6.1
Ciprol 10 160 0.21 0.13 0.09 12.6 7.5 5.1
mean (n=8) 126 0.32 0.16 0.16 16.3 8.2 8.1
(SEM) (6) (0.03) (0.012) (0.016) (1.3) (0.71) (0.71)
C iprofibrate
Ciprol 1 128 0.40 0.19 0.21 20.2 9.6 10.7
C ip ro l2 56 0.49 0.15 0.34 10.6 3.2 7.5
Ciprol 3 80 0.35 0.14 0.31 11.0 4.5 6.6
C ip ro l4 111 - 0.13 - 5.6
Ciprol 5 90 0.34 0.13 0.21 12.0 4.6 7.4
Ciprol 6 96 0.34 0.14 0.20 13.0 5.2 7.8
Ciprol 7 124 0.31 0.15 0.16 15.3 7.6 7.7
Ciprol 8 88 0.46 0.19 0.27 16.4 6.8 9.5
Ciprol 9 120 0.37 0.17 0.20 17.9 8.4 9.5
Ciprol 10 116 0.30 0.14 0.16 13.5 6.4 7.2
mean (n=8) 97 0.38 0.16 0.22 14.3 6.1 8.2
(SEM) (8) (0.02) (0.01) (0.02) (1.2) (0.76) (0.51)
P <0.02 NS NS <0.03 NS NS NS
FCR-fractional catabolic rate; RI - receptor independent ie clearance from  cyclohexanedione modified LDL; 
RM - receptor mediated calculated as the difference between native and chd modified apo-LDL; SR - 
Synthetic rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in mg divided by the body 
weight in kg; ACR is the absolute catabolic rate and is the product o f  either receptor independent or the 
receptor mediated FCR and the apo-LDL pool size divided by the body weight. Under steady state 
conditions synthetic rate and catabolic rate should be equal.
Ciprofibrate was associated with a 19% increase in the overall FCR o f apo-LDL, but this 
was not significant. However, when LDL catabolism was divided into receptor-mediated 
and receptor-independent pathways, it was observed that the FCR o f the former was 
increased by 38% (p<0.03), while the latter was unaltered. Since the alteration o f the FCR
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was accompanied by a 23% fall in apo-LDL circulating mass (p<0.02) here was no 
significant change in the absolute amount of apo-LDL cleared by either pathway.
Again examination of the plasma decay curves in conjunction with the daily urinary 
radioactivity excretion rates (shown for subject Ciprol 6 in fig  6.3 and for Ciprol 8 in fig  
6.3) revealed that the drug was perturbing LDL metabolism in a complex fashion. During 
the baseline turnover, the amount of radioactivity excreted into the urine was virtually a 
fixed proportion of the radioactivity present. On ciprofibrate, this relationship varied 
among the patients. In some (eg subject Ciprol 6, fig  6.4) the radioactivity curves were 
virtually identical in both phases whereas in others (eg subject Ciprol 8, fig  6.4) it was 
substantially altered. In this subject during the first 5-6 days o f the turnover, the plasma 
showed a more rapid decay than at baseline. The urine : plasma ratio was initially high 
(0.45) and showed a substantial fall over the first 5-6 days to the same value as in the 
control phase (0.22).
Ciprol 6 Ciprol 8
o.s 0.5
iibrofibrate
0.4
oew  o.3
&
CDE 0.23
Cibrofibrate
a t 0.3
0.1 0 . 1baseline baseline
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o 2 4 5 B K> 12 122 4 S too 6
day day
F ig. 6 .3  U rine to  P L asm a  R a d io a c tiv ity  R a tio s F o r N a tive  L D L  a t B a se lin e  a n d  on  
C ipro fibra te  T herapy
Urine to plasma ratios for 1251 native LDL in subjects Cipro I 6 and Cipro I 8 at baseline (red) and on 
ciprofibrate (black).
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6.6.3 Two Compartment Model o f  Apo B Metabolism
The effects o f ciprofibrate on apo-LDL metabolism were further studied by subjecting the 
plasma and urine radioactivities to multicompartmental analysis using SAAM 30, during 
which both baseline and drug turnovers were analysed in the same SAAM deck. The 
results are in table 6.14. Apo-LDL in the more rapidly metabolised component (pool A) 
accounted for approximately half the circulating mass and had a synthesis rate of about 
800 mg/day and an FCR of 0.50 pools/day. Overall the kinetic properties of this metabolic 
compartment were not affected by treatment with ciprofibrate. However, there were inter- 
individual differences in response. Those with the highest baseline plasma triglyceride 
(Ciprol 8, Ciprol 9) exhibited an increase in the synthesis rate o f pool A apo-LDL on drug, 
while in those with the lowest starting triglyceride (Ciprol 2, Ciprol 3) this kinetic 
parameter fell. Pool B apo-LDL, on the other hand, which had a slow FCR of 0.18 
pools/day was reduced in all subjects following ciprofibrate therapy. Its mean mass fell 
from 54% to 42% of the total, principally due to a 38% decrease in its synthesis. The net 
effect o f these perturbances was that in subjects in whom plasma and urine curves were 
almost identical before and during therapy (eg Ciprol 6, fig.6.4 ) the calculated synthesis
137
rates o f both pools A and B fell, whereas in those in whom the curves changed (eg Ciprol 
8, fig. 6.4) there was a shift in synthesis from B to A.
Table 6.14 Kinetic Parameters o f  Pools A  and B  apo-LDL on Ciprofibrate Therapy
_ _ _ _ _ _ _ _ — _ - - - - - - - - - - - - - - - - ^ ■ 2 3 2 2 1 2
. . . . . . .  s. . . . . . . . . . . . . » . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . r. . . . . . . r..
felfe '
a. ,
Baseline
Ciprol 1 1704 0.60 1026 1752 0.22 378
Ciprol 2 1759 0.41 729 1308 0.15 201
Ciprol 3 1440 0.44 642 1035 0.17 177
Ciprol 5 1673 0.66 1100 1678 0.18 294
Ciprol 6 2698 0.46 1242 1916 0.20 379
Ciprol 8 1033 0.48 498 2267 0.26 580
Ciprol 9 881 0.62 690 2815 0.10 296
Ciprol 10 1571 0.30 460 1790 0.14 255
mean 1567 0.50 798 1820 0.18 320
(SEM) (550) (0.01) (289) (548) (0.05) (45)
C iprofibrate
Ciprol 1 2691 0.49 1331 1227 0.18 216
Ciprol 2 674 0.94 633 917 0.16 144
Ciprol 3 1111 0.43 477 443 0.14 63
Ciprol 5 1113 0.51 569 1126 0.17 189
Ciprol 6 1983 0.43 860 1131 0.18 202
Ciprol 8 1547 0.60 922 853 0.20 169
Ciprol 9 2194 0.53 1154 1838 0.18 334
Ciprol 10 1160 0.43 500 1438 0.19 268
mean 1559 0.54 806 1122 0.17 198
(SEM) (677) (0.17) (316) (414) (0.018) (29)
P NS NS NS <0.001 NS <0.05
FCR-fractional catabolic rate; synthetic rate (SR) is the product o f  FCR in pools/d and the plasma pool o f
apo-LDL in mg.
6.7 Discussion
The results o f this study give valuable information not only on the mechanism o f action of 
the second generation fibrates fenofibrate and ciprofibrate but also on the underlying 
metabolic heterogeneity o f LDL.
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In the present study, fenofibrate and ciprofibrate produced beneficial perturbations in the 
levels o f all the plasma lipids and lipoproteins. There were reductions in plasma 
cholesterol (29% FF, 17% Cipro), plasma triglyceride (35% FF, 41% Cipro), VLDL 
cholesterol (36% FF, 38% Cipro) and LDL cholesterol (36% FF, 22% Cipro) with an 
increase in HDL cholesterol (8% FF, 11% Cipro). These changes were consistent with and 
in many cases better than changes previously observed with these and other fibrates. 
Fibrates are believed to reduce the levels of triglyceride through three main mechanisms, 
decreased hepatic triglyceride synthesis secondary to diminished free fatty acid flux to the 
liver (Kissebah et al, 1974), suppression of apo CIII synthesis (Staels et al, 1995, 
Haubenwallner et al, 1995) leading to a reduction in apo CIII : apo E ratio and so 
enhancing chylomicron and VLDL clearance and thirdly, increased lipolysis by stimulation 
of lipoprotein lipase activity (Wolfe et al, 1983). Since VLDL and LDL are closely linked 
in a metabolic cascade it is to be expected that changes in the turnover of the former will 
have consequences for the latter. However, the perturbances are more subtle than would be 
expected from a simple precursor-product relationship.
The kinetic results of the present study o f apo-LDL turnover in moderate 
hypercholesterolaemic subjects are concordant with and amplify those reported for other 
fibrates (Stewart et al, 1982; Malmendier et al, 1985). In the present study there was a 
difference in the magnitude of the response of the two fibrates but both increased the 
catabolic rate of native and receptor-mediated apo-LDL (native: FF 65%, Cipro. 19%; 
receptor-mediated: FF 105%, Cipro 38%). These results are the same as those in an earlier 
investigation using similar methodology from this laboratory (Stewart et al, 1982) that 
examined the effect of bezafibrate on apo-LDL turnover in type Ila hyperlipidaemic 
subjects. It was postulated then that the fibrate activated receptors so that the increased 
clearance of LDL was the result o f altered intracellular cholesterol homeostasis in 
hepatocytes. This metabolic response was similar to that proposed for resins and statins. 
However in this present study a more detailed kinetic analysis of plasma and urine was 
employed and it may be concluded that the changes in LDL metabolism were due to a 
combination o f 2 effects - a shift in synthesis, favouring the formation of the rapidly 
metabolised species (pool A) and an increase in the rate o f elimination by the receptor 
pathway.
In this study there was a decrease in the amount o f apo-LDL associated with the slowly 
metabolised pool B species (FF 2077 to 1180 mg; Cipro 1828 to 1122 mg) due to a fall in 
its rate o f synthesis (FF 422 to 258 mg/d; Cipro 320 to 198 mg/d). Pool A kinetics 
remained unaltered on ciprofibrate whereas fenofibrate increased both fractional catabolic 
rate and synthetic rate. There was no change in the elimination rate o f pool B. Fig. 6.5 
shows the relationship between the kinetic parameters obtained with fenofibrate, 
ciprofibrate and compared with those obtained from normal subjects with similar plasma 
triglyceride levels. The apo-LDL masses quoted for normals are approximately 20% lower 
than those in chapter 5 and Caslake et al (1993) as these included a small component due to 
IDL (d 1.006-1.019 g/ml) which was included in the LDL isolation.
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Fig. 6.5 Mean LDL Kinetic Parameters in Normal Subjects, Subjects at Baseline 
and on Fenofibrate and Subjects at Baseline and on Ciprofibrate, at Comparable 
Plasma Triglyceride Concentrations
This figure shows the mean production rates in mg/d, masses o f pool A and B in mg and fractional 
catabolic rates (FCR) for subjects in quiltiles I and Vfrom chapter 5, subjects at baseline and on 
fenofibrate therapy and subjects at baseline and on ciprofibrate therapy.
As suggested in chapter 5, the mass o f apo-LDL in pool B becomes predominant at higher 
triglyceride levels. There is a strong relationship (r = 0.615, pO.OOOl) between LDL pool 
B synthesis and plasma triglyceride. This association (fig 6.6) is consistent across all the 
subjects so far studied and holds both before and on therapy (n = 55).
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Fig. 6.6 Relationship Between Plasma Triglyceride and Synthesis into Pool B
Pool B synthesis in 25 normal subjects, and 15 hyperlipidaemic subjects at baseline and on fibrate 
therapy (subjects from  chapters 5 and 6). r = 0.6/5. p<0.0001
Thus it can be postulated that the main reason for the kinetic alterations observed on 
treatment with the fibrates is that the LDL particles formed were better ligands for 
receptors. This occurred because the fibrates caused a reduction in triglyceride levels 
relative to apoB synthesis in the liver and so promoted the secretion o f smaller VLDL 
precursor particles. Previous studies (Packard et al, 1984; Demant et al, 1991) have shown 
that the VLDL to LDL delipidation cascade contains parallel pathways that have the 
potential to give rise to LDL species with different metabolic properties. Larger VLDL 
appear to be metabolised to more slowly catabolised LDL (FCR 0.2 pools/d, analogous to 
pool B), while smaller VLDL are converted to rapidly cleared LDL (perhaps analogous to 
pool A). Thus it can be postulated that fibrate therapy, by diminishing the production of 
larger VLDL particles, reduced the formation o f slowly metabolised LDL. Evidence to 
support this hypothesis comes from studies in type III (Packard et al, 1986) and type IV 
(Shepherd et al, 1984) hyperlipidaemic subjects that show that fibrate treatment causes a 
reduction in the synthesis o f large triglyceride-rich VLDL] (Sf 60-400).
The mass o f pool B apo-LDL appears to regulate the overall plasma LDL level and hence, 
it may be argued, the atherogenic potential o f this lipoprotein. Clearly it is o f interest to 
determine the nature o f the LDL that contains this slowly metabolised apoB. Since its
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concentration is directly related to the plasma triglyceride level in the same way as small 
dense LDL, it is appropriate to speculate that the apo-LDL in pool B resides in the LDL III 
species. This would be in line with the finding of Thomson et al (1987) who suggested that 
small dense LDL were metabolised more slowly than their larger counterparts because of 
reduced affinity for the receptor pathway In the present study we examined the subtraction 
distribution within LDL and attempted to relate changes in it to the altered metabolic 
properties of the lipoprotein. The data indicate that there is no simple link between the 
mass o f LDL III apoprotein and the estimated amount of pool B apo-LDL. Most subjects 
prior to therapy had relatively low LDL III since in general the plasma triglycerides were 
low and, although there was a trend towards a reduction in LDL III, only 3 subjects showed 
substantial reductions in LDL III but substantial and significant reductions were observed 
in LDL II. Furthermore the mass of apo-LDL in pool B exceeded substantially that of 
apoprotein in LDL III.
In conclusion, fibrate therapy in primary, moderate hypercholesterolaemia is associated 
with highly significant and clinically relevant changes in the lipoprotein profile, associated 
with changes in the kinetic parameters describing the metabolism o f apo-LDL. In the 
latter, there are changes predominantly in the high-affinity receptor mediated clearance of 
LDL, which may be explained both by an up-regulation o f the receptors and by a drug 
induced shift in the synthesis of an LDL species which is more readily removed by the 
LDL receptor.
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Chapter 7 Ciprofibrate and LDL Metabolism 
in Moderate Hypertriglyceridaemia
7.1 Introduction
Fibrates have a complex effect on the concentration, composition and metabolism of LDL, 
the end product o f VLDL lipolysis. In subjects with elevated LDL concentrations they 
induce a fall in the level of the lipoprotein, while in those with low initial concentrations of 
LDL (i.e. hypertriglyceridaemics), therapy results in a rise in LDL. In previous studies in 
moderate hypercholesterolaemia, it was shown that bezafibrate (Stewart et al, 1982), 
fenofibrate (Caslake et al, 1993) and ciprofibrate (Gaw et al, 1994) increased clearance of 
LDL by the receptor-mediated pathway through two potential mechanisms : first, alteration 
o f the LDL itself to make it more receptor active and second, upregulation of receptor 
activity. In the last two studies, described in detail in chapter 7, there was evidence to 
suggest that the second mechanism was more important i.e. fibrate therapy perturbed the 
synthesis o f LDL in such a way as to form an LDL particle which had increased affinity for 
the LDL receptor. The basis of this was an observed metabolic heterogeneity in apo-LDL 
turnover. To explain the disappearance from plasma and the rate of appearance in urine, it 
was necessary to postulate the existence of two kinetically distinct LDL pools in plasma - 
pool A which had a rapid clearance and high affinity for receptor-mediated pathway and 
pool B with a slower catabolic rate with a reduced rate o f receptor-mediated catabolism. 
This kinetic model has been used to describe apo-LDL metabolism in a group of normal 
subjects with plasma triglyceride ranging from 0.5-1.9 mmol/l (chapter 5) and in a group of 
moderate hypercholesterolaemic subjects (chapter 6) with plasma triglyceride from 0.61-
2.3 mmol/l on and off fibrate therapy. Plasma triglyceride has been shown to have a strong 
influence on the distribution between these two pools, indicating that the mechanisms 
underlying the relationship between LDL cholesterol and plasma triglyceride are complex. 
In contrast to the situation in hypercholesterolaemia, Shepherd et al (1985) showed that in 
hypertriglyceridaemia fenofibrate suppressed hypercatabolism of LDL by receptor- 
independent pathways while at the same time activating clearance o f LDL by receptors. 
The outcome of this redirection of LDL metabolism was to normalise the initially low 
levels of LDL. There were accompanying changes in the composition of LDL so that the 
particles became enriched in cholesteryl ester and depleted in phospholipid and 
triglyceride, characteristic of an increase in particle size.
The methodology described in chapter 3 permits examination of the structural 
heterogeneity of LDL. The three subfractions isolated by density gradient 
ultracentrifugation are: LDL I-the largest, most buoyant and most lipid rich, LDL II- of 
intermediate size and density and usually most abundant and LDL III- which is small and 
dense. The concentration of LDL I is inversely related to fasting plasma triglyceride while 
that o f LDL III is highly positively correlated to plasma triglyceride levels. Austin & 
Krauss (1988, 1990) named the triad of moderately raised triglyceride, low HDL and a 
predominance of small dense LDL the ‘atherogenic lipoprotein phenotype’ (ALP) and 
demonstrated its association with a threefold increased risk of coronary heart disease. In a 
case controlled study of male myocardial infarction (MI) survivors versus normals (Chapter
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3 and Griffin et al, 1994) we have shown a sevenfold increased risk o f MI associated with a 
plasma LDL III concentration >100 mg lipoprotein/100ml plasma. This level of LDL III 
was usually only seen above a threshold level of fasting plasma triglyceride of 1.5 mmol/l. 
Since plasma triglyceride has such a profound influence on the structure and metabolism of 
LDL and fibrates exert action by lowering plasma triglyceride, the object of the present 
study was to explore further the link between the structural and metabolic heterogeneity of 
LDL by examining the effects of ciprofibrate in a group of subjects with moderate 
hypertriglyceridaemia and an ALP profile.
7.2 Method
7.2.1 Protocol
The study was carried out in an identical manner to that described in chapter 6 except for 
the method o f isolation of LDL for radiolabelling. This was prepared by isolation o f the Sf 
0-12 fraction by density gradient ultracentrifugation as described in 2.4.3. There were three 
phases to the protocol. In the preliminary screening period a three month standard 
cholesterol-reducing diet was advised during which time each patient was screened for 
cardiological, haematological, hepatic, endocrine, renal and metabolic disease by routine 
clinical laboratory testing. This was followed by a baseline study for two weeks when the 
subjects underwent measurements of lipids, lipoproteins and lipoprotein subfractions and 
determination of native and 1,2-cyclohexanedione-treated, radiolabelled LDL turnover. In 
the active treatment period subjects were commenced on ciprofibrate therapy at a dose of 
100 mg/d immediately after the baseline measurement o f apo-LDL metabolism. Patients 
remained on this dose for 10 weeks and during the final 2 weeks of this period each patient 
underwent a second turnover investigation with lipid, lipoprotein and lipoprotein 
subfraction measurements.
7.2.2 Recruitment and Conduct o f  the Study.
Recruitment took place at Lipid Clinic at Glasgow Royal Infirmary by Dr J Hinnie, who 
was responsible for the clinical aspects of the study. Dr L Forster assisted with one o f the 
subjects. The patients were visited at home each day for venepuncture by nurses Moira 
Devine, Irene Hendry and Margaret Towland, whose contribution by encouraging the 
patients to adhere to the protocol was invaluable.
7.2.3 Kinetic Analysis
Kinetic analysis was carried out using both Matthews analysis and multicompartmental 
modelling in SAAM 30. Both baseline and on-drug plasma and urine radioactivities were 
modelled together in the same SAAM deck. In an initial analysis, using the two pool 
model (fig. 5.3) proposed in chapter 5 for normal individuals and applied to apo-LDL 
metabolism in moderate hypercholesterolaemia in chapter 6, it was not possible to obtain 
an acceptable fit for the observed and calculated data. The main discrepancy occurred 
during the first few days o f the turnover when there was in the present group of 
hypertriglyceridaemic subjects a high rate of catabolism of both tracers with the appearance 
o f high levels of radiolabelled breakdown products in the urine. Close examination of the 
decay curves of plasma and the urine : plasma (U:P) ratio, a daily index of catabolic 
potential, showed that the cyclohexanedione-labelled apo-LDL was behaving differently to
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what had been observed in chapter 6. Fig. 7.1 shows the U:P ratio for this tracer for 
subjects CiproII 1 and CiproII 10 at baseline. In subject CiproII 1 it rises to a peak at 0.5 
and falls rapidly to 0.2 at 6 days, whereas in subject CiproII 10 a level of 0.2 was 
maintained throughout the turnover (as in the subjects of chapters 5 and 6). Examination of 
the plasma decay curves for the same subjects (fig. 7.2) shows an initial rapid decay for 
CHD-apo-LDL at baseline in subject CiproII 1 but not in CiproII 10.
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It was obvious that the conceptual two pool (AB) model was not adequate to explain LDL 
kinetics in the subjects in this study and so a modified model was developed. The minimal 
model which fitted the data consisted of three plasma pools A, B and C (fig. 7.3): the 
addition o f pool C permitted rapid CHD-LDL clearance. In this more complex model there 
are too many variables to estimate with certainty from the data ie. the model is not 
identifiable. So, on the basis of previous analysis in chapters 5 and 6, it was decided to fix 
the elimination rates from each of these pools to population average values (table 7.1).
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T ab le  7.1 A B C  M o d e l C a tabo lic  R a tes
------------------------------------- -— - -----------------
f tliOl i \Kfir.9 jAig i w B  
-< fi'A'j. f  j, • / /,
------------ ------ --—
w B m m m
A 0.60 0.30
B 0.25 0.15
C 0.00 0.50
As with the AB model, pool B was allowed to exchange with an extravascular pool There 
was no requirement for A or C to undergo exchange in order to achieve an acceptable fit. 
Fitting o f observed data was therefore a function simply o f distributing LDL between the 
three pools according to the nature o f the plasma and urine radioactivity data. For 
example, if  a subject had a high initial clearance o f native but not CHD tracer then more 
LDL would be placed in pool A (see chapter 6), but if both tracers exhibited rapid initial 
clearance then a high content of pool C would reflect this.
146
mg/d 
synthesis
mg
ill V
\ 1" /■pOOlfi/d M ^  J  MvlvMpmdrt
TodEeD
i
urine
77#. 7.1 A B C  Kinetic Model o f  LDL Metabolism
The plasma compartment consists o f  three pools A,B and C each o f  which has input measured in 
mg/d and elimination rates in pools /d. Pool B has extravascularvexchange.
7.2.4 Subjects
The characteristics o f the subjects are shown in table 7.2. Ten male subjects, aged 34-65 
and exhibiting Type lib hyperlipidaemia with initial plasma triglyceride concentrations of 
2.0-5.2 mmol/l and plasma cholesterol 5.2-7.5 mmol/l were recruited into the study. Six of 
the subjects were 3/3 Apo E phenotype, 2 were 2/3 , one 3/4 and one 2/4.
Table 7.2 Characteristics o f  the Subjects
-
C iproII 1 34 78.2 4/3
C ip ro II2 61 94.9 3/3
C ip ro II3 51 77.9 3/3
C ip ro II4 56 83.5 3/3
C ip ro II5 53 80.0 3/3
C ip ro II6 54 86.7 3/3
C ip ro I I7 50 102.1 2/3
C ip ro II8 53 88.3 3/3
C ip ro II9 65 100.8 2/3
C iproII 10 59 75.2 2/4
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7.3 Results
7.3.1 Lipids, Lipoproteins, Apolipoproteins and HDL Subfractions
The lipid and lipoprotein levels of the subjects are given in table 7.3 and listed in 
descending order o f fasting plasma triglyceride. The subjects exhibited a lipoprotein 
profile (mean triglyceride 3.07 mmol/l, mean HDL cholesterol 0.9 mmol/l )with a 
preponderance (69%, table 7.7) o f small dense LDL III, indicative o f ALP. Treatment with 
ciprofibrate significantly (p<0.02) reduced fasting plasma triglyceride by 34% and this was 
reflected in a 41% fall in VLDL cholesterol. Plasma cholesterol and HDL cholesterol 
remained unchanged.
Table 7.3 Lipid and Lipoprotein Levels
18 - ■
Baseline
CiproII 1 5.6 5.2 2.1 2.7 0.8
CiproII 2 7.1 4.3 2.1 4.0 0.9
CiproII 3 7.1 3.5 1.7 4.5 0.9
CiproII 4 5.2 3.3 1.7 2.6 0.9
CiproII 5 5.6 2.8 1.4 3.3 0.8
CiproII 6 7.6 2.5 1.0 5.5 1.1
CiproII 7 5.9 2.4 1.0 4.2 0.8
CiproII 8 5.6 2.3 1.1 3.5 0.8
CiproII 9 6.7 2.3 1.3 4.3 1.1
CiproII 10 5.6 2.0 1.0 3.7 0.9
mean 6.21 3.07 1.45 3.83 0.90
(SEM) (0.36) (0.33) (0.14) (0.28) (0.04)
C iprofibrate
CiproII 1 6.3 2.4 0.9 4.7 0.7
CiproII 2 6.3 2.5 1.2 4.3 0.9
CiproII 3 6.9 2.7 1.3 4.7 1.0
CiproII 4 5.6 1.3 0.6 3.9 1.2
CiproII 5 5.4 2.0 0.9 3.5 1.0
CiproII 6 6.6 2.4 0.9 4.8 0.9
CiproII 7 4.7 2.3 0.8 3.1 0.8
CiproII 8 5.0 2.0 0.7 3.5 0.8
CiproII 9 6.5 1.7 0.7 4.5 1.2
CiproII 10 4.2 1.1 0.4 2.6 1.2
mean 5.74 2.04 0.85 3.94 0.96
(SEM) (0.29) (0.16) (0.08) (0.24) (0.06)
P NS <0.02 <0.002 NS NS
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There was a varied response in LDL cholesterol with no change overall. For example, in 
subject CiproII 8 , LDL cholesterol fell from 3.7 to 2.6 mmol/l, whereas in CiproII 10 the 
change was from 4.3 to 4.5 mmol/l and subject CiproII 3 with initial low levels o f LDL 
cholesterol o f 2.7 mmol/l exhibited a rise to 4.7 mmol/l. These changes in LDL cholesterol 
were related to the change in plasma triglyceride i.e. those with an increased basal 
triglyceride tended to show an increased LDL cholesterol on therapy. There was a small 
but significant (pO .05 ) rise in HDL3 subfraction which was associated with a rise in 
apolipoprotein A II (table 7.4). The other lipoproteins Al, B and Lp(a) were unaffected by 
therapy (table 7.4 )
Table 7.4 Apoprotein and HDL Subfraction Concentrations
Baseline
CiproII 1 166 27 177 23 10 265
CiproII 2 131 28 180 3 13 226
CiproII 3 122 32 164 29 22 257
CiproII 4 90 26 147 10 11 224
CiproII 5 106 26 119 12 21 217
CiproII 6 126 36 150 84 28 303
CiproII 7 98 28 149 44 13 224
CiproII 8 96 26 134 70 16 176
CiproII 9 112 36 147 15 22 374
CiproII 10 118 26 116 46 26 267
mean 119 29 148 34 18 253
(SEM) (5) (1) (7) (8) (2) (17)
C iprofibrate
CiproII 1 136 31 127 33 11 293
CiproII 2 134 32 146 9 19 286
CiproII 3 131 36 157 28 29 294
CiproII 4 137 31 105 13 15 326
CiproII 5 103 35 164 8 18 293
CiproII 6 129 36 162 148 12 375
CiproII 7 111 28 99 30 18 234
CiproII 8 114 30 96 46 29 241
CiproII 9 114 43 122 17 31 305
CiproII 10 96 26 62 53 70 401
mean 114 34 125 39 25 305
(SEM) (5) (1) (10) (13) (6) (16)
P NS NS NS NS NS <0.05
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7.3.2 ApoB Lipoprotein Subfractions
When VLDL was subdivided into large VLDL! (Sf 60-400) and small VLDL2 (Sf 20-60) it 
was observed (table 7.5) that the reduction in VLDL was due to a significant (p<0.05) 40% 
fall in the mass o f the larger VLDL particle. There were no changes in the lipoprotein 
masses o f IDL (Sf 12-20) nor LDL (Sf 0-12).
Table 7.5 Masses o f  Lipoprotein Subfractions (Sf 0-400)
m t . ' ■ V . ; '
Baseline
CiproII 1 319 105 37 206
CiproII 2 312 152 67 232
CiproII 3 365 104 60 361
CiproII 4 226 87 42 185
CiproII 5 231 65 65 220
CiproII 6 189 121 73 290
CiproII 7 143 57 58 246
CiproII 8 105 114 62 271
CiproII 9 162 151 61 259
CiproII 10 83 70 61 227
mean 212 107 58 253
(SEM) (34) (11) (4) (52)
C iprofibrate
CiproII 1 188 82 59 306
CiproII 2 127 109 61 219
CiproII 3 201 103 72 217
CiproII 4 128 52 65 293
CiproII 5 — — — —
CiproII 6 197 89 78 292
CiproII 7 108 68 64 216
CiproII 8 96 42 106 198
CiproII 9 65 178 130 217
CiproII 10 29 43 63 186
mean 127 85 76 238
(SEM) (20) (14) (8) (46)
P (n=9) <0.05 NS NS NS
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There was a significant change in the percentages o f free cholesterol (51% decrease, 
p<0.005) o f VLDL, (table 7.61.
Table 7.6 Composition o f  Lipoprotein Subfractions (Sf 0-400)
w M w r n n m m m
VLDL,
Baseline 7.7 5.9 14.5 57.8 15.9
(0.4) (0.7) ( 1.1) (0.7) (0.9)
Ciprofibrate 8.0 2.9 15.4 59.1 14.8
n=9 (0.5) (0 .6) (1.5) (1.3) (0.7)
P (n-9) NS <0.005 NS NS NS
v l d l 2
Baseline 13.1 6.6 26.8 35.8 18.8
(0 .6) (0 .6 ) ( 1.8) (1.4) (0 .6)
Ciprofibrate 13.4 6.8 26.9 34.0 19.2
n=9 (1.3) (1.5) (1.7) (2 .0 ) ( 1.0)
P (n=9) NS NS NS NS NS
IDL
Baseline 19.6 5.8 41.1 14.4 19.1
(1.5) (0.4) ( 1.0) (1.3) (0.9)
Ciprofibrate 19.3 7.1 40.9 15.1 20.9
n=9 (1.3) (0 .8) (2.5) (1.9) (0.9)
P (n=9) NS NS NS NS NS
LDL
Baseline 26.8 6.9 40.7 7.0 18.6
(0 .8) (0 .6 ) (0 .8) (0 .6 ) (0 .6)
Ciprofibrate 26.7 7.9 41.4 7.0 19.3
n=9 ( 1.6 ) (0.9) (1.3) (0.5) (0.5)
P (n=9) NS NS NS NS NS
Values are mean (SEM)
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Ciprofibrate significantly altered the distribution o f the LDL subfraction profile as seen in 
tab le7.7.
Table 7.7 LDL Subfraction Concentrations
 ^ 1 1 i
Baseline
CiproII 1 221 22 32 166
CiproII 2 191 14 18 160
CiproII 3 356 40 66 250
CiproII 4 202 25 47 130
CiproII 5 354 0 0 354
CiproII 6 401 50 146 205
CiproII 7 256 21 84 151
CiproII 8 305 27 85 193
CiproII 9 323 19 73 230
CiproII 10 302 42 112 149
mean 291 26 « 66 199
(SEM) (23) (5) (14) (21)
C iprofibrate
CiproII 1 396 24 192 180
CiproII 2 369 56 146 167
CiproII 3 333 61 220 53
CiproII 4 395 37 124 134
CiproII 5 307 10 37 260
CiproII 6 385 76 195 114
CiproII 7 256 37 117 102
CiproII 8 304 28 148 128
CiproII 9 302 56 162 84
CiproII 10 207 42 149 16
mean 315 38 134 116
(SEM) (19) (7) (21) (24)
P NS NS <0.02 <0.02
At baseline, 69% of LDL was in the small dense fraction. Therapy significantly (p<0.002) 
reduced this to 38%, while at the same time increasing the proportion o f LDL II (22% to 
48%, p<0.001). The absolute concentrations changed accordingly. LDL I increased from 
26 to 38 mg/100ml (44%, NS), LDL II from 66 to 134 mg/lOOml (102%, p<0.02) and LDL
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III fell from 199 to 116 mg/100ml (42%, p<0.02). In subject CiproII 4 at baseline only 
small dense LDL III was detectable (fig. 7.4) with small amounts o f LDL I and LDL II 
appearing on treatment with ciprofibrate. On closer examination o f the LDL subfraction 
profile, it was observed that the LDL in subjects CiproII 1 ,2  4 and 5 was very small and 
dense. In the density gradient ultracentrifugation method we did not distinguish small 
from very small LDL, but these subjects exhibited the presence of ‘LDL IV’ as described 
by Krauss et al (1982). On ciprofibrate no ‘LDL IV’ was observed.
ii i
F ig. 7.4 L D L  S u b fra c tio n s  a t B a se lin e  a n d  o n  C ipro fib ra te
LDL subfraction profiles for subjects CiproII 1 and CiproII 10 at baseline (black) and on 
ciprofibrate (red)
7.3.3 Receptor-mediated and Receptor-independent Apo LDL Metabolism 
The parameters derived from Matthews kinetic analysis are shown in table 7.8.
The overall mean FCR remained unaltered by therapy (0.33 versus 0.35 pools/day) but 
there was a marked individual variation in response depending on the plasma triglyceride 
concentration achieved on treatment.
At baseline, 28% of apo-LDL removal was receptor-mediated but ciprofibrate induced 
significant alterations in route of removal resulting in an equal catabolism of apo-LDL by 
both receptor-mediated and receptor-independent pathways. The receptor-mediated FCR 
was significantly (p<0.002) increased by 74%, while receptor-independent FCR was 
significantly decreased by 21% (p<0.05). There was no change in the mass o f circulating 
apo-LDL but the amount of apo-LDL removed by these routes was altered in concert such 
that there was almost a doubling o f removal by the receptor-mediated pathway (p<0.0005). 
In these subjects, it was observed that receptor-independent catabolism of apo-LDL was 
positively correlated (r = 0.54, p<0.02) to the ratio of the mass of LDL III to LDL II (fig. 
7.5), linking structural and metabolic changes. Plasma triglyceride correlated with the 
ratio o f LDL III to LDL II (r = 0.63, p<0.005), receptor-independent FCR ( r = 0.80, p< 
0.0001) and receptor-mediated FCR (r = - 0.57, p< 0.01). As expected, plasma
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with VLDL, and these parameters: VLDL, with the ratio o f LDL III to LDL II (r = 0.70 , p 
<0.0001), VLDL, with receptor-independent FCR ( r = 0.63, p< 0.005) and VLDL, with 
receptor-mediated FCR ( r = - 0.54, p<0.02).
Table 7.8 Matthews Kinetic Parameters o f  Apo-LDL
1 
<
<
Baseline
CiproII 1 61.6 0.42 0.35 0.07 12.9 10.8 2.1
CiproII 2 58.4 0.39 0.27 0.12 14.8 10.2 4.6
CiproII 3 92.8 0.34 0.23 0.11 10.5 7.1 3.4
CiproII 4 53.6 0.44 0.35 0.09 14.8 11.8 3.0
CiproII 5 95.8 0.30 0.22 0.08 9.5 6.9 2.6
CiproII 6 94.0 0.24 0.22 0.02 8.3 7.7 0.7
CiproII 7 63.5 0.34 0.20 0.14 13.9 8.1 5.7
CiproII 8 82.7 0.29 0.19 0.10 10.4 6.8 3.6
CiproII 9 88.8 0.31 0.19 0.12 12.5 7.7 4.8
CiproII 10 80.2 0.28 0.18 0.09 8.6 5.7 2.9
mean 77.1 0.33 0.24 0.09 11.6 8.3 3.3
(SEM ) (5.1) (0.02) (0.02) (0.01) (0.8) (0.6) (0.5)
C iprofibrate
CiproII 1 103.8 0.26 0.16 0.10 8.2 5.0 3.2
CiproII 2 103.3 0.35 0.22 0.13 13.4 8.5 4.9
CiproII 3 73.0 0.34 0.20 0.14 10.7 6.2 4.4
CiproII 4 77.4 0.39 0.21 0.19 13.1 6.9 6.2
CiproII 5 83.2 0.33 0.20 0.14 10.7 6.3 4.4
CiproII 6 99.5 0.34 0.21 0.13 12.0 7.5 4.6
CiproII 7 56.4 0.40 0.19 0.20 16.4 8.0 8.4
CiproII 8 77.5 0.36 0.18 0.18 12.7 6.3 6.4
CiproII 9 71.8 0.35 0.19 0.16 14.2 7.6 6.6
CiproII 10 48.5 0.43 0.16 0.27 12.6 4.7 7.9
mean 79.4 0.35 0.19 0.16 12.4 6.7 5.7
(SEM ) (5.9) (0.02) (0.01) (0.01) (0.7) (0.4) (0.5)
P NS NS <0.05 <0.002 NS NS <0.005
FCR-fractional catabolic rate; RI - receptor independent ie clearance from  cyclohexanedione modified LDL; 
RM - receptor mediated calculated as the difference between native and CHD modified apo-LDL; synthetic 
rate is the product o f  FCR in pools/d and the plasma pool o f  apo-LDL in mg divided by the body weight in 
kg; ACR is the absolute catabolic rate and is the product o f  either receptor independent or the receptor 
mediated FCR and the apo-LDL pool size divided by the body weight. Under steady state conditions 
synthetic rate and catabolic rate should be equal.
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7.3.4 Three compartmental Model o f  Apo LDL Metabolism
Multicompartmental modelling o f plasma and urine radioactivity led to a distribution of 
mass of apo-LDL among the three plasma pools A, B and C as shown in table 7.9.
All o f the subjects had apo-LDL mass that was in pool B and this was significantly 
correlated with total apo-LDL mass ( r = 0.83, p<0.0001). It was the major component in 8 
out o f 10 subjects. However there were marked differences as to whether pool A or pool C 
was the other component. Plasma triglyceride was negatively correlated with pool A mass 
(r = -0.49, p<0.05), positively with pool B (r = 0.48, p<0.05) and positively with pool C (r 
=0.81, p<0.0001). For example, subjects CiproII 7-10 at baseline with plasma triglyceride 
<2.4 mmol/l had no pool C compartment and A and B were in the ratio 3:5. Ciprofibrate 
treatment altered this to 1:1. In subjects 1 - 6  with higher basal plasma triglyceride levels, 
there was no apo-LDL in pool A at baseline and pool C was more important. At 
triglyceride >4.3 mmol/l more than 80% apo-LDL mass was in pool C. Pools A and C 
were negatively correlated (r= -0.77, p< 0.0001). The synthesis of apo-LDL in each 
compartment (table 7.10), calculated as the product of the mass and FCR, showed similar 
relationships. There was a redistribution of the mass in ABC towards pools A and B, with 
a resultant decrease in the median mass o f pool C and its elimination in most individuals. 
The basis for this change is evident from the changes in the decay curves (fig. 7 2). The 
change in pool C on fibrate therapy was significant (p<0.05) using a non-parametric test 
(Mann Whitney). The mass in pool C was positively associated with receptor-independent
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catabolic rate (r = 0.60, p=0.006), % LDL III ( r = 0.48, p=0.034) and the ratio o f LDL III 
to LDL II (r =0.48, p=0.040). ‘LDL IV ’ was only observed in those subjects with plasma 
triglyceride >2.5 mmol/l and apo-LDL in pool C.
Table 7.9 Distribution o f  apo-LDL Mass in Pools A , B and C
: : . . ■ -
!fHR
E Q Z g T C Q l' '\ ' - A " ,
Wj^mn^mWSm
HBHBfif r ff I
Baseline 
C iproII 1 1927 0 15 85 0 289 1638
C iproII 2 1790 0 20 80 0 358 1432
C iproII 3 2216 14 40 47 310 887 1042
C iproII 4 2890 0 64 36 1849 1040
CiproII.5 3066 0 54 46 1655 1410
C ip ro II6 3260 0 74 26 2412 848
C ip ro II7 2592 36 64 0 933 1659 0
C ip ro II8 3575 23 74 3 822 2645 107
C iproII 9 2918 20 80 0 584 2335 0
C iproII 10 2412 40 59 1 965 1423 24
median 2741 7.0 61.5 31.0 155 1657 944
(SEM) (184) (5) (7) ( 10) (134) (261) (209)
C iprofibra
te
C ip ro II1 3247 0 100 0 0 3247 0
C iproII 2 2584 49 46 6 1266 1189 155
C ip ro II3 3920 8 62 30 314 2431 1176
CiproII 4 2273 2 71 27 45 1614 614
C iproII 5 2662 28 72 0 745 1917 0
C iproII 6 3451 18 67 15 621 2312 518
C iproII 7 2302 50 50 0 1151 1151 0
CiproII 8 2894 37 63 0 1071 1823 0
C iproII 9 3920 36 64 0 985 1750 0
C iproII 10 1458 74 26 0 1079 379 0
median 2778 32.0 63.5 0.0 865 1786 0.0
(SEM) (247) (7) (6) (3.8) (147) (250) (127)
P NS NS <0.05 NS
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Table 7.10 Synthesis into Pools A, B and C
- fWPiSmf . .  '
d _l 4 ;  ■/ ' ' , A&*u '/A ' ' '  ;
: :y. ' : ■ ’ " ' .. . ' .
y ■ ■■: : ■■■■ : ■ •■■ ■ y  ; . y
Baseline
CiproII 1 0 72 819
C ip ro II2 0 89 716
C ip ro II3 186 222 521
CiproII 4 0 462 520
CiproII.5 0 414 705
C ip ro II6 0 603 424
CiproII 7 560 415 0
C ip ro II8 493 661 54
C iproII 9 350 584 0
CiproII 10 579 356 12
median 93 415 472
(SEM) (80) (65) (105)
Ciprofibrate
C iproII 1 0 812 0
C ip ro II2 760 297 78
CiproII 3 188 608 588
CiproII 4 27 403 307
CiproII 5 47 479
C ip ro II6 373 578 259
CiproII 7 691 288 0
CiproII 8 642 456 0
CiproII 9 591 438 0
CiproII 10 648 95 0
median 482 447 0
(SEM) (97) (63) (63)
P NS NS NS
7.4 Discussion
In this study o f LDL kinetics in hypertriglyceridaemia, it was necessary to extend the 
multicompartmental model devised for normals in chapter 5 and applied to 
hypercholesterolaemia in chapter 6 , to allow for the fact that in individuals with moderate 
to high concentrations o f plasma triglyceride, LDL undergoes accelerated catabolism by the 
receptor-independent pathway (Shepherd et al, 1986). This was reflected in the baseline 
turnovers where there was present a substantial mass o f apo-LDL which was attributable to 
pool C, the LDL pool whose kinetic characteristic is that o f  a compartment catabolised 
entirely by the receptor-independent pathway at a fixed rate o f 0.5 pools/day. The ABC
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model produced highly satisfactory fits to the plasma and urine radioactivity curves for all 
subjects at baseline. Treatment with ciprofibrate reduced pool C mass with a redistribution 
towards pools A and B, while the mass of apo-LDL was unchanged at 2.7 g. Again the 
modified model was required to generate satisfactory fits to the observed and calculated 
data.
The concept of fixing the elimination rates from pools ABC to population average values 
suggests that LDL kinetics can be explained by the presence o f distinct metabolic pools and 
that the presence o f hypertriglyceridaemia and its correction by therapy with ciprofibrate 
causes LDL to switch between these pools. The presence o f pool C was highly correlated 
with plasma triglyceride (r =0.81, p<0.0001) and the necessity for pool C in those subjects 
with plasma triglyceride >2.5 mmol/1 at baseline was linked to the presence of an 
abnormally small dense species on density gradient ultracentrifugation profile i.e. LDL IV. 
A number of other investigators have shown that in individuals with similar plasma 
triglyceride levels that LDL is small and dense with reduced affinity for LDL receptors 
(Eisenberg et al, 1984, Kleinman et al, 1985, Nigon et al, 1991, Chen et al, 1994).
In the subjects in this study, we were able to see the relationships between plasma 
triglyceride, LDL structure and kinetic heterogeneity. LDL subtraction distribution ( i.e. 
the ratio of LDL III to LDL II and % LDL III) was linked to receptor-independent 
catabolism. This is the first time that a link has been shown between structural and 
metabolic heterogeneity in humans.
At present it is not entirely clear what the structural basis of the kinetic differences between 
pools A, B and C are, but from the above discussion it is clear that particle size and density 
play an important role in determining the properties o f the lipoprotein. It is proposed that a 
density and size shift induced an alteration in the conformation of apo B on LDL and this is 
the basis of the observations in this chapter. We postulate that the apo B on LDL in pool A 
is in a conformation that has a high affinity for the LDL receptor, whereas the protein in 
pool B still binds to the receptor but with lower affinity. In hypertriglyceridaemia where the 
cycles o f lipid exchange and hydrolysis generate an abnormally small particle ‘LDL IV’, 
then it is possible that apo B has undergone a further conformational change which 
activates particle clearance by receptor-independent mechanisms. These proposals are 
consistent with the known variation of epitope expression o f apo B in larger versus smaller 
LDL and the link between these variations and receptor binding capabilities in vitro. The 
activation of receptor-independent catabolism is conjectural at present.
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Chapter 8 Impact of Heterogeneity in LDL 
Structure and Metabolism
There has traditionally been a lack of consensus on the role o f plasma triglyceride as an 
independent risk factor for CAD but there is an emerging view incorporated in new 
guidelines for the prevention of coronary disease that moderately elevated plasma 
triglyceride levels associated with a low HDL cholesterol predispose to an increased risk 
for coronary disease. Evidence to support this is emerging from clinical trials as well as 
epidemiological surveys. In the Framingham study (Castelli et al, 1986) elevation of 
triglyceride was a highly significant independent risk factor in women and in the Helsinki 
Heart study (Manninen et al, 1988) the benefit o f treatment with gemfibrozil was seen 
largely in the group of subjects with plasma triglyceride > 2mmol/l and HDL cholesterol <
1.2 mmol/1. The WOSCOPS study also confirmed that the absolute risk reduction was 
greater in those subjects with triglyceride concentrations > 1.67 mmol/1 (CJ Packard, 
personal communication).
The results of this thesis, presented in chapters 3 to 7, provide evidence to support the 
contention that plasma triglyceride influences both the structural and metabolic 
heterogeneity in LDL and the associated risk of coronary disease.
8.1 LDL Heterogeneity and Apo-B Metabolism
The results o f the kinetic studies in subjects described in chapter 5 and 6 altered the 
concepts of the regulation of LDL metabolism. Fig. 8.1 shows that as plasma triglyceride 
rose from 0.6 to 2 mmol/1, the catabolic rate of LDL fell from 0.45 to 0.25 pools /d due to a 
fall in the receptor-mediated catabolism, while receptor-independent catabolism remained 
constant. This was accompanied by a rise in the concentration of LDL. However, as 
plasma triglyceride rose above 2 mmol/1, there was increased clearance via the receptor- 
independent pathway while clearance by the receptors remained constant. The classical 
(Matthews) approach to analysing the data would have attributed to the rise in mass of apo- 
LDL with increasing plasma triglyceride to a fall in its catabolic rate and the conclusion 
would have been that the elevated plasma triglyceride levels in some way down-regulated 
the LDL receptor. However recognition that LDL was not behaving as a homogeneous 
entity opened up other possibilities, namely that the variation in plasma triglyceride 
affected the nature of LDL. Two plasma pools for LDL were proposed, pool A having a 
fast clearance rate and mostly via the LDL receptor while pool B had a slower rate of 
clearance. Fig. 6.6 shows the close relationship between the synthesis of pool B and 
plasma triglyceride levels, indicating that at higher plasma triglyceride levels more mass 
appears in pool B. One way to interpret this association is to note that plasma triglyceride 
levels are a reflection o f VLDL t concentrations (Tan et al, 1995a). It is tempting therefore 
to speculate that pool B apo LDL is derived from large VLDLt and there are several lines 
of evidence from VLDL metabolic investigations to support this. Early studies on the 
metabolism of trace-labelled VLDL established its precursor relationship to LDL in normal 
and dyslipidaemic subjects (Berman et al, 1978). However, not all VLDL apo B is 
converted to LDL apo B and not all LDL apo B is derived from VLDL apoB.
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Importantly metabolic channels exist in the VLDL-LDL delipidation cascade (Packard et 
al, 1995) so that different VLDL precursors give rise to products with varying metabolic 
properties. In a large number of turnover studies (Packard et al, 1995) it has been shown 
that LDL derived from the delipidation o f VLDL] has a catabolic rate o f 0.2 pools/d while 
LDL derived from lipoproteins first secreted into the VLDL2 density range has a catabolic 
rate o f about 0.5 pools/d. (fig.8.2) These are comparable to catabolic rates calculated in 
chapters 5 and 6 for pool B and pool A apo-LDL respectively and these data suggest that 
pool B LDL is indeed the product o f VLDL1 lipolysis and this is the basis of the 
association seen in fig. 6.6.
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Turnovers o fI25I-VLDLj and1311-VLDL2 result in LDL with catabolic rates of 0.2 and 0.5 pools/d, 
akin to those calculated for pools B and A LDL.
Pool A synthesis on the other hand was poorly related to triglyceride and new evidence 
from unpublished stable isotope VLDL-LDL studies from this laboratory shows that 
rapidly removed LDL is also derived from lipoproteins secreted from the liver into the IDL 
and LDL density interval. This suggests that pool A apo-LDL is derived from particles 
released by the liver in the Sf 0-60 range. Fig. 8.3 draws this information together and 
postulates that the liver forms lipoprotein particles of differing sizes depending on the 
availability o f hepatic triglyceride and these lead to the formation o f LDL particles with 
different metabolic fates and different atherogenic potential.
---p o o m a
F ig .8 .3  H ep a tic  L ip o p ro te in  M eta b o lism
161
8 .2  R e la tin g  L D L  S tru c tu re  to  M eta b o lism
The results in this thesis provide evidence that the influence of plasma triglyceride is the 
common link between structural and metabolic heterogeneity in LDL.
Numerous in vitro studies have suggested that apoB found in smaller LDL particles has a 
reduced receptor-binding affinity which arises from a conformational change in apo B 
(Kleinman et al, 1987, Chen et al, 1994, Galeano et al, 1994). Can we say therefore that 
pool B apo-LDL is made up o f LDL III? The answer is no for two reasons. First, there is 
not enough mass in LDL III to account for the mass o f apo-LDL in pool B (tables 6.7, 6.9, 
6.14, 6.16) and secondly, the kinetic studies in chapters 5 and 6 were carried out using 
lipoprotein from a narrow density interval as described in the zonal ultracentrifugation 
procedure and so both A and B pools co-existed in this narrow density range. It is 
suggested therefore that pool B consists o f LDL III and a proportion o f LDL II. Pool A on 
the other hand is thought to be present in LDL I and LDL II because direct synthesis of 
LDL, which occurs in subjects with low plasma triglyceride, was related to concentrations 
o f LDL I plus LDL II (Gaw et al, 1995). This finding is confirmed in the unpublished 
stable isotope study where a high proportion o f direct lipoprotein synthesis in the IDL-LDL 
range was associated with low plasma triglyceride ( < 1.0 mmol/1) and a high content of 
LDL I and LDL II in plasma.
It is clear therefore, that the source o f LDL is very important in determining both its 
structure and kinetic properties. The longer LDL is resident in plasma the more likely it is 
to undergo neutral lipid exchange and hydrolysis to form small LDL. It is therefore 
proposed that pool A is comprised o f LDL which is derived from the lipoproteins in the Sf 
0-60 range and forms the majority o f LDL I and a substantial amount of LDL A, whereas 
pool B is in LDL II initially and following neutral lipid exchange and lipolysis can form 
LDL III, and pool C is LDL IV (fig. 8.4).
LDL I LDL II LDL III LDL IV
Fig. 8 .4  L in k in g  S tru c tu ra l a n d  M eta b o lic  H etero g en e ity  o f  L D L
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Fig. 7.5 links structural and metabolic heterogeneity in LDL in that receptor-independent 
catabolism is increased as the proportion of very small, dense LDL rises. In the special 
circumstances of moderate to severe hypertriglyceridaemia a new type of LDL (LDL IV) is 
formed with an apo B conformation such that it no longer binds to the LDL receptor and is 
subject to a rapid removal by non-receptor pathways.
8.3 C orrection o f  an A th ero g en ic  L ipopro tein  P heno type  by D ru g  T herapy
The studies in chapter 4 indicate that an undesirable LDL subfraction profile may be 
corrected by therapy. Those that lower LDL III concentrations principally through 
reductions in plasma triglyceride such as the fibrates (tables 4.18, 4.20, 4.22, 4.24) may be 
the drugs of choice in subjects with ALP, principally by their action of altering the quality 
of lipoprotein assembled in the liver and so reducing the precursors of atherogenic LDL. 
However it was suggested from the data(fig.4.|)that the statins in combined hyperlipidaemia 
may accelerate the removal of the large VLDL in such a way that less pool B and hence 
less LDL III is formed. This is an exciting new prospect in the treatment of ALP and 
prevention of coronary disease, with drugs that have been proven to be safe and clinically 
effective.
8.4  D irections fo r  F u tu re  R esearch
A number of questions have arisen from the studies in this thesis, some of which are 
already being addressed and others which will be the focus of future work.
It is important to learn more about the inter-relationships between the LDL subfractions 
both in healthy subjects and those presenting with an atherogenic lipoprotein phenotype. 
Turnovers using radioactively labelled purified LDL I, LDL II and LDL III have already 
been carried out in three young normal males and incorporation of a tracer amino acid L- 
(5,5,5- H3)-leucine (d3-leucine) into the three subfractions has been conducted in those 
subjects in whom VLDL stable isotope turnovers are referred to in section 8.2. At present 
the data is at the limit o f the number of compartments that SAAM 30 can handle and we 
await the new SAAM II version to analyse this data.
It would be interesting to investigate further the male/female differences in the formation of 
LDL III observed by Tan et al (1995) and examine the LDL distribution profile, hepatic 
lipase activity and androgen:oestrogen ratio in females with premature coronary disease. 
Studies are underway to measure these indices in pre- and post-menopausal female 
diabetics who appear to have lost their ‘female protection’ against coronary disease.
Further investigations are required to identify the nature of the receptor-independent 
catabolism of pool C apo-LDL and methodology will need to be developed to observe the 
binding properties and define the epitope expression to explain conformational differences.
There are only two publications in the literature to date on IDL and its subfractions. 
Evidence has been presented in this thesis that the precursors of LDL are very important in 
determining its structure and metabolism. Preliminary gradient gel electrophoresis has
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been carried out and different IDL species have been identified. It is the intention to 
develop a quantitative method for the isolation and characterisation of IDL subfractions it 
in a similar way that has been described in chapter 3 for LDL subfractions.
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HP12 4JL, UK
BDH Laboratory Supplies,
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Espoo, Finland
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Eastleigh, Hampshire, S053 3ZQ, UK.
Pharmacia Biotech Ltd,
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Resource Facility for Kinetic Analysis, 
University of Washington, Seattle, 
Washington 98195, USA.
Sanofi-Winthrop
Onslow Street, Guildford,
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Scottish Antibody Production Unit (SAPU),
Law Hospital 
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Sigma Chemical Company,
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Upjohn Ltd,
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Glossary
ACR Absolute catabolic rate
ALP Atherogenic lipoprotein phenotype
Apo Apolipoprotein
ACAT Acyl CoA: cholesterol acyl transferase
BCAIT Coronary atherosclerosis intervention trial
BHA British Hyperlipidaemia Association
BMI Body mass index
CAD Coronary artery disease
CABG Coronary artery bypass surgery
CE Cholesteryl ester
CETP Cholesteryl ester transfer protein
CHD Coronary heart disease
CHD-LDL Cyclohexanedione modified LDL
CHL Combined hyperlipidaemia
Ci Curie
Cipro Ciprofibrate
CoA Coenzyme A
d Density
DGUC Density gradient ultracentrifugation
EAS European Atherosclerosis Society
EDT A Ethylenediaaminetetra-acetate
EV Extravascular
FCR Fractional catabolic rate
FDB Familial defective B lipoproteinaemia
FF Fenofibrate
FFA Free fatty acid
FH Familial hypercholesterolaemia
GGE Gradient gel electrophoresis
HC Moderate hypercholesterolaemia
HDL High density lipoprotein
HL Hepatic lipase
HMG CoA 3-hydroxy, 3-methylglutaryl coenzyme A 
HSL Hormone sensitive lipase
HTG Moderate hypertriglyceridaemia
IDL Intermediate density lipoprotein
IV Intravascular
LCAT Lecithin: cholesterol acyl transferase
LDL Low density lipoprotein
Lp(a) Lipoprotein (a)
LPL Lipoprotein lipase
LRC Lipid Research Clinics
LRP LDL receptor related protein
MAAS Multi-centre anti atheroma study
MI Myocardial infarction
MTP Microsomal triglyceride transport protein
NCEP National cholesterol education program
NIDDM Non insulin dependent daibetes mellitus
OD2go Optical density at 280 nm
PLTP Phospholipid transfer protein
PMI Post myocardial infarction
PPAR Peroxisome proliferator activated receptors
REGRESS Regression growth evaluation statin study
rpm Revolutions per minute
SAAM Simulation, analysis and modelling
SCRIP Stanford coronary risk intervention program trial
SD Standard deviaton
SDS Sodium dodecyl sulphate
SEM Standard error of the mean
Sf Svedberg flotation units
SR Synthetic rate
TFPI Tissue factor pathway inhibitor
Trig Triglyceride
Tris Tris hydroxymethylamino methane
U Input
U/P Urine to plasma ratio
VLDL Very low density lipoprotein
WOSCOPS West of Scotland Coronary Prevention Study
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